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Epilepsy affects  approximately  1% of the world population and is the most serious 
neurological conditions.  In the UK, 30-35,000 new cases of epilepsy are diagnosed 
each year, resulting in a prevalence of 300,000 nationwide.  There is significant need 
for new drug treatments.  Yet we have  a poor understanding of how many of these 
drugs  mediate  their  antiepileptic  effect,  and  how  and  where  they  are  distributed 
within  the  brain.  This  thesis  sought  to  investigate  the  pharmacokinetic  and 
neuropharmacokinetic  inter-relationship  and  the  neuropharmacology  of  two  new 
antiepileptic drugs, vigabatrin and levetiracetam; two drugs with distinct mechanisms 
of action.
Firstly,  a  freely  moving  and  freely behaving  rat  model  was  used  to  determine  the 
pharmacokinetics  of  vigabatrin  and  levetiracetam  simulatneously  in  serum, 
cerebrospinal fluid (CSF) and brain frontal cortex and hippocampal extracellular fluid 
(ECF).  Secondly, amino acid neurotransmitter concentrations were monitored in CSF 
(by  direct  CSF  sampling)  and  brain  ECF  (by  microdialysis)  after  vigabatrin  and 
levetiracetam administration.  Thirdly, the effects of vigabatrin and levetiracetam on 
paired-pulse  inhibition  recorded  in  the  dentate  gyrus  evoked  by  perforant  path 
stimulation were established.
Vigabatrin  rapidly  entered  the  blood  (serum),  CSF  and  ECF  (frontal  cortex  and
hippocampus)  compartments  with  concentrations  increasing  linearly  and  dose-
dependently.  Time to maximum concentration (Tmax) was achieved at a mean value
of 0.4  ±  0.06  minutes  in  the  blood  compartment,  0.9  ±0.1  minutes  in  the  CSF
compartment and 0.8 ± 0.1  minutes in both the frontal cortex and hippocampal ECF
compartments.  Although the CSF kinetics of vigabatrin paralleled that seen in serum,
CSF  vigabatrin  concentrations  represented  only  2%  of  serum  vigabatrin
2concentrations and did not reflect free drug concentrations in serum.  Vigabatrin was 
not  protein  bound  in  serum.  Furthermore,  the  efflux  of vigabatrin  from  the  CSF 
compartment was  significantly slower (mean terminal half life  {* 1/2}  values, 2.2-3.3 
h) than that suggested by serum values (mean t\a values,  1.1-1.4 h).  Distribution in 
the brain ECF was brain region  specific;  vigabatrin concentrations  achieved  in the 
frontal cortex were 2-fold greater than concentrations achieved in the hippocampus. 
However, the efflux of vigabatrin from the two brain regions was essentially identical 
(mean  t\n  values,  2.4-3.6  h)  and  indeed  was  similar  to  values  seen  in  the  CSF 
compartment.  The  findings  are  consistent with  an active  uptake  and  elimination of 
vigabatrin from the CSF and ECF.
Levetiracetam  rapidly  entered  the  blood  (serum)  and  ECF  (frontal  cortex  and 
hippocampus)  compartments  with  concentrations  increasing  linearly  and  dose- 
dependently.  Mean Tm& x  values were 0.4 -  0.7 minutes in the blood compartment and 
1.8  -   2.5  minutes  in  both  the  frontal  cortex  and  hippocampal  ECF  compartments. 
Levetiracetam  was  not  protein  bound  in  serum.  In  contrast  to  vigabatrin, 
levetiracetam did not exhibit brain region specificity in that its neuropharmacokinetic 
profiles in frontal cortex and hippocampal ECF were essentially identical.  However, 
the efflux of levetiracetam from the two brain regions was slower (mean t\u values,
3.1  -  3.3  h)  compared to that which occurred in the blood compartment (mean t\n 
values, 2.2 h).
In the CSF compartment, vigabatrin administration was associated with changes in 5 
of the 16 amino acid neurotransmitter concentrations measured over time. Thus whilst 
arginine  and tyrosine concentrations decreased,  homocamosine,  glycine  and taurine 
concentrations increased.  Although y-aminobutyric acid (GABA) was not measured 
in CSF, the fact that homocamosine (a GABA conjugate) concentrations increased is
3consistent  with  a  GABAergic  action  for  vigabatrin.  In  the  frontal  cortex  and 
hippocampal  ECF  compartments,  vigabatrin  administration  was  associated  with 
significant  changes  in  various  amino  acid  concentrations  but  the  changes  did  not 
parallel  those  seen  in  CSF.  The  most  profound  change  was  that  with  GABA. 
However, whilst ECF  GABA concentrations  increased  6-fold  in the  frontal  cortex, 
concentrations  in the hippocampus were unaffected.  These  GABA changes  did not 
parallel  the  concentration  versus  time  profile  of  ECF  vigabatrin;  nevertheless 
vigabatrin concentrations in the frontal cortex were 2-fold higher than those achieved 
in the hippocampus. These findings indicate that CSF amino acid measurements may 
be a poor reflection of ECF amino acid changes and that changes in ECF amino acids 
is regionally specific.  That vigabatrin reduced paired pulse inhibition in the dentate 
gyrus evoked by perforant path stimulation at 20 ms interpulse interval but not at 50 
ms  and  100  ms  intervals  would  suggest  that  vigabatrin by increasing  extracellular 
GABA may either desensistise synaptic GABAa receptors or inhibit GABA release 
through an action on GABAb receptors.
In  the  brain  ECF  compartment,  levetiracetam  administration  was  associated  with 
changes in only two (taurine and  glutamate)  of the 20  amino  acid neurotransmitter 
concentrations measured over time.  The significance of these changes in relation to 
the mechanism  of action of levetiracetam is unknown.  However,  the  fact that ECF 
GABA  concentrations  were  unaffected  by  levetiracetam  administration  further 
indicates that levetiracetam has no  effect on the GABAergic system.  Indeed such a 
conclusion is reinforced by the observation that levetiracetam was without effect on 
paired-pulse inhibition.
In  summary,  both  vigabatrin  and  levetiracetam  have  favourable  kinetic  features  in 
that they exhibit linear dose-dependent pharmacokinetics and neuropharmacokinetics,
4rapidly enter the central CSF and brain ECF compartments and that their efflux from 
these  compartments  are  prolonged  compared  to  that  seen  in  serum.  The  brain 
distribution of vigabatrin is region specific (higher vigabatrin concentrations achieved 
in the frontal cortex versus the hippocampus), and this specificity is also reflected in 
relation to changes in ECF GABA concentrations; although the concentration versus 
time profiles for vigabatrin and GABA do not coincide and in fact are distinct. GABA 
is  clearly  a  component  of  the  mechanism  of  action  of  vigabatrin.  In  contrast 
levetiracetam  neither  affects  ECF  GABA  concentrations  nor  appears  to  act  via  a 
GABAergic mechanism.
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The term “Epilepsy” is derived  from the  Greek word  epilepsia and  is the 
tendency  to  experience  seizures  of  major  or  minor  intensity  and  of  varying 
characteristics.  Epilepsy affects approximately 1% of the world population about 50 
million  people  worldwide  and  is  one  of the  most  common  serious  neurological 
conditions.  The  incidence  of epilepsy  is  40-80  per  100,000  people  per  year  and 
seizures are for the most part self-terminating (Hopkins,  1987).  The life-time chance 
of developing epilepsy is 3-5% (Sander and Shorvon,  1987).  However, on occasion, 
seizures  can  continue  unabated  and  they  are  then  considered  as  a  separate  entity, 
status epilepticus  (SE).  SE is one of the most common life-threatening neurological 
disorders.
The treatment goal  for patients with epilepsy is to make them seizure free. 
The  established  antiepileptic  drugs  (AEDs)  carbamazepine,  ethosuximide, 
phenobarbitone,  phenytoin  and  valproate,  can  render  approximately  80%  of newly 
diagnosed  patients  seizure-free;  the  remaining  20%  of  patients  with  refractory 
epilepsy often require polytherapy regimens  involving two  or more drugs.  Seizure 
control  is, however,  far from optimal  in those patients who receive multiple AEDs, 
and  they  are  invariably  faced  with  adverse  effects  that  may be  intolerable.  Most 
patients with chronic  intractable epilepsy therefore rely on the development of new 
AEDs as their only hope for seizure control.
Several developments have underpinned the acceleration in the evolution of 
new  AEDs.  Testing  of  compounds  in  animal  models  has  enabled  a  greater 
understanding  of the molecular basis  of seizures,  and  of clinical  pharmacokinetics. 
However, most of the new AEDs have been identified and developed consequent to
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efficacy screening in animal models and without regards to any detailed knowledge of 
how  they work (Loscher & Schmidt, 1993).
Understanding the principle of epilepsy and knowing the exact mechanism 
of action of a drug can result in a more rational approach to epilepsy management and 
seizure  control.  Therefore  this  thesis  focuses  on  the  pharmacokinetics, 
neuropharmacokinetics  and the mechanism  of action of two  new  AEDs,  vigabatrin 
and levetiracetam, in animal models.
1.1  THE CLASSIFICATION AND DEFINITION OF EPILEPSIES
The most widely used classification of the epilepsies is the proposal from the 
Commission on Classification and Terminology of the International League Against 
Epilepsy  (ILAE,  1981).  Table  1   summarises  the  international  classification  of 
epileptic seizures.  This classification has two major divisions, which are partial and 
generalised.
1.1.1  Partial seizures
Partial seizures originate in a focal region of the cortex  and can be subdivided 
into  those  that  do  not  impair  consciousness,  sample  partial  and  those  that  do  impair 
consciousness, complex partial.  Partial seizure can spread rapidly to other cortical areas 
through neuronal networks, resulting in secondary generalized tonic-clonic seizures.
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Table 1.1:  International classification of epileptic seizure
Partial seizures 
(beginning locally)
Generalized seizure 
(convulsive or non-convulsive)
Simple partial (without impaired 
consciousness)
Absence 
- typical
- with motor symptoms - atypical
- with somatosensory or 
special sensory symptoms
Myoclonic
Clonic
- with autonomic symptoms
Tonic
- with psychic symptoms
Tonic-clonic
Complex partial (with impaired 
consciousness) Atonic
- simple partial onset Unclassified
followed by impaired 
consciousness
- impaired consciousness at 
onset
Partial, evolving into secondary 
Generalized seizures
*  Adapted  from  Commission  Classification  and  Teminology  of  the
  international League Against Epilepsy. 1981_____________________________
(Brodie et al, 2005)
1.1.1.1  Simple partial seizure
Simple partial seizures begin locally in the cortex and are often preceded by 
an  aura  which  reflects  the  functional  role  of that  part  of the  cortex  in  which  the 
seizure begins.  The symptoms and signs of simple partial seizures depend on the site 
of origin of the abnormal electrical discharge.  Those arising from the motor cortex 
cause  rhythmic  movements  of the  contralateral  face,  arm  or  leg.  Seizures  arising
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from  sensory regions  or  areas  responsible  for  emotions  and  memory may produce 
olfactory,  visual  or  auditory  hallucinations,  fear,  panic  or  euphoria  (Brodie  et  al, 
2005).
1.1.1.2  Complex partial seizures
Complex partial  seizures  are differentiated  from  simple partial  seizures by 
varying  degrees  of impairment  of consciousness  and  are  frequently  succeeded  by 
post-ictal  confusion.  Complex  partial  seizures  typically  last  less  than  3  minutes. 
During that time, patients may appear awake, but lose contact with their environment 
and do not respond normally to instructions or questions.  Patients usually stare and 
either  remain  motionless  or  engage  in  repetitive  semi-purposeful  behaviour  called 
automatisms (Brodie et al, 2005).
1.1.2  Generalised Seizures
1.1.2.1  Tonic-clonic seizure
Tonic-clonic  seizures  are  the  most  common  form  of generalised  seizure. 
The  patient  initially  has  a  tonic  phase,  associated  with  respiratory  arrest;  reflex 
emptying of the bladder and bowel may occur.  Next the patient enters a clonic phase 
of rhythmic  generalised jerking  lasting  for  a  variable  length  of time.  Deep  coma 
follows with an ascending conscious level which often includes a post-ictal phase of 
confusion and automatic behaviour.  It takes 15-60 minute to become fully conscious. 
Afterwards people often complain of a generalised headache, a feeling of lethargy and 
a desire to sleep.
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1.1.2.2 Myoclonic seizures
Myoclonic  seizures  occur  in  a  number  of differing  epileptic  syndromes. 
These seizures may be associated with both typical and atypical  absences but more 
commonly occur without  impairment of consciousness.  The  arms tend to be most 
frequently involved in a sudden flexion movement (Chadwick, 2003).
1.1.2.3  Absence seizures
Typical absence seizures
Typical absences last 5-10 seconds and commonly occur in clusters.  They 
manifest as sudden onset of motor arrest,  staring and impaired consciousness.  This 
seizure type is associated with regular 3Hz spike-wave in the electroencephalograph 
(EEG).
Atypical absence seizures
Atypical  absences  are  less  common  and  usually  occur  in  symptomatic 
epilepsies in children with pre-existing brain damage.  These seizures are frequently 
associated with myoclonic activity.
1.1.2.4.  Clonic seizures
Clonic  seizures  are  characterized  by  rhythmic  or  semi-rhythmic  muscle 
contractions, typically involving the upper extremities, neck and face.
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1.1.2.5.  Tonic seizures
Introduction
This seizures cause sudden stiffening of extensor muscles, often associated 
with impaired consciousness and falling to the ground.
1.1.2.6.  A ton ic seizures
Atonic  seizures  produce  sudden  loss  of  muscle  tone  with  instantaneous 
collapse, often resulting in facial or other injuries.
1.2  MECHANISMS OF EPILEPSY
Neuronal  networks  can  be  made  to  discharge  abnormally  by  electrical 
stimulation, by alterations in basic metabolic environment as well as by application of 
specific neurotransmitters or drugs. Using such means it is possible to induce seizures 
in a “normal” brain. This has to be differentiated from the occurrence of spontaneous 
seizures in an altered network that is the characteristic of epilepsy.
1.2.1  Brain development and motor system
Certain  regions  may  be  considered  seizure  sensitive  and  have  a  low 
threshold and high susceptibility such as the motor cortex, the limbic structures and 
regions  involved  in  autonomic  function.  The  temporal  lobe  and  its  deeper  limbic 
nuclear  aggregates  (amygdala)  and  hippocampus  are  particularly  susceptible  to 
seizure  development.  Age  and  development  are  also  important  factors  from  the 
perinatal period onward with a delay often noted between a specific brain insult and 
the later appearance of seizures.
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1.2.2  Neu roan atomic and pathological changes
Introduction
Hippocampal tissue removed during temporal  lobe resection for intractable 
epilepsy  demonstrates,  in  addition  to  the  expected  neuronal  loss  and  gliosis, 
significant  changes  in  dendritic  complexity  and  organization  (Thom  et  al,  2002; 
Billinton  et  al,  2001).  This  suggests  that  there  are  changes  in  connectivity  and 
organisation of the neuronal network.  The role that gliosis plays in the development 
of  epilepsy  is  unknown;  gliosis  could  play  a  part  in  the  dysregulation  of  the 
neurochemical  environment  including  “spill-over’  of  neurotransmitters  and 
neurotransmitter accumulation.  In addition to the anatomical  changes there are also 
physiological  changes  including  changes  in  receptors  and  channels  that  may  all 
contribute to the epileptogenic state. These changes are not modified by our present 
antiepileptic  treatments,  which  instead  aim  to  redress  neuronal  and  network 
dysfunction  and  dysregulation.  To  this  end,  specific  targets  for  antiepileptic  drugs 
have been identified.
1.2.3  Voltage-dependent membrane conductance
1.2.3.1  Voltage-sensitive sodium channels (VSSCs)
The  VSSCs  were  originally  found  to  be  the  molecular  targets  of specific 
AEDs (e.g. carbamazepine and phenytoin).  These AEDs bind to the inactivated state 
of the VSSC, slowing the post-opening recovery phase.  This effect may underlie the 
capability of these AEDs to prevent high frequency activity and reduce late VSSC- 
mediated sustained depolarisations that may contribute to seizure generation (Segal et
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al,  1995). Genetic variation in splicing of a subunit of VSSCs may  be predictive of 
the effective dose of anti epileptic drugs acting at this target (Tate et al, 2005).
1.2.3.2  Voltage-gated calcium channels (VGCCs)
There is considerable evidence available concerning the role of VGCCs in 
epileptogenesis.  In particular genetic mutations in human calcium channel genes or 
those of several mouse species have been associated with epileptic phenotypes (Chen 
et al, 2005).  The T-type VGCC has been implicated in playing a significant role in 
controlling  epileptiform  spike  wave  discharges  associated  with  absence  seizures 
(Gomora et al, 2001). There is evidence that both ethosuximide and valproate may act 
at this target, thus specifically modulating absence seizures (Coulter et al, 1989).
1.2.3.3  Voltage-gate potassium channels (VGPCs)
VGPCs have many key roles including setting resting membrane potential, 
determining  firing  threshold,  action  potential  repolarization  and  determination  of 
postsynaptic excitability (Errington et al, 2005).  Therefore it would be expected that 
potentiation of potassium  currents  should have  an antiepileptic  effect.  Madeja et al 
(2003) have suggested that paradoxically the anti epileptic properties of levetiracetam 
may be partly explained by a reduction in the  conductance  of delayed rectifier K+ 
channels.  It  has  been  reported  lamotrigine  is  able  to  potentiate  outward  KA  
conductance  at concentrations  similar to those  at which they exert  sodium  channel 
inhibition  (Zona  et  al,  2002).  The  functional  diversity  amongst  the  K+  channels 
makes them prospective targets for future AED development.
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1.2.4  Synaptic mechanisms
1.2.4.1  Introduction
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Epilepsy  has  been  proposed  to  be  associated  with  excessive  stimulated 
release of glutamate and /or a failure of GABA modulated inhibition (van Gelder & 
Bowers, 2001).  GABA and glutamate are undoubtedly involved in the mechanisms 
of  epilepsy.  However,  GABA  and  glutamate  are  not  the  only  amino  acid 
neurotransmitters related to epilepsy, others have also been implicated.  These include 
the excitatory transmitter aspartate, and the inhibitory transmitters glycine and taurine 
(Borgeat,  1997; Sveinbjomsdottir et al,  1993).  This chapter will focus on these five 
amino  acid  neurotransmitters,  There  are  other neurotransmitters  such  as  serotonin, 
dopamine, acetylcholine and noradrenalaine, and peptides such as NPY, galanin and 
subtance P, which play important roles in the regulation of cortical excitability, but 
which do not form a part of this thesis.
1.2.4.2  Inhibitory mechanisms 
GABA
GABA  has  had  a  central  role  in  neural  control  theory  since  it  was  first 
discovered  in  1950  (Roberts  & Frenkel,  1950).  GABA was  later shown to  inhibit 
seizure activity after its direct cerebral application (Meldrum,  1978).  This gave rise 
to the hypothesis that GABAergic inhibition is an important factor in the suppression 
of seizure activity in epileptic patients.
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1.  GABA synthesis and metabolism
The main pathway of GABA synthesis involves the decarboxylation of L- 
glutamate by glutamic acid decarboxylase (GAD) (Tina et al,  1999).  The synthesis 
and  metabolism  of GABA  associated  with  nerve  terminals  has  been  linked  to  a 
substrate  cycle  between  neurons  and  astrocytes  involving  glutamate,  GABA,  and 
glutamine  (Shank et  al,  1993).  In  this  cycle,  nerve-terminal  GABA is  synthesized 
from  glutamate  and  enters  the  ECF  by  neurotransmitter  release;  it  is  then  either 
recycled into the nerve terminal or taken up by astrocytes (Figure 1.1).
Astrocyte
v< sicular release
GABA transporter
GAB
GAD
transr prj
transporter
GAB
SSAD
succinate glutamine
mitochondrion
Neuron
Figure 1.1: A schematic of the GABA synapse.
In  astrocytes,  GABA  is  broken  down  by  GABA  transaminase  and 
resynthesized into glutamate.  Astrocytic glutamate is converted into glutamine that is
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taken up by nerve terminals.  In the nerve terminal,  the glutamine is hydrolyzed to 
glutamate by glutaminase (Olsen & DeLorey, 1999).
2.  GABA receptors
GABAergic  neurotransmission  may  be  divided  into  slow  and  fast 
components.  GABAb (metabotropic) receptors produce slow, long lasting inhibition 
since  they  are  only  indirectly  coupled  to  calcium  and  potassium  channels,  via  G- 
protein.  GABAa and GABAc (ionotropic) receptors are directly coupled to chloride 
channels, generating a fast inhibitory response (Olsen & DeLorey, 1999).
3.  GABA and epilepsy
Although the GABA hypothesis has been supported by data suggesting an 
association  between  low  GABA  concentrations  and  recent  seizures  (Petroff et  al, 
1996b),  it  is  apparent  that  the  changes  in  GABAergic  transmission  with  the 
development  of  epilepsy  are  more  complex  with  changes  in  GABAa  receptor 
subtypes  (Brooks-Kayal  et  al.  1998;  2001)  and  changes  in  the  somatodendritic 
distribution of inhibition (Crossart et al, 2005).
4.  GABA and antiepileptic drug therapy
There are several ways of increasing GABA activity in the brain by AEDs. 
(1)  GABA  agonists  (e.g.  progabide,  diazepam  and  phenobarbital)  directly  increase 
inhibitory chloride conductances  and up regulate the effect of synaptically released 
GABA  on the  GABAa receptors.  (2)  GABA transporter blockers  (e.g.  tiagabine) 
prolong the action of GABA in the synaptic cleft by inhibiting uptake and increase
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extracellular GABA concentrations.  (3)  Stimulating GABA synthesis and release of 
synaptic GABA during neuronal activation.  (4) Slowing degradation of GABA (e.g., 
vigabatrin) by inhibiting GABA transaminase (GABA-T), and increasing intracellular 
and extracellular GABA concentrations.
Glycine
Glycine is a key neurotransmitter in CNS.  Two separate systems have been 
identified.  The  first  one  is  an  inhibitory  function  that  is  mediated  by  glycine 
receptors  at  the  site  of action  of the  convulsant  strychnine.  The  second  type  of 
glycine recognition site is part of the NMD  A receptor complex.  Glycine potentiates 
the excitory action of glutamate (Tunnicliff, 2003).
1.  Glycine synthesis and metabolism
Glycine  is  metabolically  derived  from  serine  by  the  action  of D-serine- 
transhydroxylmethylase (Figure 1.2).
Tetrahydrofolate  5,10-Methylene tatrahydrofolate
H
H
nh-3 —c —coo-  - - - - - - - - - - - - - - - -  ►   nh-3—  c — coo-
I   f  H
CH2  :
|  Serine  Glycine
OH  transhydroxymethylase
Serine 
A
Glucose
Figure 1.2:  Glycine formation from serine by serine transhydroxymethylase
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2.  Glycine receptors
Glycine  receptors  are  formed  either  from  a  subunts  alone,  or  from  both  a  and  P 
subunits.  Heteromeric glycine receptors have subunit composition a3p2 (9-11)  and 
three agonist-binding sites, rather than the two sites found in nicotinic acetylcholine 
or GABAa receptors.
3.  Glycine and epilepsy
Glycinergic  inhibition  occurs  primarily  in  the  spinal  cord  and  brain  stem 
where it mediates fast inhibitory synaptic transmission via chloride permeable glycine 
receptors.  In  audiogenic  seizure-susceptible  rats,  glycine  levels  were  significantly 
decreased  in  the  hippocampus  and  pons  after  habituation  was  obtained  by 
stimulations  repeated  at  2  minutes  interval.  The  mechanism  for  this  is  unknown 
(Hategan et al, 1990).
The involvement of glycine in human epilepsy is less clear and the few 
studies  were  rather  contradictory.  Crawford  &  Chadwick  (1987)  investigated  the 
amino acid changes in CSF  from  69 epileptic  and  51  control patients.  They found 
that  glycine  concentrations  were  significantly  reduced  in  the  patients  CSF  with 
epilepsy  compared  to  the  CSF  from  healthy  controls.  In  contrast,  Honda  (1984) 
found  that  CSF  glycine  concentrations  had  increased  in  children  with  convulsive 
disorders.  In  surgical  patients,  glycine  concentration  is  significantly  increased  in 
epileptogenic  cerebral  cortex  (Sherwin,  1999).  When  glycine was  administered  in 
combination with phenobarbital or carbamazepine, glycine significantly enhanced the 
anticonvulsant potency of phenobarbital and carbamazepine.  Glycine also potentiated 
the  anticonvulsant  actions  of  MK-801  and  diazepam  in  the  model  of  maximal
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electroshock  seizures  (Peterson  et  al,  1990).  These  findings  suggested  a possible 
interaction  between  glycine  and  anticonvulsant  drugs  at  NMDA  receptors,  the 
mechanism of which is unclear.
4.  Glycine and epileptic therapy
There is no glycine receptor agonist available for treating epilepsy.  Glycine 
antagonists MDL  100,458  and MDL  102,288 had different efficacies in the DBA/2 
mouse model, although both substances showed comparable results in binding assays 
for  the  glycine  binding  site  of the  NMDA  receptor.  SM-319000,  a  glycine  site 
antagonist  with  high  selectively  and  affinity was  shown  to  be  anticonvulsant  after 
systemic administration in NMDA-induced convulsions (Jansen & Dannhardt, 2003).
Taurine
The  precise  role  of taurine  in  synaptic  transmission  is  uncertain  but  its 
antiepileptic effects have been confirmed in several models of experimental epilepsy 
and in short-term clinical studies (Fariello et al, 1985; Lombardini,  1992; van Gelder, 
1992; Richards et al,  1995).  Several clinical trials involving taurine supplementation 
in  epileptic  patients  have  been  reported  and  variable  success  has  been  achieved 
(Timothy & Birdsall,  1998).  The mechanisms of action of taurine  in the treatment 
epilepsy may be via binding to GABA or to glycine receptors, but it still lacks unique 
population of receptor sites (Gupta et al, 2005).  Taurine modulates release of GABA 
but their bio-chemical action is different.  Similarly, taurine and glycine have several 
similar activities but they work on a different receptor.  How taurine concentrations in
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the ECF relate to epilepsy onset and the relationship between its mechanism of action 
and efficacy are still unknown.
1.2.4.3  Excitatory mechanisms
The two mainly excitatory amino acids, namely glutamate and aspartate are 
known  to  act  as  agonists  at  all  subtypes  of ionotropic  glutamate  receptors.  These 
excitatory amino acids play an important role in burst generation, and an integral part 
in the generation and spread of seizures.
Glutamate
Glutamate’s  excitatory  potential  was  first  noted  in  1951  following 
intracarotid  injections  of glutamate  in the  study of epileptic phenomena (Okamoto, 
1951).  A year later, Hayashi (1952) injected small amounts of glutamate directly into 
the cortex, which demonstrated that a local application of glutamate could induce the 
firing  in  rat  neocortical  neurones  of the  rat  brain.  After  the  1980’s,  the  role  of 
glutamate as the major cause of seizure mediated neuronal damage was studied with 
particular emphasise on the NMDA receptors.
1.  Glutamate synthesis and metabolism
Glutamine  and  a-ketoglutarate  are  thought  to  be  the  major precursors  for 
glutamate.  Glutamine is taken up  into the presynaptic terminal via an active, Na+- 
dependent uptake protein.  The glutamate in the terminal is then actively taken up into 
vesicles for future release  into the cleft.  From the cleft, glutamate is either actively 
taken back up via glutamate transporters or diffuses form the cleft and is taken up by
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glutamate  transporters  on  glia.  Once  in  glial  cells,  glutamate  is  metabolized  via 
glutamine synthase into glutamine or a-ketoglutarate. Glutamine is transported out of 
the  glial  cells  and back into  the presynaptic neurone  for subsequent resynthesis  of
2.  Glutamatergic receptors
Glutamate  receptors  include  ionotropic  and  metabotropic  receptors.  The 
ionotropic receptors are further divided into three types - AMPA, kainate and NMDA 
receptors.  The  AMPA  and  kainate  receptors  are  thought  to  mediate  rapid 
depolarizing responses at most synapses in the mammalian CNS (Lerma et al,  1997). 
NMDA receptor activation contributes to diverse physiological responses, including 
synaptic  formation  and  plasticity  (Kirkwood  et  al,  1995).  The  metabotropic
glutamate (Danbolt, 2001) (Figure: 1.3).
Ca2 +
Presynaptic Neurone mGluR recepor
AMPA receptor
Mitochondria
a-ketoglutarate
Glutamine
a-ketoglutar. Postsynaptic
Neurone
a-ketoglutarate
Glutamine
Figure 1.3:  Schematic diagram of a model excitatory synapse
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receptors consist of at least eight different subtypes which are coupled to intracellular 
enzymes and to ion channels (Robinson, 1999).
3.  Glutamate and epilepsy
Animal models of limbic region epilepsy mimic human temporal lobe 
epilepsy and  its genesis.  They demonstrate how  glutamate receptor signalling may 
contribute  to  the  formation  of pathologic  synaptic  networks.  Increased  glutamate 
neurotransmitter  release  occurs  in  a  variety  of  epilepsy  models,  and  glutamate 
receptors  play  a  critical  role  in  the  generation  of  these  models  (Bames  & 
Slevin,2003).
Glutamate  plays  a role  in  the  initiation  and  spread  of  seizure  activity  in 
human. There are observations of elevated levels of glutamate in patients with various 
forms of epilepsy (Maragakis  & Rothstein,  2001;  Tessler et  al,  1999).  It has been 
suggested  that  a  defect  of uptake  might  be  responsible  for  increases  in  glutamate 
concentration seen in the brain of patients with various forms of epilepsy (Bames et 
al, 2003; Giger et al, 2000).
4.  Glutamate and antiepileptic drug therapy
Although glutamate receptor antagonism would seem an ideal approach to 
the  development  of  antiepileptic  drugs,  specific  antagonists  have  not  become 
established in clinical practice (often due to unacceptable side-effects). Nevertheless 
some  antiepileptic  drugs  may have  an  action  at  glutamate  receptors;  these  include 
topiramate at AMPA receptors and felbamate at NMDA receptors.
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1.3  GENERAL PRINCIPLES OF NEW ANTIEPILEPTIC DRUGS
1.3.1  Mechanisms of action of new antiepileptic drugs
In general, new AEDs appear to decrease neuronal excitability or to enhance 
inhibition by altering sodium, potassium or calcium conductances or by affecting the 
activity  of GABA,  glutamate,  or  other  neurotransmitters  that  may  be  involved  in 
seizures.  Although  several  AEDs  share  common  mechanisms,  each  has  distinct 
actions.  Many new  AEDs  have  mechanisms  of action different  from those  of the 
more established agents (see Figure 1.4, LaRoche & Helmers, 2004).
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Figure 1.4:  The principal mechanisms of action of the new AEDs.
1.3.1.1  Modulators of voltage-gate sodium channels
The  voltage-gated  sodium  channel  is  involved  in  the  generation  and 
propagation  of  Na+-dependent  action  potentials,  and  delaying  its  reactivation
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significantly  limits  the  frequency  of  neuronal  firing.  Like  carbamazepine  and 
phenytoin, the new AEDs  oxcarbazepine, lamotrigine, felbamate and topiramate act 
via modulating the voltage-gate of sodium channel (LaRoche & Helmers, 2004).
1.3.1.2 Modulators of GABAergic inhibition
Although the mechanism of action of the new AEDs vigabatrin, gabapentin 
and  tiagabine  are  different,  they  commonly  enhance  GABAergic  inhibition. 
Gabapentin  is  a  cyclic  GABA  analog  designed  to  mimic  a  restricted  static 
conformation  of GABA with high  lipid  solubility  for penetration  of BBB,  initially 
intended to act as a GABA agonist. Its mechanism of action, however, mainly seems 
to be via an action at calcium channels.  Vigabatrin,  a synthetic structural analog of 
GABA,  acts  as  an  enzyme-activated  irreversible  inhibitor  GABA-T  to  increase 
GABA  levels  in the brain.  Tiagabine,  a derivative  of nipecotic  acid,  potently and 
selectively inhibits neuronal and glial GABA uptake (Bialer et al, 2004).
1.3.1.3 Modulators of calcium channels
The  mechanism  of action  of the  new  AEDs  felbamate,  lamotrigine  and 
topiramate have an action in suppressing Ca++ current and attenuating the propagation 
of seizure discharge and focal epileptigenic activity (LaRoche & Helmers, 2004).
1.3.1.4 Other mechanisms
Felbamate has multiple mechanism of action.  It acts at the GABAa receptor 
and may also have an antagonism effect on glutamate (LaRoche & Helmers, 2004). 
Levetiracetam’s  mechanisms  of action  are  still  largely  unknown.  There  is  some
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evidence  to  suggest  that  synaptic  vesicle  protein  (SV2A)  is  the  binding  site  for 
levetiracetam,  which  suggest  the  protein  involved  in  mechanism  of levetiracetam 
(Lynch et al, 2004).
1.3.2  Principles of pharmacokinetics of new antiepileptic drugs
The pharmacokinetics  for intraperitoneal  administration  (I.P.)  is  similar in 
pattern to that obtained after intravenous (I.V.)  administration.  The experiments in 
this thesis used I.P. administration.  The concepts of clearance (Cl), extraction ratio, 
volume of distribution (Vd) and half-life (O/2) are described in this section.
1.3.2.1  One-compartment model
When drug distribution is rapid compared with drug elimination, the entire 
body mass can be treated mathematically as a single compartment (one compartment) 
of volume  (Fig.  1.5).  The  one-compartment  can  be  seen  after  I.V.,  I.P.  or  S.C. 
administrations  and  refers  to  the  fact  that  immediately  after  administration,  drug 
concentration  at  the  site  of reference  (blood  or  plasma)  declines  over  time  in  an 
apparent monoexponential fashion with no visible distribution phase.
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Figure 1.5:  The time course of drug in blood following a single I.P. or I.V. 
dose  in  one-compartment  model.  The  solid  line  represents  the  line  drawn 
through a series of plasma concentration determinations.
1.3.2.2  Half-life
T\/2 is defined as the time required for blood drug concentration to decrease 
by  50%.  This  relationship  shows  that  the  larger the  elimination  rate  constant,  the 
shorter the half-life.
TV l  =  0.693IK
1.3.2.3  Area under curve
Area  under  curve  (AUC)  is  the  pharmacokinetic  parameter  that  closely 
related to the clearance {Cl) of a drug.  A measure of this area can be a useful index 
of the biological availability of the drug and a means of estimating its CL  Figure 1.6 
shows how AUC is calculated using the trapezium rule.
AUC  =  (a + b) x (tl -  tO)
2
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Figure 1.6:  Graph showing how AUC is calculated using the trapezium rule.
1.3.2.4  Drug distribution and elimination
When drug is administered as a single bolus dose, the initial concentration in 
the body has a value Co.  The amount (A) of drug in the body is Ao and a volume of 
distribution (Vd) can be determined by the ratios.
Vd  =  D/Co  =  A/C
For drugs exhibiting one-component compartment behaviour, this  Vd is also 
the ratio of drug amount in the body to blood drug concentration (C) at any time after 
administration.
Clearance (Cl) is the apparent volume of blood completely cleared of drug 
per unit time.  If pharmacokinetics is linear, clearance is dependent of dose.
Cl = Dose/AUC
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1.3.3.  Principles of new AEDs therapy
New  AEDs  are  necessary  for  patients  with  chronic  epilepsy  and  for 
improving upon established AEDs as first-line therapy.  Main new AEDs are listed in 
Table 1.2 along with their current status or to whether they are first, second and third 
choice in the treatment of various seizure types and epilepsies.
Table 1.2:  Efficacy of newer antiepileptic drugs against common seizure types and
syndromes
Partial Secondary
generalized
Tonic-
clonic
Absence Myoclonic Lennox-
Gastaut
Infantile
spasms
FBM + + ?+ ?+ ? + ?
GBP + + ?+ - - ? ?
LEV + + + ?+ + ? ?
LTG + + + + +* + ?+
oxc + + + - - 0 0
PGB + + ? ? ? ? ?
TGB + + ? - ? ? ?+
TPM + + + ? + + ?+
VGB + + ?+ - - ? +
ZNS + + + ?+ + ?+ ?+
*  Lamotrigine may worsen myoclonic seiszures in some cases 
+  proven efficacy;  ?+ probable efficacy;  0 ineffective;  - worsens control;
?  unknown.  (Brodie et al, 2005)
1.4  DRUG INVESTIGATED IN THE THESIS
In  this  thesis,  two  new  AEDs,  vigabatrin  and  levetiracetam,  were 
investigated  in  relation  to  their  pharmacokinetics  and  neuropharmacokinetics
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characteristics,  and  also  their  effects  on  brain  neurotransmitters  and 
electrophysiological properties.  Levetiracetam is a new AED and has been licensed 
in  Europe  and  American.  Its  mechanisms  of  action  have  not  been  completely 
elucidated.  In  contrast,  vigabatrin  is  an  AED  drug  with  a  well  estrablished 
mechanism of action -  inhibiting GABA-T which decreases GABA breakdown and 
increases brain GABA concentrations. This  thesis aims to investiage and comparethe 
pharmacokinetics, neurophamacokinetics and mechanisms of these two drugs.
1.4.1  Vigabatrin
1.4.1.1  Chemistry
Vigabatrin,  4-amino-hex-5-enoic  acid;  gamma-vinyl  GABA,  is a structural 
analogue of GABA (Figure  1.7) and it is freely soluble in  water (pH value 4.02 and 
9.72).  Presently it is supplied as a racemic mixture of its two enantiomers: the S(+) 
and R(-)  enantiomers.  Only the S(+)-enantiomer is pharmacologically active.  The 
R(-)-enantiomer does not interfere, and neither undergoes in vivo inversion (Haegele 
& Schechter, 1986).
N h 2 n h 2
Vigabatrin GABA
Figure 1.7:  Chemical structure of vigabatrin and GABA (Richens, 1989)
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1.4.1.2  Pharmacology
Introduction
Mechanism of action
Vigabatrin, as an analogue of GABA, acts by replacing GABA as a substrate 
of GABA-T.  It irreversibly and covalently binds to the enzyme and enhances GABA- 
mediated inhibition by preventing GABA degradation (Angehagen et al, 2003).  In an 
early  study  (Jung  et  al,  1977),  vigabatrin  was  shown  to  produce  dose-related 
inhibition  of  GABA-T  in  mice.  They  injected  vigabatrin  to  male  mice 
intraperitoneally  with  increasing  doses.  Eight  hours  post  treatment,  GABA 
concentrations, GABA-T, and GAD activities were measured in the brain.  GABA-T 
activity decreased in a dose-dependent manner.  Even at the smallest vigabatrin dose 
(100 mg/kg) a 45 % reduction in GABA-T activity was found.
Changes  in CSF  GABA and other neurotransmitters  in humans  have been 
observed  after  vigabatrin  therapy  (Grove  et  al,  1981;  Ben-Menachem  et  al,  1989; 
Rothman et al,  1993; Mattson et al, 1994).  Increasing vigabatrin dosage from 3g/day 
to 6g/day did not result in a further increase in brain GABA concentrations (Rothman, 
et al,  1994).  Vigabatrin  50 mg/kg/day as  add-on  therapy was  given to  11  patients 
with drug-resistant complex partial seizures as a single-dose,  every third day, every 
other day and daily (Ben-Menachem et al,  1989).  Serial lumbar punctures taken pre- 
and  post  treatment  revealed  that  total  GABA,  free  GABA  and  homocamosine 
concentrations increased significantly in a dose-dependent manner.
NMR spectroscopy of epileptic patients treated with vigabatrin in addition to 
conventional  AEDs  has  demonstrated  increased  brain  GABA  concentrations
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consequent  to  vigabatrin  therapy  (Petroff  et  al,  1995).  The  authors  also  found 
increased levels of glutamine and decreased levels of glutamate by 9% compared to 
other patients  on  conventional  AED  therapy  alone.  In  another study,  CSF  GABA 
increases were correlated with decreases in regional cerebral metabolism determined 
by PET studies (Spanaki et al,  1999).  Although originally considered not to have an 
effect  on  GABA  uptake  (Schousboe  et  al,  1986),  evidence  now  suggests  that 
vigabatrin may in part act through this mechanism (Jolkkonen et al, 1992).
Anticonvulsant activity in seizure models
The anticonvulsant effects of vigabatrin have been observed in a variety of 
experimental  models  of  epilepsy.  It  is  effective  against  seizures  induced  by 
strychnine,  pentyleneterazole,  electroshock,  methionine  sulphoxide,  picrotoxin, 
isoniazid and  ethionine and mercaptopropionic acid (Miller et al,  1987; Tossi  et al, 
1987;  Bemasconi  et  al,  1988;  Bonhaus  &  McNamara,  1988;  Sarhan  et  al,  1984; 
Sayin et al,  1993).  It is also effective in genetically susceptible seizure models such 
as  autogenic  DBA/2  mice,  hyperthermia-induced  chicks  and  in  photoepileptic 
baboons  (Schechter  et  al,  1977;  Meldrum  &  Horton,  1973).  The  drug  has  both 
antiepileptogenic and anti-seizure properties in the kindling model (Shin et al,  1986; 
Stevens  et  al,  1988).  Vigabatrin  has  also  been  shown  to  protect  hippocampal 
structures  and  function  in  the  perforant  pathway  stimulation  model  of  epilepsy 
(Ylinen et al, 1991).
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Anticonvulsant action in epileptic patients
Vigabatrin  is  used  as  first  line  AED  for  treatment  of infantile  spasms 
(Hancock et al, 2003; Riikonen, 2005).  In a randomized study in UK, vigabatrin was 
effective in 54% of the children.  The difference in favour of hormonal treatment on 
spasms  (70%)  was  significant  at  day  14  (Lux  et  al,  2004).  There  is  evidence  to 
suggest that vigabatrin is the treatment of choice in patients with tuberous sclerosis 
with infantile spasms, with a mean response rate of 74% in eight studies (Riikonen, 
2004).  The numbers of patients who were seizure-free at 3-4 months after ACTH or 
vigabatrin treatment are very similar (Riikonen, 2005).
Vigabatrin was also used in complex partial seizures.  The early six double 
blind, placebo-controlled, crossover studies were conducted between  1984 and 1987. 
Patients with partial seizures were given a dosage range from 2-3g/day of vigabatrin 
as add-on therapy to other AEDs.  All six studies showed a significant improvement 
in seizure frequency (Rimmer & Richens,  1984; Gram et al,  1985; Remy et al,  1986; 
Tassinari et al,  1987).  Currently, the observation that vigabatrin causes visual  field 
defects  in  at  least  a third of patients  has  led to  a restriction  in  its  use.  Therefore, 
vigabatrin is not being used in America, but remains in EU market on a provisional 
basis.  The  approved  indications  have  been  restricted  to  partial  epilepsy  when  all 
other  appropriate  drug  combinations  have  proven  inadequate  or  have  not  been 
tolerated (Bialer et al, 2004).
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1.4.1.3  Pharmacokinetics
Absorption
Vigabatrin shows rapid absorption in both animal model and patient studies. 
In  animal  models,  Jmax  of vigabatrin was about  1   hour in mice  (Jung et  al,  1977). 
Plasma AUCs of vigabatrin were similar in i.v., i.p. and oral administrations (Patsalos 
&  Duncan,  1995).  r m ax  for  the  dog  was  5  minutes  and  1   hour  for  I.V.  and  oral 
respectively.  Comparison to oral  and I.V.  AUC  values in dogs  suggested that oral 
bioavailability of vigabatrin was high (Smithers et al, 1985).
Table  1.3 lists the key pharmacokinetic characteristics of vigabatrin in man. 
In  a  single-dose  kinetic  study,  vigabatrin  was  determined  for  both  enantiomers 
(Haegele & Schechter,  1986).  Peak plasma concentrations for both enantiomers were 
reached at between 0.5 and 2 hours after a 1,500 mg dose.  The concentration of the 
two  enantiomers  did not differ after 24 hours.  The  absorption was rapid,  with the 
peak  concentration  reached  in  the  first  2  hours  after  dosing  of between  0.5-3  g. 
Elimination half-life ranges from 5  to 7 hours and vigabatrin was still detectable in 
the  plasma  after  24  hours.  Food  ingestion  does  not  affect  either  the  rate  or  the 
amount of vigabatrin absorbed (Frisk-Holmberg et al, 1989).  The kinetics of multiple 
dose  vigabatrin  (1.0-4.0  g  daily)  was  consistent  with  that  of  single  dose  acute 
administration (Hoke et al,  1993).  There appeared to be no significant difference in 
kinetics  when  healthy volunteers  and  patients  with  epilepsy  were  compared.  The 
bioavailability of vigabatrin has not been ascertained in man in absolute terms, since 
an I.V.  formulation is not available for clinical use.  However,  it has recently been 
confirmed  that  80-90%  of an  oral  dose  of vigabatrin  is  recovered  in  the  urine  ofChapter 1  Introduction
healthy  volunteers  (Durham  et  al,  1993),  suggesting  that  the  bioavailability  of 
vigabatrin is at least 80-90%.
Table 1.3: Vigabatrin Pharmacokinetics in patients
Tm ax 1-4 hours (unaffected by food)
11/2 5-7 hours
Protein binding 0%
Elimination 70 % renal
Vd 0.81/kg
Active metabolites None
Drug interaction Minimal (reduce phenytoin levels?)
Liver enzyme induction No
Accumulation No
(Ben-Menachem, 1995)
Distribution
Only limited data have been reported as to the distribution of vigabatrin in 
animals.  The unpublished data of distribution into various body tissues of rats, using 
radiolabel  vigabatrin  showed  that  vigabatrin  was  widely  distributed  and  that 
distribution occurred rapidly with a half-life of distribution at  1-2 hour (Patsalos & 
Duncan,  1995).
The  Vd of vigabatrin in patients is 0.8 1/kg (Table  1.5), which is similar to 
that of total body water 0.6 1/kg (Schechter,  1989).  Vigabatrin is not protein-bound 
and since it is  a highly water-soluble compound,  a wide distribution in the body is 
observed.  The tissue distribution of vigabatrin has not been investigated in man.
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Elimination and metabolism
There was no report of elimination and metabolism of vigabatrin in animals. 
In epileptic patients,  vigabatrin is minimally metabolised.  It did not affect hepatic 
microsomal enzyme activity (Bartoli et al, 1997) and is excreted as unchanged drug in 
urine  with  a  clearance  similar  to  that  of glomerular  filtration  rate  (Durham  et  al, 
1993).  Elimination was not dose-dependent at doses of 0.5-4.0 g and followed first- 
order kinetics (Grove et al, 1984; Hoke et al, 1993).  In healthy volunteers, the values 
for elimination half-life and renal clearance, of both enantiomers, were 5-7 hours and
1.3  ml/min/kg,  respectively (Haegele  &  Schechter,  1986;  Saletu  et  al,  1986;  Frisk- 
Holmberg et al,  1989).  Only two metabolites (a lactam conjugate) of vigabatrin have 
been  detected  in  the urine  of man  and these  represent  less  than  5%  of the  total 
vigabatrin dose (Durham et al, 1993).
1.4.1.4  Neuropharmacokinetics
Jung  and  his  colleges  were  the  first  time  to  investigate  vigabatrin 
concentration  in  the  mouse  brain  (1977).  Vigabatrin  rapidly  entered  the  brain 
following  I.P.  administration.  The  peak plasma  concentrations  of vigabatrin  were 
reached (30 ±1.4  pg/g) within one hour, concentrations then declined according to 
first order kinetics.  The half-life of vigabatrin in the brain was 16-17 hours and it was 
still detectable 3 days late.  Bemasconi et al (1988) also showed the Tm ax of vigabatrin 
in rat CSF and the brain were achieved within 0.8 and 1  hour respectively.
The neuropharmacokinetics of vigabatrin in patients have only been studied 
in the CSF.  An early study was carried out by Grove et al (1981).  Patients with
54Chapter 1  Introduction
various neurologic conditions received vigabatrin 0.5,  1,  2  or 6  g daily for 3  days. 
CSF  concentrations  of  vigabatrin  increased  in  a  dose-response  manner.  Ben- 
Menachem  (1989)  reported that vigabatrin readily entered the  CNS  of patient with 
epilepsy,  CSF  concentrations  of vigabatrin  was  approximately  10-15  %  of blood 
concentration.  Maximum vigabatrin concentration (11.5pmol/L) in CSF occurred at 
6  hours  after oral  ingestion  of  50  mg/kg  vigabatrin  (Ben-Menachem  et  al,  1988). 
Patients  given repeated doses  of vigabatrin  exhibited  substantial  variability in  CSF 
vigabatrin concentrations at 24 hours post-dose.  Vigabatrin was not detectable at 72 
hours (Ben-Menachem et al, 1989).
1.4.1.5  Effect on amino acids 
GABA
Vigabatrin increases brain GABA concentrations by inhibiting GABA-T at 
presynaptic neurones (see Figure  1.8).  June et al (1977) was the first to investigate 
this effect in a mouse model.  Vigabatrin  1500mg/kg was administered by I.P., and 
whole  mice  brain  GABA  concentration  was  increased  following  a  decrease  in 
GABA-T.
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Figure  1.8:  Synthesis,  release,  action  at  the  GABAa  receptor,  and  re­
uptake  of  GABA  after  vigabatrin  administration.  Vigabatrin  acts  by 
destroying GABA-T, the enzyme responsible for the breakdown of GABA.
The resultant increased in GABA available for release into the synaptic cleft 
increases the probability of binding to GABAa receptor
The  effect  of  vigabatrtin  on  extracellular  GABA  content  was  also 
investigated  by microdialysis  (Sayin  et  al,  1995).  It  was  observed  that  vigabatrin 
administration induced a 4-6-fold increase in the extracellular content of GABA after 
lOOOmg/kg  administration.  This  increase  lasted  for  at  lease  72  hours.  In  the 
hippocampus,  GABA  concentration  was  monitored  in  rat  after  two  doses  of 
vigabatrin (1.6 and 8.0 mM) perfusion via the microdialysis probes .  It was observed 
that  vigabatrin  caused  a  transient  increase  in  the  basal  GABA  outflow  (10  fold) 
during the period of drug perfusion.  The immediate increase of GABA outflow after 
vigabatrin may be due to a direct blockade of GABA uptake sites.  These findings
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indicated that the action of GABA transaminase inhibitors may be mediated in part 
through GABA uptake inhibition (Jolkkonen et al, 1992)
Human  studies  showed  that  the  total  GABA  concentrations  in  CSF  were 
significantly increased after vigabatrin administration (Riekkinen et al, 1989a, b; Ben- 
Menachem  et  al,  1989,  1991  &  1993).  Using  serial  in  vivo  NMRS,  Petroff & 
Rothman  (1998)  studied  25  patients  undergoing  treatment  for  intractable  epilepsy 
with vigabatrin.  Their data suggested that brain GABA levels increased to  178% of 
pre-treatment  with  lg  vigabatrin  and  increased  to  226%  with  3g  vigabatrin.  The 
fractional  elevation of brain GABA with vigabatrin  doses  were  similar to  the CSF 
GABA  increase  suggesting  a  proportional  relationship  between  intracellular  and 
extracellular GABA concentrations.
The  increase  in  GABA  release  after  GABA-T  inhibition  has  been  now 
attributed  to  a  Ca++-independent  process  mediated  through  the  reversal  in  the 
direction of GABA transports (Wu et al, 2001, 2003).  Extracellular GABA depends 
on  that  of intracellular  GABA,  the  elevated  intracellular  GABA  due  to  GABA-T 
inhibition  would  generate  a  condition  allowing  for  an  increase  in  the  reversal  of 
GABA transporters, leading to increased transport-mediated GABA release (Chen et 
al, 2005).
Glycine
The  potential  anticonvulsant  effect  of glycine  have  been  reported  in  two 
generalized convulsive models early (Toth et al,  1983).  In these models, vigabatrin 
and  glycine  was  administered  in  combination  and  seizures  were  suppressed.  The
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results  showed  that  when  glycine  was  given  alone,  it  provided  partial  protection 
against convulsive seizures.  While the treatment of glycine combined with vigabatrin 
significantly suppressed seizures and enhanced the aggravating effect of vigabatrin on 
spontaneous spike and wave discharges in these models.
In  epileptic  patients,  Pitkanen  et  al  (1988)  showed  that  glycine 
concentrations  in CSF were increased by  128%  after vigabatrin administration, but 
they  suggest  that  this  effect  was  not  necessarily  related  to  the  clinical  response. 
Glycine  concentration  was  also  significantly  increased  in  epileptogenic  cerebral 
cortex.  These patients exhibited a two-fold increase in mean glycine concentrations 
after vigabatrin treatment (Sherwin, 1999).
Homocarnosine
Vigabatrin  increase  in  central  homocarnosine  concentrations  in both brain 
and CSF have been reported in many studies in animal models (Bohlem et al,  1980; 
Palfreyman  et  al,  1980,  1983;  Halonen et  al,  1990).  Total  conjugated  GABA  and 
homocarnosine elevation parallel the free GABA increase in CSF and they occur in 
relatively high  concentrations  and  can be  assayed  more  easily than  free  GABA  in 
human CSF.  Therefore, measuring conjugated GABA and homocarnosine were more 
reliable  clinical  indicators  of brain  free  GABA  concentration  (Pikanen  et  al,  1988; 
Petroff et al, 1999).
In patients treated with vigabatrin,  a dose-related increase in both free and 
total GABA and homocarnosine concentrations in the CSF has been observed (Grove 
et  al,  1981;  Schechter  et  al,  1984;  Pitkanen  et  al,  1988;  Ben-Menachem,  1989;
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Rothman et al,  1993; Mattson et al,  1994).  Analysis of amino acid content of brain 
tissue from a patient who underwent left side temporal lobectomy after treatment with 
vigabatrin  for  3-5  years,  revealed  a  three-fold  increase  in  total,  free  GABA  and 
homocarnosine (Pitkanen et al, 1988; Halonen et al, 1988; Riekkinen et al, 1988).
NMRS  studies  also  showed  that  homocarnosine  and  vigabatrin  increased 
linearly  with  daily  vigabatrin  administration  and  seizure  control  improved  with 
increasing  CSF  homocarnosine  concentrations  (Petroff  et  al,  1998  b  and  1999; 
Simister et al, 2003).  Daily low-dose (2g) vigabatrin increased both homocarnosine 
and  GABA,  and  seizure  control  was  associated  with  the  higher  homocarnosine 
concentrations.  GABA and homocarnosine concentrations increased in proportion to 
a daily vigabatim dose (Petroff et al,  1999).  Similarly, CSF observed from patients 
with epilepsy showed that homocarnosine and vigabatrin increased linearly and that 
seizure control improved with increasing CSF homocarnosine (Petroff et al,  1998a). 
They gave a single oral dose of vigabatrin and the rate of GABA synthesis in human 
brain was estimated at  17% of the Krebs cycle rate.  As the daily dose of vigabatrin 
was  increased up  to  3g,  the  fractional  elevation of brain GABA was  similar to the 
increase  seen  in  CSF.  Two  important  relationships  were  proposed  by  them.  1), 
Elevated CSF GABA and homocarnosine concentrations are an index of high brain 
GABA concentrations.  2),  Elevated CSF and brain GABA and homocarnosine were 
associated  with  improved  seizure  control  and  that  homocarnosine  may  serve  as 
storage  form  of  GABA,  helping  the  GABAergic  neurones  control  GABA 
concentration.
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Glutamate and other amino acids
Vigabatrin  has  been  reported  to  affect  the  concentrations  of  other 
neurotransmitters.  However,  the changes  in glutamate,  glutamine  and other amino 
acids  are  somewhat  controversial.  Glutamate,  glutamine,  aspartate  and  alanine 
concentrations  decreased  and  lysine  concentration  increased  in  cortical  tissue  after 
vigabatrin administration ( Bemasconi et al,  1988).  A dose-dependent decrease in rat 
whole brain tissue concentration of glutamate after I.P. vigabatrin administration has 
been  described  (Halonen  et  al,  1991;  Smolders  et  al,  1997).  After  21  days  of 
150mg/kg  vigabatrin  administration,  glutamate  concentration  was  also  reduced  in 
different  areas  of rat  brain  (Waniewski  &  Martin,  1995).  Furthermore,  vigabatrin 
caused  a decrease in the brain content of the excitatory amino  acids  glutamate and 
increase GABA was reported in a microdialysis  study (Benturquia et al, 2004).  In 
contrast, Halonen et al (1990) reported that elevation of glycine and taurine content 
coincided with peak level of vigabatrin in rat brain.  Glutamate concentrations were 
also increased but the increase occurred somewhat late when the effect of vigabatrin 
on  GABAergic  transmission  had  markedly  diminished.  However,  glutamine, 
aspartate and taurine concentration were reported as unaffected.
A  decrease  in  CSF  glutamate  concentrations  has  been  described  in  the 
patients  receiving vigabatrin as monotherapy (Kalviainen  et  al,  1993).  Using  []H] 
NMR spectroscopy with vigabatrin at dose of 3-6 g/day, glutamate decreased by 9% 
in a group  of 14 patients with epilepsy (Petroff et al,  1995).  These changes  could 
already be detected in brain tissue at 2-5 hours after administration of vigabatrin.  The 
concentration of glutamine in human CSF decreased significantly after a single dose
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of vigabatrin (Ben-Menachem,  1989).  However, some studies indicated that glycine, 
glutamate,  glutamine,  aspartate,  asparagines  and  taurine  concentrations  did  not 
change in patient CSF (Pikanen et al, 1988; Halonene et al, 1988).
1.4.2  Levetiracetam
Levetiracetam  (Keppra  ™,  ucb  L059),  (S)  -a-ethyl-2-oxo-pyrrolidine 
acetamide)  is  a  novel  drug  which  not  only  has  potent  anticonvulsant  properties 
(Gower  et  al,  1995;  Margineanu  & Wulfert,  1997;  Loscher et  al,  1998),  but also 
displays  a highly favourable therapeutic  index.  Adverse  effects  in  animal  models 
were minimal with mild sedation and muscle relaxation occurring at doses 50 to 100- 
fold  higher  than  those  associated  with  seizure  protection  (Gower  et  al,  1992; 
Klitgaard et al, 1998).
In humans, levetiracetam has been observed to possess significant efficacy, 
good tolerability and a desirable therapeutic index (Kasteleijn-nolst et al, 1996;  Betts 
et al, 2000; Cereghino et al, 2000, Welty et al, 2002).  It has recently been licensed 
for use as add-on therapy in patients with intractable partial epilepsy.
1.4.2.1  Chemistry
Levetiracetam,  is  the  S-enantiomer  of the  ethyl  analogue  of piracetam,  a 
widely used  nootropic  agent  (Loscher  &  Schmidt,  1993).  Its  molecular weight  is 
170.21  and  chemical  structure  is  shown  in  Figure  1.9.  Levetiracetam  is  highly 
soluble  in  water  (104.0g/100mL).  Only  the  S-enantiomer  of  levetiracetam  has 
anticonvulsant effects.
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Figure 1.9:  Chemical structure of levetiracetam (Patsalos, 2000)
1.4.2.2  Pharmacology 
Mechanism of action
The  precise mechanism  of action  of levetiratetam  is  not  fully understood. 
Its  action  is  independent  of excitatory  and  inhibitory  neuronal  pathways  (Nash  & 
Sangha, 2001), and it failed to interact with classical receptors and ion channel sites 
in the brain (Noyer et al, 1995).
Recently it was shown that levetiracetam binds to  SV2A, opening the new 
field of drugs acting on vesicle exocytosis (Lynch et al, 2004).  SV2A is enriched in 
synaptic vesicles and has an apparent molecular mass of -  90 kDa.  Brain membranes 
and purified synaptic vesicles from mice lacking SV2A did not bind a levetiracetam 
derivative, indicating that SV2A is necessary for levetiracetam binding.  There was 
also strong correlation between the affinity of a compound for SV2A and its ability to 
protect  against  seizures  in  an  audiogenic  mouse  animal  model  of epilepsy.  The 
experimental  results  suggest that  SV2A is  the binding  site  for levetiracetam  in the 
brain.
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In  brain  synapses,  nitric  oxide  (NO)  synthase  activation  is  coupled  to 
NMDA-mediated calcium entry at postsynaptic densities through regulatory protein 
complexes, and NMD  A/NO inhibit the release of pre-synaptic glutamate (Sequeira et 
al,  2001).  The  inhibitory  retrograde  action  of  postsynaptic  NO  on  presynaptic 
terminals (Micheva et al, 2001) could contribute also to the effects of levetiracetam. 
The results (Dagonnier et al, 2005) confirm that NO should be considered as one of 
the  key  mediators  involved  in  the  effects  of this  growingly  used  medication  for 
neurological disorders, including epilepsy.  Madeja et al (2003) have suggested that 
the antiepileptic properties of levetiracetam may be substantially contributed to by a 
reduction  in  the  conductance  of  delayed  rectifier  K+  channels.  This  study 
demonstrated  using  acute  isolate  rat  and  guinea  pig  CA1  neurones  by  whole  cell 
patch  clamp  technique,  that  a 26% reduction  in the  delayed rectifier K+  current  is 
produced by lOOpM levetiracetam. (Madeja et al, 2003).
Anticonvulsant action in seizure models
Various rodent models were used for testing the anticonvulsant efficacy of 
levetiracetam in vivo.  Levetiracetam lacks anticonvulsant activity in both MES and 
PTZ  tests  in  rodents  (Klitgaard  et  al,  1998).  Other  seizure  paradigms  in  rodents 
involving  threshold  tests  (Loscher,  1993)  have  shown  only  a  weak  anticonvulsant 
activity by levetiracetam (Gower et al, 1992).
However,  levetiracetam is associated with a very potent protection against 
seizures in spontaneously epileptic rat (SER).  The tonic convulsions and absence-like 
seizures in SERs were induced and the seizure activities were inhibited by 80,  160 
mg/kg single dose of levetiracetem.  When the drug was repeatedly administered at
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80mg/kg  for  5  days  to  SERs,  the  inhibitory  effects  on  seizures  increased  with 
administration  time.  This  long-lasting  treatment  effect  of  levetiracetam  was  not 
shared with other AEDs (Ji-qun et al, 2005).  The long -lasting anti-seizure effects of 
levetiracetam  have been  also  observed  in  SER in  another  study  (Yan  et  al,  2005). 
Furthermore, seizure activity expression was prevented in both audiogenic susceptible 
mice.  In contrast, other new AEDs are not so effective against these types of seizures 
(Leppik, 2001).
Anticonvulsant action in epileptic patients
The efficacy of levetiracetam as add on therapy has been assessed in partial 
seizure with refractory epilepsy.  Three groups were tested in 904 patients (Shorvon 
& Rijckevorsel, 2002). The percentage reduction of seizure from baseline was 32.5 % 
for patient receiving levetiracetam treatment compared with 7% for patient’s receving 
placebo.  Cereghino and colleagues (2000) concluded that levetiracetam was effective 
and well  tolerated  as  adjunctive  therapy  for partial-onset  seizures,  with  or without 
secondary generalization.  There are some indications that the drug would be useful in 
a  wider  range  of  seizure  types  and  syndromes,  these  include  SE  (Rossetti  & 
Bromfield,  2005),  refractory  epilepsy  (Mohanraj  et  al,  2005;  French  et  al,  2005), 
myoclonus  (Lim  &  Ahmed,  2005)  and  different  types  of  epilepsy  in  children 
(Vigevano,  2005;  Mandelbaum  et  al,  2005).  Levetiracetam  has  also  been  used  as 
monotherapy  for treating  seizures.  Alsaadi  et  al  (2005)  investigated  levetiracetam 
monotherapy  in.  46  patients  with  a  history  of partial  seizures  with  and  without 
secondarily generalization.  Thirty-five patients have completed the study for a year. 
At  the  follow-up,  nineteen  of the  35  patients  (54  %)  were  seizure  free  for past  6
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months.  Four patients (11.4%) had > 75% reduction in seizure frequency and nine 
patients  had  seizure  reduction  >  50%.  This  study  suggests  that  levetiracetam  as 
monotherapy can be effective and well tolerated in newly diagnosed epilepsy patients 
as  well  as  for  chronic  epilepsy  patients  who  failed  multiple  AEDs  prior  to 
levetiracetam treatment.
1.4.2.3.  Pharmacokinetics
The pharmacokinetic profile of levetiracetam has been determined in a rat 
(Doheny et al,  1999),  a dog (Isoherranen et al, 2001)  and healthy volunteer studies 
(Shorvon  & van Rijckevorsel,  2001;  Nash  &  Sangha,  2001).  Table  1.4  shows the 
pharmacokinetic  parameters  of  levetiracetam  following  oral  administration  in 
patients.
Table  1.4:  Pharmacokinetic  profile  of  levetiracetam  in  humans  following  oral
administration
Parameters Effect
Absorption Rapidly and completely (> 95%)
Jmax  1.3 hr
Food: rate of absorption slowed by 1.5 hr
Distribution
Dose linearity linear
Time to plasma steady-state Approximately 48 hr
Plasma protein binding 0 %
Volume of distribution 0.5-0.7 L/kg
Elimination
Half-life Adults, 6 - 8  hr; elderly, 10-11 hr;
Children, 6 hr.
Metabolite In urine:  6 6 % as parent drug,
24% as UcbL057
(Nash & Sangha,2001; Patsalos 2003 & 2004)
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Absorption
In the rat, levetiracetam rapidly appears in serum after I.P. administration at 
three doses (20, 40 and 80mg/kg).  The concentration of levetiracetam rose linearly 
and  dose-dependently,  with  mean  peak  concentration  being  achieved  at  0.25-0.5 
hours  after  levetiracetam  administration  (Doheny  et  al,  1999).  In  the  dog, 
levetiracatam  also  quickly  entered  the  plasma  compartment  and  was  detectable  at 
time  of first  sampling  after  I.V.  administration  of 20mg/kg  levetiracetam.  Plasma 
Cmax values were  100 and 40 mg/L for S-enantiomer and R-enaltiomer respectively 
(Isoherranen et al, 2001).
In patients, levetiracetam is rapidly and almost completely (> 95%) absorbed 
following  oral  administration  of doses  ranging  from  250  to  5000  mg.  Maximum 
plasma concentration of levetiracetam  generally  occurred  within  1   hour.  Absolute 
oral bioavailability was nearly 100% (Patsalos, 2000).  Following oral ingestion, peak 
plasma  concentrations  (Cmax)  were  achieved  within  1  hour  and  then  declined  to 
baseline within 48 hours.  Following a single  1000 mg levetiracetam daily dose and 
repeated  1 0 0 0   mg  twice  daily doses,  Cm ax  values  were  typically  31  and  43pg/mL, 
respectively.  In healthy volunteers, Cm ax and the AUC values displayed dose linearity 
in the  range  of 500-5000 mg.  Steady-state  concentrations  were  generally  attained 
after  2  days  of  repeated  twice-daily  dosing.  In  multiple  dose-ranging  studies, 
levetiracetam  exhibits  predictable,  linear,  and  dose-proportional  steady-state 
pharmacokinetics.  Levetiracetam was not affected by food in a study of 20 healthy 
male volunteers (Patsalos, 2000 & 2003).
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Distribution
In the rat the  Vd of levetiracetam is 0.5-0.7 L/kg (Doheny et al,  1999).  In 
the dog, the  Fds of levetiracetam were calculated to be 0.45 ± 0.13L/kg and 0.51  ±
0.11  respectively for S- and ^-enantiomers after I.V. administration of levetiracetam 
(Isoherranen  et  al,  2001).  Distribution  studies  in  the  rat,  mouse,  rabbit  and  dog, 
showed that levetiracetam was rapidly distributed in tissue, with high concentrations 
occurring in blood and kidneys and with lower concentrations in the lens and adipose 
tissue (Patsalos, 2003).
Although tissue distribution data in humans are not available, levetiracetam 
is  not  bound  to  plasma  protein.  Thus,  the  risk  for  protein-binding  displacement 
interactions being clinically significant is negligible.
Elimination and metabolism
The major route of excretion for levetiracetam is through urine.  In rat 
models,  levetiracetam elimination tm values  are  1.8-3.0 hours (Loscher et al,  1998; 
Doheny et al, 1999), whilst in the dog tm values are 3.6-4.3 hours.  Cl  values for dog 
are 1.5 ml/min/kg (Isoherranen et al, 2001).
In healthy young volunteers, the elimination tm of levetiracetam was 6 to  8  
hours,  allowing  a  twice-daily  dosing  regimen  (Patsalos  et  al,  2000;  Perucca  et  al,
2003).  Importantly, the elimination tm of levetiracetam was increased to 10-11 hours 
in elderly patients, and also was increased in patients with renal impairment (Patsalos,
2004).
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Sixty-six percent of the administered dose is eliminated unchanged and 24% 
is excreted in urine as inactive metabolites (Patsalos, 2004).  Excretion via the faecal 
route  accounts  for  only  0.3%  of the  administered  dose.  Levetiracetam  is  cleared 
fairly  rapidly,  with  93%  of  drug  excreted  within  48  hours  following  oral 
administration.  Renal clearance of levetiracetam occurs at a rate of 40ml/min/1.73 m2 
(0 .6  ml/min/kg), which indicates excretion of levetiracetam by glomerular filtration 
and  partial  subsequent  tubular  re-absorption  (Patsalos,  2000).  Levetiracetam  is 
metabolised by enzymatic hydrolysis of the acetamide group to one major metabolite, 
ucb L057; two minor metabolites have also been isolated (Nash & Sangha, 2001).
Drug-drug  interaction
Evidence  of the  lack  of significant  influence  of levetiracetam  on  the  serum 
concentration of concurrently administered drugs  is by the results of formal interaction 
studies  in  vitro  and  human.  In  vitro,  levetiracetam,  tested  at  therapeutically relevant 
concentrations,  has been shown not to inhibit a variety of drug metabolizing enzymes, 
including  cytochrome  CYPs  (Patsalos,  2000).  In  human,  levetiracetam  does  not 
significantly  affect  steady-state  serum  concentrations  of  concomitantly  administered 
carbamazepine,  phenytoin,  valproic  acid,  lamatrigine,  gabapentin,  phenobarbital,  or 
primidone (Gidal et al, 2005).  Levetiracetam was also equally found not to affect the 
pharmacokinetic profiles of digoxin (Levy et al, 2001),  S-warfarin (Ragueneau-Majlessi 
et al, 2001), and steroid oral contraceptives (Ragueneau-Majlessi et al, 2001).
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1.4.2.4  Neuropharmacokinetics
Although brain tissue distribution data in humans are not available, studies 
conducted  in  rats  indicate  that  levetiracetam  readily  crossed  the  BBB  and  rapidly 
enters CSF (Doheny et al,  1999).  r m ax values for the CSF compartment were  1.3 -  
1.9  hours.  The  dose-dependent  increased  levetiracetam  in  serum  and  CSF 
concentrations after levetiracetam administration (20, 40 and 80 mg/kg), suggest that 
transport across the BBB is not rate limiting over the concentration range observed 
(Doheny et al,  1999).  The efflux  of levetiracetam  from the CSF compartment was 
significantly slower (mean 0 /2 4.4 to 4.9 hours) than that from serum (mean 0 /2  1.8 to 
2.8 hours), and confirms similar observations with some other AEDs (Sokomba et al, 
1988; Semba et al, 1993; Lolin et al, 1994; Walker et al, 1998).
1.4.2.5  Effect on amino acids
Whilst there were only a few reports of the effect of levetiracetam on amino 
acids  in  animal  models,  there  are  no  studies  describing  such  effects  in  humans. 
Margineanu  &  Wulfert  (1997)  have  confirmed  that  there  was  no  direct  effect  of 
levetiracetam  on  GABA  receptor  or brain  GABA  concentrations.  Using  classical 
labelled  amino  acids  as  radioligands  to  assess  the  binding  sites  of levetiracetam, 
Noyer et al (1995) showed no significant affinity by levetiracetam for known GABA, 
benzodiazepine  or  various  excitatory  amino  acid-related  receptors.  Gower  et  al 
(1994)  have  confirmed  that  levetiracetam  did  not  directly  interact  with  the 
benzodiazepine-GABA ionophore.  Furthermore, levetiracetam failed to influence the 
concentration  of GABA,  glutamate  and  glutamine  in  mouse  brain  following  both 
single  and  repeated  administrations  of levetiracetam.  These  results  suggest  that
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levetiracetam  does  not  have  any  direct  effect  on  GABA  metabolism  nor  does  it 
interact with GABA receptors (Welty et al, 2002).  Another study (Rigo et al, 2000) 
evaluating the effect of levetiracetam on GABA- and glycine-gated neuronal currents, 
showed  that  levetiracetam  was  devoid  of any  effects.  In  contrast  to  other AEDs, 
minimal effects were observed on GABA-gated neuronal currents and levetiracetam 
had no effects on glutamate (Hans et al, 2000; Sills et al, 1997).
1.5  INTRACEREBRAL MICRODIALYSIS
1.5.1  Introduction
Microdialysis was originally developed as a technique to obtain information 
about the concentration of endogenous compounds in brain ECF (Fenstermacher et al, 
1981).  After  several  decades,  the  technique  of microdialysis  has  been  improved 
greatly and it is now widely used for investigating drug concentrations, transporters, 
amino  acids  and neurotransmitters in different tissues  and  organs,  especially in the 
brain. (Reddy, 1998; Khan et al, 1999; Potschka et al, 2002 and 2004).
1.5.2  Principle of microdialysis
The  microdialysis  technique  employs  dialysis  principle,  in  which  a 
membrane, permeable to water and small solutes, is introduced into the tissue.  The 
key  elements  in  microdialysis  are  the  dialysis  probe,  connective  tubing,  perfusion 
medium, prefusion pump and sample collection device (Figure 1.10).  The basic tool 
for microdialysis sampling is a semipermeable dialysis membrane in a microdialysis 
probe (Figure 1.11).
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Figure  1.10:  Schematic diagram of a basic microdialysis system consisting 
of syringe pump for perfusate delivery,  microdialysis probe,  and connective 
tubing.
Perfused
Dialysis
membrane
Figure  1.11:  Illustration of the microdialysis probe with perfusion tube,
sampling tube and dialysis membrane.
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The probe is inserted into tissue and is  perfused with a medium (artificial 
CSF) by the pump.  The solutes are transported  across the membrane by diffusion. 
The  diffusion  coefficient  (e.g.  the  concentration  gradients  between  the  solution 
outside probe  and  the perfusion)  dictates  the  migrations  of the  solutes.  It  usually 
permits  free  diffusion  of  5-30  kD  molecules,  but  resists  the  transport  of  large 
molecules such as proteins and other macromolecules.  The dialysate travels between 
the inner and outer cannulae into the outlet tubing and then into the sample collector. 
Importantly the BBB should be intact shortly after implantation of the probe, so that 
samples can be collected from ECF with a continuous perfusion.  Therefore, it is a 
suitable  method  for  studying  of amino  acids  and  drug  concentrations  in  the  brain 
tissues of animal models and human.
Pharmacokinetic  profiles  can  be  obtained  in  normal  brain  as  well  as  in 
affected or diseased brain sites, for example, in brain tumours.  Substances around the 
semipermeable part of the probe will also diffuse into or out of the perfusate, in the 
direction  of the  lowest  concentration.  Subsequently  the  dialysate  is  collected  for 
analysis.  This technique has a number of advantages:  (1)  Concentration versus time 
profiles  can  be  obtained  from  individual  animals;  (2)  Concentrations  can  be 
determined in a specific region;  (3)  Dialysate samples permits measurement of drug 
concentrations  by  virtually  every  analytical  technique,  which  contributes  to  the 
selectivity and sensitivity;  (4)  The dialysis provides protein free samples so clean up 
procedures can be avoided and potential ex vivo enzymatic degradation is eliminated; 
(5)  The  dialysate  samples  can be measured  for  drug  and amino acid content at the 
same time and thus studies of drug mechanisms can be undertaken.
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1.5.3  Neuropharmacokinetic studies of new AEDs using microdialysis
In animal studies, the microdialysis  technique has been used to investigate 
the neuropharmacokinetics of a variety of new AEDs including felbamate (Potschka 
et al, 2002 & 2003), gabapentin  (Welty et al,  1993; Wang & Welty, 1996; Rada et al, 
1998;  Luer  et  al,  1999;  Timmerman  et  al,  2000),  pregabalin  (Feng  et  al,  2001), 
topiramate  (Masucci  et  al,  1998),  lamotrigine  (Walker  et  al,  2000;  Potschka et  al, 
2002  &  2003;  Ahmad  et  al,  2005),  levetiracetam  (Potschka  et  al,  2004)  and 
oxcarbazepine (Van Belle et al, 1995; Clinckers et al, 2005).
Potschka  et  al  (2 0 0 2 &  2003)  reported  that  P-Glycoprotein  (Pgp,  multiple 
drug  transport)  and  multidrug  resistance  protein,  ABCC2,  -mediate  efflux  of 
felbamate  and  lamotrigine  at  BBB  from  rat  frontal  cortex.  In  these  experiments 
verapamil,  a PGP  inhibitor, was prefused into  the frontal cortex via a microdialysis 
probe  and microdialysate  felbamate  and  lamotrigine concentrations were measured. 
It was observed that both felbamate  and lamotrigine concentrations were increased, 
and  therefore  Pgp  in  brain  tissue  is  likely  to  limit  brain  access  of felbamate  and 
lamotrigine.  This mechanism may play a crucial role  in the phenomenon of drug- 
refractory  epilepsy  (Potschka  et  al,  2002).  Interestingly,  there  were no  significant 
differences in felbamate and lamotrigine concentrations in ECF between nonmutant 
rats  and  ABCC2-deficient  TR  rats,  which  suggest  that  ABCC2  does  not  affect 
modulate  felbamate  and  lamotrigine  entry  into  brain  (Potschka  et  al,  2003).  In  a 
further study,  Potschka et al  (2004) reported that ECF  levetiracetam concentrations 
were unaffected by  administration  of a  variety  of  multidrug  transporter  (Pgp  or 
MRP 1/2)  protein inhibitors.
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The  concentration versus time profiles  of gabapentin  in plasma  and brain 
were determined following a single 15mg/kg intravenous bolus dose of rats (Welty et 
al,  1993).  E C F   gabapentin  concentrations  were  observed  to  be  only  3-6%  of the 
plasma concentrations and that the anticonvulsant effect of gabapentin was delayed 
by time-dependent  events  other than distribution  from blood to brain (Welty et al, 
1993).  Wang and Welty (1996) reported on the influx and efflux BBB permeabilities 
of gabapentin using a microdialysis pharmacokinetic approach.  They observed that 
the total brain tissue concentration of gabapentin was significantly higher than these 
in the  E C F .   Thus  it would  appear that  gabapentin  accumulated  in  intracellular or 
bounded  to  brain  tissue.  Using  microdialysis  techniques,  Luer  et  al  (1999) 
determined  gabapentin  concentrations  in  the  brain  E C F ;   these  coincided  with 
proportional changes in plasma concentrations.  The ratios of AUCecf to  A U C p iaSm a  
and brain  E C F   to plasma gabapentin concentration for each collection interval were 
determined  to provide indicators  of the relative  amount  of gabapentin  crossing the 
BBB.  Although higher AUCecf values were obtained with higher A U C p iaS m a   values, 
changes  in  AUCecf were  less  than proportional  to  observed  changes  in  AUCpiaS m a. 
BBB  saturation of gabapentin transport was evident as the A UCecf ratio decreased 
with increased  A U C p ia s m a   ratio.  These result  support the carrier-mediated transport 
mechanism of gabapentin through the BBB.
The  rate  of  brain  penetration  of  lamotrigine  and  topiramate  were  also 
investigated by microdialysis in a rat model (Walker et al, 2000; Masucci et al, 1998). 
Using  in  vivo  recovery  corrected  microdialysis  in  the  frontal  cortex  and  the 
hippocampus, the calculated penetration rate of lamotrigine was observed to be not 
significantly different from that for CSF (Walker et al, 2000).  The concentrations of
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lamotrigine in ECF were similar to those for CSF, but concentrations of lamotrigine 
in  plasma were  much  higher than  that  found  in  the  ECF  and  CSF.  Furthermore, 
lamotrigine concentrations in the hippocampus were higher than those in the frontal 
cortex.  Using  in  vivo  microdialysis,  the neuropharmacokinetics  of topiramate was 
studied by Masucci  et  al  (1998)  who reported that the  Cm ax  of topiramate  in brain 
ECF was approximately  lOpM and the  Tm ax occurred at 45  minutes post topiramate 
(50mg/kg) i.v. administration.
In  human  neuropharmacokinetic  studies,  Alves  et  al  (2003)  used 
intracerebral microdialysis to provide a safe and efficient tool for continuous in vivo 
evaluation of the bioavailability and efficacy of topiramate.  Topiramate crossed the 
BBB  at concentrations that may be neuroprotective,  and  could modulate  glutamate 
concentrations.  In  a  single  patient  with  drug-resistant  partial  epilepsy  study 
(Lindberger et al,  1999), topiramate concentrations were measured in three different 
compartments (brain ECF, CSF and plasma).  The mean of ECF/CSF topiramate ratio 
was  0.93  and  protein  bounding  of topiramate  in  plasma  was  approximately  13%. 
Topiramate concentrations in the CSF were approximately the same as the unbound 
plasma concentrations.
At  present,  microdialysis  is  becoming  an  increasingly  useful  tool  for 
monitoring  AED  concentrations  in  the  brains  of  patient  that  are  undergoing 
investigation for possible brain surgery for the treatment of their epilepsy (Lindberger 
et al, 1998 & 2001; Hammarlund-Udenaes, 2000).
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1.5.4  Amino acid studies of new AEDs using microdialysis
Introduction
As  highlighted  earlier,  microdialysis  can  assess  mechanisms  and 
pharmacodynamic actions of AEDs.  Most studies in this respect were undertaken in 
animal models and relate to AEDs that have GABAergic mechanisms.  Jolkkonen et 
al (1992) first investigated the acute effect of vigabatrin on the GABAergic system in 
a rat model by using microdialysis.  They perfused vigabatrin via the microdialysis 
probe and found the immediate increase of GABA outflow, which suggested that the 
result may be due to the direct blockade of GABA uptake sites and concluded that 
GABA-T inhibitors may be mediated partly through GABA uptake inhibition.  In the 
limbic  seizure  model,  GABA,  glutamate  and  dopamine  concentrations  in  the 
hippocampus were studied.  5 mM vigabatrin was perfused into rat hippocampus via a 
microdialysis probe  and it was observed that GABA concentrations were increased 
and glutamate and dopamine concentrations were decreased (Smolders et al, 1997).
The effect of topiramate on excitatory amino acids were investigated using 
in vivo microdialysis in hippocampus (Kanda et al, 1996).  Topiramate (40mg/kg I.P.) 
reduced  both  glutamate  and  aspartate  concentrations  in  the  hippocampus  of SER. 
Lamotrigine  and  oxcarbazepine  also  inhibited  extracellular glutamate  and  aspartate 
levels in different animal models (Waldmeier et al,  1996; Bacher & Zomow,  1997). 
The results  showed that  lamotrigine and oxcarbazepine were  effective in inhibiting 
extracellular  glutamate  which  might  explain  the  neuroprotective  properties  of 
lamotrigine and oxcarbazepine.
To gain insight into the mechanism of action of the AEDs gabapentin, the
effects  of gabapentin  on  the  in  vivo  ECF  GABA  concentration  in  rat  brain  were
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studied using microdialysis.  Gabapentin was studied under basal, K+, nipecotic acid 
and glutamate-stimulated conditions.  Gabapentin administered at a dose of lOOmg/kg 
that did not have any significantly effect on ECF GABA concentrations, regardless of 
experimental conditions (Timmerman et al, 2000).  A study was also carried on the 
effect of gabapentin on spinal cord amino acid release (Feng et al, 2003).  Gabapentin 
was  administered  at  various  doses  (50,  100,  or  200  mg/kg)  and  dialysate  was 
collected  from  the  spinal  subarachnoid  space.  It  was  observed  that  gabapentin 
effectively inhibited the acetic acid evoked release of excitatory amino  acids in the 
spinal cord.
The effects of combined lamotrigine and valproate on ECF amino acids with 
different  drug  concentrations  were  investigated  in  rat  microdialysis  (Ahmad  et  al,
2005).  Lamotrigine (lOmg/kg) and valproate (300mg/kg) did not significantly alter 
basal  levels  of aspirate,  glutamate  or taurine  concentration  when  they were  given 
alone.  However,  the  two  drug  administered  together  significantly  reduced  ECF 
aspartate and glutamate concentrations while increasing taurine levels.  Additionally, 
only valproate  increased  ECF  GABA concentrations.  Pharmacokinetic profiles  in 
three  compartments  were  unchanged  after  co-administration  of  lamotrigine  and 
valproate.  These results suggest that the changes of the amino acids are unlikely due 
to  pharmacokinetic  contribution  and  probably pharmacodynamic  interaction  of the 
two drugs.
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1.6  PAIRED-PULSE INHIBITION
Introduction
1.6.1  Introduction
Paired-pulse  stimulation  is  well-suited  to  detect  excitability  changes  in 
hippocampal  pathways,  since  the  first  or  ‘conditioning’  stimulus  acts  to  recruit 
recurrent excitatory (Cronin et al, 1992) or inhibitory activity (Sloviter, 1991) in these 
pathways.
1.6.2  The mechanisms of paired pulse inhibition and hippocampus
One  of the  most  frequently  tested  sites  for  paired-pulse  inhibition  is  the 
dentate gyrus of the hippocampus.  In the hippocampus, neuronal population can be 
divided  into  two  broad  classes:  principal  neurones  that  are  excitatory  and  use 
glutamate  as  a  neurotransmitter  and  inter-neurones  which  are  inhibitory  and  use 
GABA as a neurotransmitter (Freund & Buzsaki,  1996).  In normal tissue, principal 
neurones, which represent 90% of the neuronal population,  are under the control of 
inter-neurones.  Alteration of the balance of inhibitory and  excitatory is one of the 
hypotheses  for  mechanisms  underlying  the  occurrence  of  epilepsy.  Paired-pulse 
inhibition reflects inhibition in the hippocampus
In the paired-pulse protocol, the first pulse delivered to the input pathway, 
activates intemeurons (feed forward inhibitions) and firing of the target neurons can 
also  recruit  intemeurons  (feed  back  inhibition).  The  second  pulse  will  then  be 
inhibited if the inter-pulse interval (IPI) falls within the period of recurrent or feed­
forward and feedback inhibitions (Figure 1.12).
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Figure  1.12: Paired-pulse inhibition in the perforant path  model of status 
epilepticus.  The pulse-interval was 20 ms.  A, the  first  pulse,  delivered  to 
the input pathway, activates cell discharge.  B, the second pulse, is inhibited 
via the feed-forward and feed-back inhibition.
Hippocampal  inhibition has  been  studied  extensively  using  field  potential 
recordings  and  paired-pulse  stimulation,  and  is  measured  by  the  inhibition  in  the 
second  (test)  population  spike  (PS)  and  excitatory  postsynaptic  potential  (EPSP) 
slope. This inhibition is mediated over short interpulse interval by GABAa receptors 
and by GABAb receptors over longer time intervals. (Figure 1.13).
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Figure  1.13:  Schematic diagram of mechanism of paired-pulse inhibition in 
hippocampus.
1.6.3  Paired-pulse inhibition  in epilepsy
Several studies have used the paired-pulse technique to monitor inhibition in 
the dentate gyrus during epilepsy in animal models (Sloviter,  1987; Sayin et al, 2003; 
Kobayashi  &  Buckmaster,  2003,  Naylor  &  Wasterlain,  2005).  An  early  study 
(Sloviter, 1987)  reported  a  decrease  in  paired-pulse  inhibition  in  the  dentate  gyrus 
following  induction of SE  by prolonged  periods  of electrical  stimulation.  Similar 
results  were  also  found  by  Haas  and  his  colleagues  (1996).  Sayin  et  al  (2003) 
reported that paired-pulse inhibition  in the  dentate  gyrus  was  reduced or  lost after 
approximately 90-100 evoked seizures in association with emergence of spontaneous 
seizures.  The loss of paired-pulse inhibition was accompanied by loss of subclasses 
of inhibitory  inter-neurones  labelled  by  cholecystokinin  and  the  neuronal  GABA 
transport  GAT-1.  These  indicated  that  seizure-induced  loss  of  inter-neurones
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providing the  inhibition could play an important role  in generation of spontaneous 
seizures.  Recent  studies  have  suggested  that  reduced  paired-pulse  inhibition  was 
likely the  consequence  of an interaction with  GABAb  autoreceptors  (Gloveli  et al, 
2003).  Repeated  stimuli  produce  a  decrease  in  inhibitory  postsynaptic  potential 
(IPSP) amplitude, which was produced to a large extent by activation of presynaptic 
GABAb  receptors  (Pitler  &  Alger,  1994;  Pearce  et  al,  1995;  Lambert  &  Wilson, 
1993).  In  a  SE  model,  loss  of paired-pulse  inhibition  occurs  after  brief 5  mins 
perforant-path stimulation in vitro and in vivo with the paired-pulse population spike 
amplitude  ratio  (P2 /P 1)  increasing.  After  perfusion  with  the  GABAa  antagonist, 
bicuculline, the ratio also increased from a baseline. These results suggest that loss of 
inhibition at GABA synapses may be an important early event in the initiation of SE 
(Naylor & Wasterlain, 2005).
Most studies of paired-pulse inhibition in the human are using hippocampal 
slices from temporal lobe epileptic patients (Urun et al,  1994 & 1995; Swanson et al, 
1998) and only a few in  vivo studies in human have been performed (Wilson et al, 
1998).  Uruno  et  al  (1995)  examined  brain  slices  from  temporal  lobe  epileptic 
patients.  Paired-pulse  depression  (PPD)  was  examined  using  perforant  path 
stimulation of low to moderated intensity at an inter-stimulus interval of 20ms.  The 
results are consistent with less or reduction of feedback inhibition by bicuculline and 
baclofen,  which  occurred paired-pulse  facilitation  in the  dentate  gyrus  of temporal 
lobe epileptic patients.  The data suggests the re-evaluation of the role of inhibition in 
epilepsy.  Swanson  et  al  (1998)  also  analyzed  paired-pulse  depression  in  dentate 
slices from 9 patients with temporal lobe epilepsy.  Their data showed that comparing 
feedback inhibition between human and rat tissue,  the human inhibition was much
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greater,  increased  in  amplitude  and  occurring  at  all  inter-stimulus  intervals.  This 
increased feedback inhibition could reflect species differences between rat and human 
dentate physiology, or be a unique feature of epileptic dentate.  Wilson et al (1998) 
used paired-pulse  stimulation to  investigate changes  in excitability in anaesthetized 
patients  with  temporal  lobe  epilepsy.  A  total  of 20  patients  with  temporal  lobe 
epilepsy  were  studied  during  chronic  depth  electrode  monitoring  for  seizure 
localization.  The  mean  paired-pulse  inhibition  was  significantly  greater  for 
epileptogenic perforant path response than for contralateral perforant path responses. 
The  results  suggest  that  enhanced  inhibition  may  be  homeostatic  mechanism  to 
inhibit  seizures  and  maintain  the  interictal  state,  ultimately  contributing  to  the 
characteristic of the epileptogenic hippocampus.
1.6.4  Paired-pulse inhibition and new AEDs.
Paired-pulse  stimulation  is  a  technique  that  is  largely  used  to  assess 
convulsant and anticonvulsat drugs for GABA inhibition (Stringer, 2000;  Stringer & 
Taylor, 2000).  In animal models, Xiong and Stringer (1997) investigated the effects 
of  three  new  AEDs,  felbamate,  lamotrigine  and  gabapentin  on  excitability  and 
inhibition  in  rat  hippocampus.  They  found  that  all  three  drugs  caused  a  dose- 
dependent decrease in the duration of seizure discharge.  None of the drugs altered 
excitability, while only gabapentin altered (decreased) paired-pulse inhibition.  The 
effect of gabapentin on paired-pulse inhibition suggested a proconvulsant rather than 
antiepileptic  effect.  The  same result of gabapentin reduced paired-pulse  inhibition 
was  also  found  in  urethane-anesthetized  model  (String  &  Lorenzo,  1999).  Pre­
treatment with  vigabatrin, had no effect on the ability of gabapentin to reduce paired-
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pulse inhibition.  These data suggest that the mechanism of action of gabapentin is 
probably not through  an increase in basal  levels  of GABA  (String  & Aribi,  2002). 
Topiramate  has  several  anticonvulsant mechanisms.  Both  in  animal  model  and in 
hippocampus slices demonstrated that topiramate was associated with an increase in 
paired-pulse inhibition (Wu et al, 1998; String, 2000).
The  acute  of  effects  of  vigabatrin  on  GABAergic  inhibition  were 
investigated  in  the  hippocampal  slice  using  paired-pulse  inhibition.  The  results 
showed that a concentration-dependent decrease in GABAergic inhibition (Jackson et 
al,  1994a).  Similar results were also  seen in  vitro and in  vivo studies (Sayin et al, 
2001).  The effect of vigabatrin on paired-pulse inhibition in the rat dentate gryrus 
was investigated by perforant path stimulation.  After administration lg/kg vigabatrin 
(I.P.),  there  was  a  loss  paired-pulse  inhibition  at  both  15  and  25  ms  interpulse 
intervals  (IPI).  Sayin et al (2 0 0 1 ) suggested that activation of presynaptic  GABAb 
receptors,  by increased extracellular GABA, might be one of the contributing factors 
to the apparent paradoxical effect of vigabatrin on paired-pulse inhibition.
As  paired-pulse  inhibition  is  an  accepted  technique  to  functionally assess 
GABAergic mechanisms, Margineanu and Wulfert (1995) investigated the effects of 
paired-pulse inhibition of levetiracetam in the bicuculline seizure model.  The results 
showed that levetiracetam neither affected paired-pulse inhibition nor reduced paired- 
pulse inhibition in bicuculline-induced hyperexcitability.  Subsequently Margineanu 
and  Klitgaard  (2003)  investigated  whether  levetiracetam  affected  the  paired-pulse 
inhibition of the field potentials evoked in the dentate gyrus of urethane-anesthesized 
rats.  This  model  revealed  a  strong  paired-pulse  inhibition  at  20ms  interstimulus
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interval.  Bicuculline  and  baclofen  markedly  depressed  paired-pulse  inhibition  at 
2 0 ms  interstimulus  interval,  whiles  clonazepam,  diazepam  and  phenobarbital 
enhanced paired-pulse inhibition.  In contrast to these GABAa and GABAb receptors 
acting  drugs,  levetiracetam  has  no  significant  effect  on  paired-pulse  inhibition 
interaction  in  the  rat;  this  would  suggest  that  the  mechanism  of  action  of 
levetiracetam  does  not  involve  in  the  GABAergic  mechanisms  (Margineanu  & 
Klitgaard, 2003).
1.7  AIMS OF THE STUDY
Using an animal model  that allows  the temporal  (blood) pharmacokinetics 
and  central  (CSF  and  ECF)  brain  neuropharmacokinetics  of  a  drug  and 
pharmacodynamic  correlates  (amino  acid  neuro  transmitters),  and  an 
electrophysiological  model,  this  thesis  sought  to  investigate  various  aspect  of two 
new AEDs (vigabatrin and levetiracetam).
1. The blood pharmacokinetics and CSF and ECF neuropharmacokinetics of 
vigabatrin after acute intraperitoneal administration were compared.
2.  The  blood  pharmacokinetics  and  ECF  neuropharmacokinetics  of 
levetiracetam after intraperitoneal administration were determined.
3.  The  effect  of  vigabatrin  and  levetiracetam  on  candidate  amino  acid 
neurotransmitters in CSF and ECF were determined and compared.
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4.  The  effects  of vigabatrin  and  levetiracetam  in  paired-pulse  inhibition 
were determined and compared.
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2.1  MATERIALS
Methodology
2.1.1  Animals
Male Sprague-Dawley rats (Charles River, Margate, Kent, U.K.), weighing 
300-350 g, were used in all experiments.  Rats were individually housed in groups of 
3 for 5-7 days prior to surgery and were allowed free access to water and to a normal 
laboratory  diet  (SDS  R  and  M  number  1  expanded,  Scientific  Dietary  Services, 
Witham,  Essex,  U.K.).  A  12  hours  light/dark cycle  (light  on 07:00 hours)  and  an 
ambient temperature of 25°C were maintained.
2.1.2  Antiepileptic drugs
Vigabatrin  was  obtained  from  Hoechst  Marion  Roussel  Ltd  (Kingfisher 
Driver,  Swindon.  U.K.).  Levetiracetam was  supplied  by the UCB  Pharmaceutical 
Sector  (Chemin  du Fories,  Belgium).  Since  these  two  AEDs  are  hydrophilic  and 
water soluble,  saline was used as the vehicle of choice.
2.1.3  Blood catheter and CSF cannulae
The  blood  catheter  comprised  of a  5  cm  silastic  tubing  (2.5mm  ED  and 
1.1mm OD,  Bio pure technology Ltd, UK) connected to  a  12  cm polythene tubing 
(0.58 mm ID and 0.96mm OD, SIMS portex Ltd, UK).  Catheters were constructed 
by connecting these two tubings together by inserting the polythene tubing into the 
silastic tubing  (Figure 2.1).  The silastic tubing was fixed in the jugular vein whilst 
the polythene tubing was used for collecting blood samples and accessible externally 
(Figure 2.1).
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Figure 2.1:  A schematic of a blood catheter.
The  construction  of the  CSF  cannulae  was  as  described by Patsalos  et  al 
(1992).  The CSF cannula comprised of an outer (0.58 mm ID and 0.96mm OD) and 
inner (0.26 mm ID and 0.61mm OD) polythene tubings (Figure 2.2).  The dimensions 
of both tubing were specifically chosen to allow insertion (with tweezers) of the inner 
polythene tubing into the outer polythene tubing after the button was formed, but not 
to allow the inner tubing to be readily withdrawn.  The button was formed by gentle 
heating of the catheter over a soldering iron.  This resulted in a tight fit around the 
inner polythene tubing (0.28mm  ID,  0.61mm OD).  A 37 G copper wire (Scientific 
Wire Co., London, UK) was inserted through the inner tubing.  This afforded rigidity 
to the catheter and aided the puncturing of the brain dura.
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Figure 2.2:  A schematic of a CSF cannula.
2.1.4  Microdialysis probe
Concentric microdialysis probes with filtral  12 and a dialysis membrane (4 
mm  long,  200  pM  diameter,  Hospal  Rugby,  U.K.)  were  used.  The  probes  were 
constructed as Figure 2.3 and internal tubes were used by vitreous silica tubing (SGE, 
Milton Keynes, UK).  Two silica tubes were held in place in a 15 mm 24-G steel tube 
with epoxy resin.  The dialysis membrane was placed over the 4 mm protruding silica 
tube and passed up into the steel tubing.  The membrane was then fixed in place and 
the end with epoxy resin.  Two 27-G steel tubes  ( 8 mm long) were inserted into the 
polythene tubing (i.d.  0.28  mm), placed over the silica tubing at the other end and 
held in place with epoxy resin. These were then sealed with hot melted adhesive.
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Figure 2.3:  A schematic of a microdialysis probe.
2.2  SURGICAL PROCEDURES AND SAMPLING
2.2.1  Anaesthetics
All surgical procedures were performed under general anaesthesia according 
to  Home  Office  ANIMALS  (SCIENTIFIC  PROCEDURES)  ACT  1986.  The  rats 
were  first placed in an induction chamber with 4  %  halothane  (May & Baker Ltd, 
Dagenham, UK) in oxygen for about 10 min.  When rats became unresponsive to foot 
pinch,  they  were  transferred  to  a  stereotaxic  frame  for  surgery  (Stoelting  Co.  IL, 
USA).  Halothane  (1-2%)  in  oxygen at  a flow  rate  of 2L/min was provided via  a 
specially constructed facemask until the surgery was completed.
2.2.2  Surgery for blood catheter and CSF cannulae insertion
The  procedure  for  inserting  the  blood  catheter  and  CSF  cannula  was  as 
previously described (Patsalos et al,  1992).  Rats were firstly placed on their backs, 
and fixed by their forelegs to a surgical table by adhesive tape.  The skin between the
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right clavicle and sternum was shaved, and a  1 - 2 cm long incision was made in skin 
rostral but parallel to the clavicle.  The external jugular vein was exposed by blunt 
dissection.  After removing the tissue surrounding the vein with a pair of tweezers, 
three cotton threads were passed under the vein causally and rostrally and the vein 
was ligated using the rostral-most thread. Using a pair of fine scissors, the vein was 
perforated just below the medial thread, the catheter was inserted into the vein by 3.5 
cm for a 300g rat, and by 4.0 cm for a 350g rat.  The tip was lying in or just above the 
right ventricle, and blood flowed readily in and out of the catheter.  The caudal-most 
thread was tied around the vein thus holding the catheter within the vein, the other 
two threads were tied around the catheter to keep it in place.  A cut was then made 
just behind the right ear and the catheter was passed under the skin and through this 
incision.  The wounds were then sutured.  The catheter was further flushed with 5U/1 
heparin and the end was cut so that 2-3 cm protruded out of the skin, and the end of 
the catheter was tied.
For the CSF cannulae surgery, the animal was placed in a stereotaxic frame 
with both ear bars set at zero and the nose piece set to + 5  mm.  The skin and the 
atlantoccipital membrane were retracted.  Two burr holes were made, the first was 3 
mm lateral and 4 mm caudal to lambda for the placement of a stainless steel anchor 
screw,  and  the  second  was  2  mm  lateral  to  the  midline  and  3  mm  caudal  to  the 
external occipital crest and at an angle of about 40° for the catheter insertion.  The 
cannulae were inserted until the button rested on the skull surface.  The wire was then 
withdrawn and the cannulae sealed in place with dental acrylic (De Trey, Weybridge, 
Surrey,  UK).  CSF was  introduced into  the  cannulae by a  slight negative pressure 
using a syringe.  Finally, the cannula was cut to approximately 2 cm, and heat sealed.
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After surgery, rats were housed individually in perspex cages and allowed food and 
water ad libitum.
2.2.3  Surgery for the microdialysis probe insertion
Rats were anaesthetised as described previously.  The hair on the head was 
clipped and the skin surface was sterilised using an alcoholic sterile.  The animal was 
then placed in a stereotaxic frame with both ear bars set at zero and the nose piece set 
to + 5 mm.  A 2 cm incision was made 8 mm caudal to lambda and external occipital 
crest.  A small piece of skin was excised (about 0.5 cm wide and  1.0 cm long), and 
the atlantoccipital membrane was retracted.  Microdialysate probes were implanted in 
either  the  hippocampus  (from  bregma  5.3  mm  posterior,  4.5  mm  lateral,  7.5  mm 
ventral), or the frontal cortex (from bregma 3.0 mm anterior, 2.5 mm lateral, and 5.0 
mm ventral) according to the atlas of Paxinos and Watson (1986).  Two burr holes 
were made for two  screws fixing the probe.  The probes were sealed in place with 
dental acrylic cement (De Trey, Wey-bridge, Surrey, UK).
2.2.4  Blood and CSF sampling
Blood sampling was achieved by connecting the jugular vein catheter via a
1.5  cm stainless steel connector to a 60 cm polythene tubing (i.d. 0.58 mm).  Blood 
was  slowly  withdrawn  until  it  reached  the  bottom  of the  syringe  containing  the 
lOU/ml heparin.  The cannula was closed using a small clip and a new syringe was 
attached.  0.1  ml  of blood was  withdrawn to  the  syringe.  In  order to  prevent the 
development  of  hypovolaemia,  an  equivalent  volume  of  heparinized  saline  was 
administered  after  each  sampling.  Two  baseline  samples  were  taken  at  30  min 
intervals before drug administration, then blood samples were withdrawn at  2 0  min
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intervals in the first hour, and at 30 min intervals for the subsequent 7 hours.  Blood 
samples were collected into 0.5 mL centrifuge tubes and then centrifuged for 5 min at
11,000  g to separate the cells from the serum.  The serum was transferred into a new 
tube and stored at -70°C until required for analysis.
Sampling of the CSF was achieved by connecting the implanted cannulae to 
a tube attached to a 23 G needle and 1 mL syringe.  The tube consisted of 30 cm (i.d. 
0.28  cm) polythene tubing, which was  attached to 40 cm  (i.d.  0.58  mm) polythene 
tubing. The polythene tubing  (i.d. 0.58 mm) was marked at  8 cm with a marker pen, 
and this corresponded to a volume of 20 pL.  Two baseline samples were taken at 30 
min  intervals  before  drug  administration,  and  CSF  samples  withdrawn  at  30  min 
interval or up to  8 hours.  CSF was dispensed into 0.5 mL polypropylene tubes and 
stored at -70°C until required for analysis.
2.2.5.  Microdialysate (ECF) sampling
The ECF sampling was achieved by connecting the implanted microdialysis 
probe with  20  cm  polythene  tubing  (i.d.  0.28  mm).  During  the  first  2  hours,  the 
dialysate  sample  was  discarded  so  as  to  allow  stable  sampling  conditions  to  be 
established.  Then base  line  samples were collected by an hour and  15  minutes  for 
each sample point.  After drug administration, dialysate samples were collected at 20 
min  intervals  for  4  hours  and  then  for  30  min  intervals  for  a  further  4  hours. 
Dialysate  samples  were  collected  into  0.5  mL  polythene  tubes  (Treff  AG, 
Switzerland)  and stored at -70°C until they were  analysed  for drug and amino acid 
content.
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2.2.6  Microdialysis pump, artificial CSF and microdialysis probe recovery
A Harvard Apparatus 22 micro-pump (Model:  55-22228, Harvard, U.S.A.) 
was used.  The  microdialysis flow rate was typically 1-2 pL/min but was varied for 
different experiments.  A  1   mL syringe was  fixed to the pump containing artificial 
CSF (composition in mM: NaCl 125, KC1 2.5, MgCl2 1.18 and CaCh 1.26).
In  vitro recovery for each probe was determined by placing the probe in a 
beaker containing a 40 pmol/L drug solution constituted in artificial CSF.  The probes 
were  then  perfused  at  1   pL/min  for  vigabatrin  and  2  pL/min  for  levetiracetam. 
Samples were collected every 20 min for  1 hour and stored at -70°C until analysis for 
drug content.
2.3  SAMPLE ANALYSIS
The analyses of vigabatrin, levetiracetam and amino acids were undertaken 
by high  performance liquid chromatography (HPLC) and were based on the methods 
described by Ratnaraj & Patsalos (1998) and Ratnaraj et al (1996).
2.3.1  Measurement of vigabatrin concentration
Vigabatrin  serum  concentration  (total  and  free  non-protein  bound)  were 
determined using HPLC with fluorescene detection as previously described  (Ratanraj 
& Patsalos,  1998).  All solvents were of HPLC grade and reagents were of “Analar” 
grade, purchased from BDH-Merck (Poole, UK).
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2.3.1.1  Extraction procedure
Methodology
Vigabatrin serum and CSF concentrations were measured by adding 30  pL 
serum,  15  pL CSF or ECF into  1.5 mL polypropylene microcentrifuge tube (Scltkab 
Ltd, Coat-bridge, Lanarkshire, UK), and adding ortho-phthaldialdehyde (OPA) 60 pL 
for serum and 30 pL for CSF and ECF respectively.  Samples were then mixed for 10 
seconds  using  a  Vibrax  electronic  shaker  (Sartorius-IKA,  Epsom,  U.K.)  and 
centrifuged  for  5  min  at  11,000  g  using  a  microcentrifuge  (Abbott,  Maidenhead, 
U.K.).  The  supernatant  (80  pL  for  serum  and  40  pL  for  CSF  and  ECF)  was 
transferred  into  a  Chromacol  vial  (Anachen  Ltd,  Bedfordshire,  U.K.)  and  the  vial 
sealed with a screw cap.  The vials were then loaded into the HPLC autosampler.  10 
pL samples were subsequently injected into the chromatograph.
2.3.1.2  HPLC instrumentation and chromatographic condition
A Gilson HPLC (Anachem Ltd, Luton, UK) was used and comprised of the 
following modules: a Gilson 302 and 305 pump, an autosampler (Gilson model 234) 
and  a Gilson  811C  dynamic mixer.  A Perkin Elmer fluorescence  detector (Perkin 
Elmer  Ltd,  Beaconsfield,  Bucks,  UK)  was  used  and  set  at  250  nm  and  550  nm. 
Chromatograms  were  run  at  35°C  using  a  model  7955  column  chiller  (Jones 
Chromatography Ltd,  Hengoed, Mid.  Glamorgan, UK)  and a Hypersil BDS-C18,  3 
pM,  125x  3  mm  column  (Hewlett  Packard,  Stockport,  Cheshire)  with  pre-column 
LiChrospher select B 4x4 (5pM) (Hewlett Packard,  Stockport, Cheshire) was used. 
Phosphate buffer (145mM) was for line A (Gilson pump 305) and a mobile phase of 
acetonitrile and water was for line B (Gilson pump 302).  Line A and B buffer 42:58 
vol/vol was used in the beginning and continually changed to 00 (line A)TOO (line B)
95Chapter 2 Methodology
vol/vol at a flow rate of 0.45 ml/min and at 2.5 psi.  A typical chromatogram for the 
analyse of vigabatrin is shown in Figure 2.4.
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Figure 2.4:  A typical HPLC chromatogram of vigabatrin (VGT).
23.13  Preparation of buffer and standard solutions
Phosphate  buffer  (145mM)  was  prepared  by  mixing  320  mL  of  stock 
solution (phosphate buffer 250 mM), with 95  mL of acetonitrile and 550 mL water. 
A final pH of 6.5  was obtained by using 5M  sodium hydroxide (NaOH).  This was 
passed through line A of the HPLC.  Line B comprised of a mobile phase of 280 mL 
acetonitrile, 240 mL methyl alcohol (MeOH) and 480 mL water.  The borate buffer 
(0.4M) was made of boric acid in water and adjusted to pH  10.5 using 5  M NaOH. 
The  OPA (Sigma,  Poole,  Essex,  BDH,  Dagenham,  Essex,  UK)  derivitising reagent 
consisted  of  0.4  mL  MeOH,  3.6  mL  borate  buffer  and  50  pL  2-mercaptoethanol 
(Sigma, UK).
96Chapter 2  Methodology
Area  under  the  peak  corresponding  to  vigabatrin  was  calculated  and  was 
compared to a standard curve. The internal standard was prepared using L-norvaline 
with methanol.  The L-norvaline solution comprised of 0.1171 g L-norvaline in 100ml 
of 50% methanol/FLO.  Calibration standards and internal quality controls for serum 
were prepared with blank human sera to provide concentration of  25, 50,  100, 200, 
300  and  400  pmol/L  for  standards  and  40,  150  and  350  pmol/L  for  the  quality 
controls.  The vigabatrin standards for CSF were:  2.5, 5,  10, 20, 40 and 80 pmol/L, 
and for dialysate they were:  5,  10, 20, 40, 80 and  160 pmol/L respectively.  Typical 
standard  curves  are  shown  in  Figure  2.5.  The  lower  limit  of detection  was  0.2 
pmol/L.
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Figure 2.5:  Typical vigabatrin standard curves for (A) serum, (B) CSF and 
(C) dialysate.  The least mean squares regression lines are shown.
2.3.2  Measurement of levetiracem concentration
Levetiracetam serum concentrations (total and free non-protein-bound) were 
determined using HPLC with ultraviolet detection as previously described (Ratanraj 
et al,  1996).  All solvents were of HPLC grade and reagents were of “Analar” grade 
and were purchased from BDH-Merck (Poole, U.K.).
2.3.2.1  Extraction procedure
Letiracetam  serum  concentrations  were  measured by adding  15  pL  serum 
and  dialysate,  25  pL  5M  sodium  hydroxide  solution  and  25  pL  of the  working 
internal  standard  (50mM,  a,2,2-trimethyl-5-oxo-l-pyrrolidineacetamide;  UCB 
Pharmaceutical Sector,  Chemin du Foriest, Belgium) into a  1.5 mL microcentrifuge 
tube (Sarstedt Ltd, Leicester, U.K.)  After mixing the contents for 10 seconds using a 
vortex mixer, 250 pL dichloromethane were added and mixed for a further 1   minute 
using  a  Vibrax  electronic  shaker.  The  mixture  was  centrifuged  for  5  minutes  at
11,000  g (Abbott, Maidenhead, U.K.).  The upper aqueous layer was discarded and
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the  solvent  extract  was  then  transferred  to  a  clean  microcentrifuge  tube  and 
evaporated  to  dryness  at  50°C  using  a  Gyro  Vap  centrifugal  evaporator  (Howe, 
Banbury, U.K.).  The residue was then reconstituted in 50  pL of mobile phase and 
samples were injected on to the HPLC system.
2.2.2.2.  HPLC instrumentation and chromatographic condition
The  HPLC  system  comprised  of a  Spectra-Physics  spectra  system  pump 
P4000,  an  AS  3000  autosampler,  a  UV2000  detector  and  a  chromjet  integrator. 
Chromatograms were run at 35°C on a steel cartridge column (250 x 4mm I.D.) with 
a precolumn (4x4 mm I.D.) packed with LiChrospher 60 RP-Select B, 5 pm (Merck, 
Poole,  U.K.).  A  mobile  phase  of acetronitrile  :  50  mM  phosphate  buffer pH  5.6 
(15:85) with a flow rate of 0.8 mL/min at 1300 psi was used (Figure 2.6 graph from 
HPLC).  The column eluent was monitored at 220 nm with a sensitivity range of 1.0 
a.u.f.s and a chart speed of 0.25 cm/min.  Figure 2.6 shows a typical chromatogram of 
levetiracetam.
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Figure 2.6:  A typical HPLC chromatogram of levetiracetam (LEV).
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2.3.2.3  Preparations of buffer and standard solutions
Phosphate buffer (50 mM) was prepared by mixing potassium dihydrogen 
phosphate  and water and this comprised buffer A.  A second phosphate buffer (50 
mM) was prepared from disodium hydrogen phosphate  solution and water and this 
comprised buffer B.  95% of buffer A and 5% of buffer B was mixed together and the 
pH adjusted to 5.6 by using orthophosphoric acid.  A flow rate 0.8 mL/min at  1300 
psi was used.
The stock solution of levetiracetam (10 mM) was prepared by using water. 
The  stock  solution  of ucb  17025,  the  internal  standard  (lmg/mL),  was  prepared 
using  methanol.  The  internal  standard  was  prepared  in  50%  acetonitrile  and  a 
phosphate  buffer  (50mM,  pH  5.6)  mixture  to  give  a  final  concentration  of 217 
pmol/L.  The levetiracetam standards for serum and dialysate were 25, 50, 100, 200, 
300 pM and 2.5, 5,  10, 20, 40, 80 and  160 pM respectively.  The quality controls 
were  40,  75  and  150pmol/L  and  8.5  and  26  pmol/L  for  serum  and  dialysate 
respectively.  The  area  under  the  peak  corresponding  to  levetiracetam  was 
calculated for serum and ECF and expressed as a ratio compared to the area under 
the peak for the internal standard and these were compared to a standard curve The 
typical standard curves for serum and dialysate are presented in figure 2.7.
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Figure 2.7: Typical levetiracetam standard curves for (A) serum and (B) 
dialysate.  The least mean squares regression lines are shown.
2.3.3  Measurement  of  free  non-protein  bound  serum  vigabatrin  and 
levetiracetam concentration
The  procedure  used  for  the  determination  of the  free  non-protein  bound 
serum vigabatrin and levetiracetam concentrations was essentially the same as that for 
total  concentration  except  that  samples  were  first  filtered  through  an  Amicon 
Centriffee  Micropartition  Systerm  (Amicon,  Stonehouse,  U.K.)  by using  a  Sorvall
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RC-5B refrigerated centrifuge (Du Pont,  Stevenage,  U.K.)  set at 25°C.  Fifteen  pL 
samples of the resultant ultrafiltrate were then processed as described above.
2.3.4  Measurement of CSF amino acid concentrations
2.3.4.1  HPLC instrumentation and chromatographic condition
The  HPLC  comprised  of  Gilson  302  and  a  305  pump,  a  Gilson  234 
autosampler, and Unipoint software (Anachem, Luton, UK).  Eluents were monitored 
with a Perkin-Elmer (Beaconsfield, UK) fluorescence detector and a computer (Dell 
Computer, Swindon, UK) was used to control the system.  Chromatograms were run 
at 35 °C on a steel cartridge column (125x 3 mm ID) with a precolumn (4x4 mm ID) 
packed with 3pm Hypersil BDS C-18 (Hewlett-Packard, Stockport, UK).  A flow rate 
of 0.45  ml/minute  at  2400 psi  was  used.  Slovents  A  and  B  were  filtered through 
0.22-pm  filter  (Millipore,  Amicon,  Stonehouse,  UK)  before  use.  The  gradient 
program  used  was  42%  A  and  52%  B  (0-7  minutes),  35%  A  and  65%  B  (7-13 
minutes), 25% A and 75% B (13-16 minutes), 0% A and 100% B (16-23 minuets, and 
42%  A  and  58%  B  (23-28  minutes).  This  gradient  program  allowed  the  optimal 
separation of amino acids and internal standard (L-norvaline) from other endogenous 
amino  acid  in the  CSF.  The column  eluent was monitored  at  excitation  340 mm, 
emission 440 nm.  Precolumn derivatization of amino acid with OPA reagent, control 
of  the  HPLC  system,  calibration  curves,  and  concentration  calculations  were 
automatically undertaken using the Unipoint (Anachem) software.  lOpL CSF and 10 
pL  OPA  were  injected  automatically  into  the  HPLC  for  analysis.  A  typical 
chromatograph is shown in Figure 2.8.
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Figure  2.8:  A typical  HPLC  chromatogram  of amino  acids measured  in CSF. 
(Ala: alanine; Arg: arginine; Asn: asparagine; Asp: aspartic acid; Glu: glutamate; 
Gly:  glycine; Lie:  lsoleucine; Leu:  leucine; Phe: phenylalanine; Ser:  serine; Tau: 
taurine;  Thr:  threonine;  Trp:  tryptophan;  Tyr:  tyrosine;  Val:  valine;  HMC: 
homocamosine).
2.3.4.2  Preparations of buffer and standard solutions
Mobile-phase  solvent  A  (pH  6.5)  comprised  of  250  mM  phosphate, 
acetonitrile and HPLC grade water (32:9.5:58.5, vohvolvol) and mobile-phase solvent 
B comprised of acetonitrile, methanol and HPLC: grade water (28:24:28, vol/vol/vol). 
Borate  buffer  was  prepared  by  adjusting  boric  acid  (0.4M)  to  pH  10.5  with  5  M 
sodium  hydroxide  solution.  The  OPA  derivatization  reagent  was  prepared  by 
dissolving 30 mg OPA in 0.4 ml methanol and adding 3.6 ml borate buffer and 50 pi 
2-mercaptoethanol.  A stock solution of amino acid standard (10 mM) was prepared 
using 0.1% HC1.  Calibration standards comprised of 2.5, 5, 10, 15, 30 and 50 pmol/L 
concentration of the various amino acids.  QC samples were prepared so as to contain 
3, 20, 40 pmol/L of the various amino acids.  CSF amino acids measured included: 
alanine,  arginine,  aspartic  acid,  asparagine,  glutamate,  glutamine,  glycine,  leucien,
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lycine,  homocamosine,  phenylanine,  serine,  taurine,  threonine,  trytophan,  tyrosine 
and valine.
2.3.5  Measurement of microdialysate (ECF) amino acids
Amino  acid  concentrations  in  microdialysate  from  the  frontal  cortex  and 
hippocampus  after vigabatrin and  levetiracetam  administration were  determined by 
HPLC and were measured by Dr. M.  O’Connell (Cambridge Brain Repair Centre). 
Microdialysate  amino  acids  measured  include:  arginine,  aspartic  acid,  asparagine, 
citrulline,  GABA,  glutamate,  glutamine,  glycine,  isoleucine,  leucine,  lycine, 
methionine, phenylanine, serine, taurine, threonine, tryptophan, tyrosine and valine.
2.3.5.1  HPLC instrumentation and chromatographic conditions
Five pL of dialysate were used for precolumn derivatization of amino acids 
by means of an OPA/3-mercaptoptopionic acid (MPA) reaction.  Derivatization was 
conducted using an autoinjector, and the dialysate/reagent mixture was injected onto 
the HPLC  system via a valve  fitted with  a 2  pL  sample  loop.  The HPLC  system 
consisted of two high pressure pumps with a gradient controller and mixing chamber 
(Micro-tech Scientific, Aunnyvale, USA).  Separation of amino  acids was achieved 
using an Amino Quant column and guard cartridge (HP, Cheshire, UK) placed inside 
a column oven operating at 40°C, using a linear gradient  (5 to  100% elution mobile 
phase B in  18 minutes).  The detector was a Gilson model  122 fluorometer (Gilson, 
Middleton, USA) fitted with a 5  pL flow cell and was operated with excitation and 
emission wavelengths of 340 and 450 nm respectively.  Figure 2.9  shows a typical 
amino acid chromatogram.
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Figure  2.9:  A  typical  HPLC  chromatogram  of amino  acids  measured  in
dialysate  (Ala:  alanine;  Arg:  arginine;  Asn:  asparagine;  Asp:  aspartic  acid;
Cit: citrullilne; Gin: glutamine; Glu: glutamate; Gly: glycine; Lie: lsoleucine; 
Leu:  leucine;  Lys:  lysine;  Met:  Methionine;  Phe:  phenylalanine;  Ser:  serine; 
Tau: taurine; Thr: threonine;  Trp: tryptophan; Tyr: tyrosine; Val: valine).
2.3.5.2  Preparations of buffer and standard solutions
Mobile  phases  A  and  B  were  prepared  exactly  as  described  in  the 
AminoQuant  method  (Agilent  Technologies  UK  Limited,  West  Lothian,  UK). 
Calibration of the system was achieved using aqueous working standards prepared by 
dilution of an amino acid standard mixture (Agilent Technologies UK Limited, West 
Lothian,  UK)  following  the  additions  of  L-asparagine,  L-glutamine,  citrulline, 
GABA,  norvaline  (internal  standard)  and  L-tryptophan.  Calibration  curves  were 
constructed to cover the ranges 0.005 to 200 pM for each amino acid.
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2.4  PROCEDURES  FOR STIMULATION AND  RECORDING  OF  PAIRED- 
PULSE INHIBITION
2.4.1  Electrode construction
All parts, unless otherwise specified, were purchased from Plastics One Inc 
via  Semat  Technical,  Herts,  UK.  Wire  was  purchased  from  Advent  Research 
Materials,  Suffolk,  UK.  Bipolar stimulating electrodes were  constructed  from two 
125 pm teflon coated stainless steel wires twisted together that were then attached to 
gold female connectors by soldering.  The gold connectors could be mounted in a six 
holed plastic pedestal along with the connectors for the recording electrode and earth. 
The tips of the  electrode were cut such that they were  separated by 0.5  mm.  The 
construction of the recording electrode was identical except that only one wire was 
used  for  unipolar  recording,  the  other  wire  gave  the  electrode  stability.  Later 
experiments improved this set up by using a single 250 pm electrode coated stainless 
steel wire as the recording electrode.  The earth was an electrode silver wire, which in 
the  freely-moving experiments was connected to  an  anchor screw.  For the  freely- 
moving experiments the electrodes were kept in place using dental cement (De Trey, 
Surrey, UK) and three anchor screws.
2.4.2  Stimulator
Constant current stimuli were delivered from a Neurolog stimulator (NL304 
period  generator,  NL  301  pulse  generator,  NL  505  flip-flop,  NL  800  stimulus 
isolators: Digitimer Ltd, Welwyn Garden City, UK) as shown in Figure 2.10.
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Figure 2.10:  Stimulator arrangement:  The pulse width could be  set at 50,
150  or  500  ps;  the  frequency  of pulses  could  be  set  from  0-10kHz;  the 
amplitude  could  be  set  from  0-1 OmA,  and  using  the  alternating  switch  the 
polarity of the pulses from the constant current generators could be alternated 
(Walker, 1997).
The pulse generator could be gated so that the pulses could be synchronised with the 
computer recording.  This gating also enabled fixed length trains to be generated, and 
using  a purpose  built  series  of flip-flop  circuits,  it  was  possible  to  generate  fixed 
length trains that occurred at fixed intervals.
2.4.3  Recording equipment
Potentials  were  amplified  and  filtered  (0.1  Hz  to  5  kHz  band pass)  via a 
Neurolog  amplifier  (NL  100  A  pre-amp,  NL  104  A  amplifier,  NL  125  filter: 
Digitimer Ltd, Welwyn Garden City, UK) onto a storage oscilloscope (Figure 2.11).
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Figure 2.11:  Amplifier arrangement.  The amplifier was a differential AC 
amplifier with B connected to earth, and a built in high pass filter set at 0.1 
Hz.  A  low  pass  filter  set  at  5kHz  was  also  necessary  to  reduce  high 
frequency interference that seemed to be due to computer equipment. Then 
the signal was amplified and pass to oscilloscope.
2.4.4  Electrode implantation
The  animals  were  fully  anaesthetised  with  1-2  %  halothane  in  oxygen  as 
previously  described.  A  subcutaneous  silver  electrode  was  used  as  earth.  A 
recording electrode was implanted stereotaxically into the hippocampus (coordinates,
2.5  mm lateral, 4 mm posterior from bregma).  A twisted (teflon- coated)  stainless 
steel wire was  advanced into the  angular bundle  (co-ordinates,  4.4  mm  lateral,  8.1 
mm posterior to bregma) to stimulate the perforant path.
Unipolar recordings were made from the recording electrode and potentials 
were  amplified  and  filtered  (0.1  Hz to  5  kHz band pass)  via a Neurolog  amplifier 
(Digitimer  Ltd,  Welwyn  Garden  City,  U.K.)  onto  a  storage  oscilloscope  and  then 
stored  on  a  computer  using  Labview  5.0  (National  Instruments,  Berkshire,  U.K.).
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The stimulating electrode was advanced 3-4 mm ventral from the dural surface. The 
recording electrode was lowered until the electrode entered the granule cell layer of 
the dentate.  The depths of the electrodes were adjusted to maximise the slope of the 
population EPSP.
During  field  EPSPs,  positive  charge  flows  into  dendrites  resulting  in  a 
decrease in the potential of the fluid surrounding dendrites and charge  flows out of 
soma and axons resulting in an increase in the potential surrounding soma and axons. 
Thus,  in  the  dendritic  region  the  field  potential  from  neuronal  depolarisation  is 
negative with respect to surrounding tissue, whilst in the cell layer the field potential 
is positive with  respect  to  surrounding  tissue.  If the  intracellular depolarisation  is 
large enough to result in an action potential, then the axon becomes very permeable to 
sodium and sodium ions flow into the axon and the circuit is reversed.  This results in 
typical dentate granule cell field potentials (Figure 2.12 and 2.13)
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Figure 2.12:  Field potential recorded from dentate granule cell layer 
following single pulse stimulation of the perforant path.
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Figure  2.13:  Measurement  of the  dentate  gyrus  field  response  components. 
Response  recorded  from  the  dentate  gyrus  after  perforant  path  stimulation 
shows stimulus artifact (leftmost deflection) followed by a small fibre response 
and  a  large  EPSP  (positive  wave)  and  population  spike  (negative  wave) 
response.  EPSP amplitudes were determined as the maximum rate of rise of the 
EPSP  between  its  onset  and  the  onset  of  the  population  spike  (PS).  PS 
amplitudes were measured from the extrapolated EPSP baseline to the peak of 
the PS waveform (dotted).  EPSP and PS thresholds were defined as the lowest 
stimulus intensities producing an identifiable response (Joy & Albertson, 1992).
Once  the  recording  electrode  was  positioned  in  the  dentate  granule  cell 
layer, the depth of the stimulating electrode was adjusted to maximise the slope of the 
population EPSP.  Constant-current stimuli were delivered from a Naurolog stimular 
(Digitimer Ltd, Welwyn Garden City, U.K.).  Test shocks consisted of l-2mA, 50 ps 
monopolar pulses every 10s.  The recording electrode was lowered until it entered the 
cell layer of dentate.
110Chapter 2  Methodology
2.4.5  Paired-pulse stimulation protocols
Three  days  after  recovery  from  anaesthesia,  the  perforant  path  was 
stimulated with 3-6mA,  50 ps monopolar paired pulses.  The stimulus strength was 
adjusted in order to achieve a population spike that was 50 % of maximum.  Paired 
pulses were delivered at a frequency of 0.2 Hz with alternating paired pulse intervals 
of  20,  50  and  100  ms.  A  baseline  was  recorded  for  30  minutes  prior  to 
administrations.  The rats were then administered with either  1000 mg/kg vigabatrin 
or 80mg/kg levetiracetam i.p.  Immediately, paired pulse recordings were made for 5 
minutes  every  30  minutes  until  8  hours  after  vigabatrin  and  levetiracetam 
administration.  A further recording was made 24 hours later.  Because paired pulse 
inhibition  is  dependent  on  the  size  of  the  population  spike  resulting  from  the 
conditioning  pulse,  the  stimulus  amplitude  was  adjusted  to  maintain  a  constant 
conditioning population spike.
2.5  STATISTICS
2.5.1  Pharmacokinetic and neuropharmacokinetic data
Kinetic parameters were calculated using each individual animal at each 
time point.  The concentration versus time profiles  for serum,  CSF and  ECF were 
analysed  according  to  a  one  compartment  model  using  Statistica  5.  Time  to 
maximum plasma concentration (rm ax) and the maximum concentration (Cm ax) were 
estimated  from  the  concentration  versus  time  plots.  The  area  under  the  plasma 
concentration versus time curve (AUC) to the last plasma concentration was obtained 
using  the  linear  trapezoidal  rule  for  t=0 -x  (where  x=last  time  point)  and  was 
extrapolated to infinity by calculating AUCx-oc =C  (x)/p.  The elimination half-life
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{t\/i)  was  calculated  from the  slope  (\z ),  estimated by  log  linear regression  of the 
terminal  phase  of the  plasma  concentration-time  curve.  Results  are  presented  as 
mean ± sem.  Data were compared using Student’ /-test.
2.5.2  CSF and ECF amino acids
Amino acid concentration after administration of vigabatrin or levetiracetam 
at  each  time  point  was  compared  to  the  3  baseline  points  or  control  group.  The 
results were generalised, and were presented as mean ± sem.  Data were compared 
using Student’s t-test and ANOVA for dialysate amino acids and Student’s t-test for 
CSF amino  acids.  The Student’s t-test used the mean of three baseline data which 
were compared to each subsequent time point and ANOVA (single factor) used AUC 
summary  data to  analyse  serial  measurements  and  to  compare  the  drug  to  control 
group at each time point.
2.5.3  Paired-pulse inhibition data
From  each  5  minute  epoch,  paired  pulses  were  chosen  in  which  the 
conditioning  population  spike  (pi)  remained  within  1 0  %  of the  amplitude  of the 
baseline conditioning population spike.  Averages were taken of these paired pulses, 
and paired pulse inhibition was  expressed as the  amplitude  of the population spike 
following  the  test  pulse  (p2 )  divided  by  the  amplitude  of  the  population  spike 
following the conditioning pulse x  1 0 0 .
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3.1  INTRODUCTION
The  action  of a  drug  is  dependent  on  its  pharmacokinetics.  It  is  therefore 
important  to  understand  the  pharmacokinetics  of  a  drug  and,  in  particular,  its 
concentration at its site of action.  Although there have been numerous studies reporting 
the  peripheral  (blood)  pharmacokinetics  and  central  (CSF  and  ECF) 
neuropharmacokinetics of vigabatrin in man (Haegele & Schechter,  1986; Hoke et al, 
1993;  Schechter,  1989;  Ben-Menachem,  1995,  Ben-Menachem  et  al,  1988  &  1989; 
Durham et al,  1993; Grove et al,  1984 & 1981) and in animal models (Jung et al, 1977; 
Smithers  et  al,  1985;  Bemasconi  et al,  1988;  Patsalos  &  Duncan,  1995),  these have 
usually  involved  composite  values  derived  from  single  time  point  determinations. 
Furthermore,  the  inter  relationship  between  the  peripheral  and  central  kinetics  of 
vigabatrin has not been systematically investigated.  In this chapter the inter-relationship 
of vigabatrin  pharmacokinetics  in  blood  (serum),  neuropharmcokinetics  in  CSF  and 
brain  ECF  (frontal  cortex  and  hippocampus)  were  investigated  after  intraperitoneal 
administration of vigabatrin in the freely behaving  rat.
3.2  EXPERIMENTAL PROTOCOL
Male Sprague-Dawley rats (Charles River, Margate, Kent) weighing 300-350 g 
were used.  Two types of experiments were undertaken.  In the first, a blood catheter 
and a CSF cannulae were surgically implanted into the right jugular vein and cistema 
magna respectively.  In the second, a blood catheter was implanted into the right jugular 
vein  and  two  microdialysis  probes  (one  in  the  cerebral  cortex  and  the  other  in  the 
hippocampus)  were  surgically  implanted.  The  surgical  procedures  are  described  in 
Chapter 2.  Two days after recovery from surgery, baseline CSF and blood samples were
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taken  and  the  cannulated  animals  were  administered  by  intraperitoneal  injectionwith 
250,  500  and  1000  mg/kg  vigabatrin  for  serum  and  CSF  sampling  and  500  and 
lOOOmg/kg for ECF sampling.  Venous blood samples (lOOpl) were withdrawn every 20 
minutes for the first hour and then at 30 minute intervals for a further 7 hours.  CSF 
samples (15 pL) were collected at 30 minute intervals for 8 hours and dialysate samples 
(20  pL)  were  collected every 20 minutes  for 4  hours  and  subsequently at 30 minute 
intervals  for a  further 4 hours.  Vigabatrin concentrations were determined in  serum, 
CSF and ECF as described in Chapter 2.
3.3  RESULTS
3.3.1  Serum pharmacokinetics
The  vigabatrin  serum  concentration  versus  time  profiles  after  250,  500  and 
1000  mg/kg  vigabatrin  administrations  are  shown  in  Figure  3.1.  Intraperitoneally 
administered vigabatrin demonstrated rapid absorption.  Peak vigabatrin concentrations 
(7max)  were  achieved  at  0.4h  ±  0.  06  (mean  ±  sem)  and  were  dose  independent. 
Subsequently, vigabatrin concentrations gradually declined and the elimination half-life 
was 1.1± 0.1 hours at the lower doses, and 1.4 ± 0.1 hours at the higher dose.  Table 3.1 
shows the apparent pharmacokinetic constants for individual rats together with the mean 
values  as  calculated  from  the  concentration versus  time plots.  The pharmacokinetic 
constants for individual rats showed some variability within each dose group.  The mean 
values of Cm ax and AUC for vigabatrin increased proportionately with increasing dose. 
Half-life values were  dose independent and it was prolonged at the higher dose (p < 
0.05).  Since  Cm ax  and  rm ax  values  were  determined  by  visual  inspection  of  the 
concentration versus time curve and as the first sampling time point was at 2 0  minutes,
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these values may have been under-estimated and over-estimated respectively.
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Figure  3.1:  Serum  concentration  versus  time  profiles  for  vigabatrin  after
250mg/kg  (♦),  500  mg/kg  (■)  and  1000  mg/kg  (A)  vigabatrin  intraperitoneal 
administration. Data are mean ± sem of 5-7 animals.
The  free non-protein bound vigabatrin  concentration was  determined  from 9 
samples that spanned the concentration range and the time range studied in this study. 
Figure 3.2 shows the free/total vigabatrin concentration ratio for the 9 samples and the 
calculated mean free fraction was 0.99 ± 0.01.  These data indicate that vigabatrin is not 
protein bound.
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Table 3.1: Serum vigabatrin pharmacokinetic constants after intraperitoneal
administration  of 250, 500 and 1000 mg/kg vigabatrin
Rat No. T m ax r ^ m ax AUC tVi
(h) (pmol/L) (pmol h/L) (h)
Vigabatrin 250 mg/kg
1 0.3 1030.7 1455.7 1.0
2 0.7 585.7 893.8 1.2
3 0.3 1101.2 1765.8 1.3
4 0.3 1105.8 1820.5 1.2
5 0.3 925.8 1539.0 1.0
Mean 0.4 949.8 1495.0 1.1
±SEM 0.07 96.7 166.0 0.1
Vigabatrin 500 mg/kg
1 0.3 1803.8 4022.3 0.8
2 0.3 1578.4 3276.9 1.4
3 0.3 1528.5 3634.9 1.2
4 0.3 1289.4 2786.5 1.1
5 0.3 1558.7 3275.1 1.2
6 0.7 1814.2 3507.1 1.0
Mean 0.4 1595.5 3417.1 1.1
±SEM 0.06 79.8 169.2 0.1
Vigabatrin 1000 
mg/kg
1 0.3 2744.1 6311.0 1.6
2 0.3 3412.5 7818.4 1.6
3 0.3 3310.8 8394.8 1.7
4 0.3 2992.3 6871.7 1.4
5 0.7 2733.8 7169.2 1.3
6 0.7 2581.0 7394.5 1.5
7 0.3 2815.0 6914.6 1.0
Mean 0.4 2941.3 7267.7 1.4
±SEM 0.06 118.4 258.0 0.1
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Figure 3.2: Vigabatrin free/total concentration ratios versus time profile.
3.3.2  CSF neuropharmacokinetics
Figure  3.3  shows  the  CSF  concentration  verses  time  profiles  after  intra- 
peritoneal administration of 250, 500 and  1000 mg/kg vigabatrin.  It can be seen that 
vigabatrin was detectable in the CSF compartment at the first sampling time point (30 
minutes).  The time to the peak concentration (rm ax) occurred at approximately 1   hour 
after  vigabatrin  administration,  and  then  fell  exponentially.  CSF  vigabatrin 
concentrations rose linearly and dose-dependently.  The apparent neuropharmacokinetic 
constants  for  individual  rat  together  with  the  mean  values  as  calculated  from  the 
concentration versus time curves are shown in Table 3.2.  Mean rm ax values ranged from
0.8-1.2 hours and mean half-life values were 2.0 h, 3.2 h and 3.3  h for 250, 500 and 
lOOOmg/kg vigabatrin administration respectively (Table 3.1  & 3.2).  However, whilst 
half-life  values  were  significantly  different  (P <   0.005)  between  250  mg/kg  to  500 
mg/kg  and between 250 mg/kg and 1000 mg/kgvigabatrin administration, there was no
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difference  between  500  and  1000  mg/kg  vigabatrin  administration.  Half-life values 
were also significantly longer than those values in the serum (P <  0.001) at all doses. 
Table: 3.2: Neuropharmacokinetic constants after intraperitoneal CSF vigabatrin
administration of 250, 500 and lOOOmg/kg vigabatrin
Rat  No. T m „ r ^   max AUC t'A
(h) (pmol/L) (pmol h/L) (h)
Vigabatrin  250 mg/kg
1 1.0 19.5 61.7 1.9
2 1.5 21.9 56.6 1.3
3 1.0 17.8 83.8 2.7
4 2.0 15.2 72.8 2.7
5 1.0 22.4 85.0 2.4
6 0.5 14.8 68.1 2.1
Mean 1.2 18.6 71.8 2.2
±SEM 0.2 1.3 4.4 0.2
Vigabatrin 500 mg/kg
1 0.5 20.7 95.8 3.4
2 1.0 30.4 108.2 2.8
3 1.0 46.6 189.6 2.8
4 1.0 27.3 99.8 4.3
5 0.5 36.4 130.8 2.5
6 1.0 29.5 114.0 3.2
Mean 0.8 31.8 123.0 3.2
±SEM 0.1 3.6 14.2 0.3
Vigabatrin lOOOmg/kg
1 1.0 37.2 180.6 3.5
2 1.0 31.1 129.4 2.9
3 1.0 80.1 412.7 3.6
4 1.0 47.0 267.4 4.1
5 0.5 45.2 190.8 2.9
6 0.5 63.3 239.1 2.9
Mean 0.8 50.6 236.7 3.3
±SEM 0.1 7.4 40.3 0.2
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Figure  3.3:  CSF  concentration  versus  time  profiles  for  vigabatrin  after 
intraperitoneal  administration  of  250mg/kg  (♦),  500mg/kg  (■)  and 
lOOOmg/kg (▲) vigabatrin. Data are mean ± sem of 6 animals.
3.3.3  ECF neuropharmacokinetics
The  mean  ±  SEM  in  vitro  relative  recovery  for  vigabatrin  from  28 
microdialysis probes was 21.69 ±  1.46 % at a dialysate flow rate of 1   pL/min.  These 
data were used to adjust the in vivo concentration data accordingly.
Following 500 mg/kg vigabatrin administrated intraperitoneally, vigabatrin was 
rapidly detected in the dialysate in both the frontal cortex and hippocampus (Figure 3.4 
A).  Vigabatrin  concentration  peaked  at  approximately  1   hour  post  vigabatrin 
administration  and  then  declined  exponentially.  A  similar  pattern  was  observed 
following  1000 mg/kg vigabatrin administration  (Figure 3.4  B).  Vigabatrin was also 
rapidly  detected  in  the  dialysates  of both  the  frontal  cortex  and  the  hippocampus. 
Vigabatrin  concentration  peaked  at 0.8  hour  and  then  declined  exponentially.  From 
figure 3.5 it can be seen vigabatrin concentrations increased in the frontal cortex (A) and
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the hippocampus (B) in a dose dependent manner.
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Figure 3.4:  Vigabatrin concentration versus time profiles for frontal cortex 
(♦) and for hippocampus (■) after intraperitoneal administration of vigabatrin 
(A) 500 mg/kg  and (B) 1000 mg/kg. Values are mean ± sem of 7 rats.
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Figure  3.5:  Vigabatrin  concentration  versus  time  profiles  for  the  frontal
cortex  (A)  and  the hippocampus  (B)  after  intraperitoneal  administration of 
vigabatrin 500 mg/kg (♦) and 1000 mg/kg (■). Values are mean ± sem of 7 
animals.
Cm ax  values in the frontal cortex were greater than those in hippocampus and
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this occurred for both doses.  Vigabatrin concentrations were 22.5 jimol/L ±3.2 for the 
frontal cortex and  12.7  pmol/L ±1.6 for the hippocampus after 500 mg/kg vigabatrin, 
and were  113.3  pmol/L ±  11.1  for the  frontal  cortex  and  51.7  pmol/L ± 4.8  for the 
hippocampus after  1 0 0 0 mg/kg vigabatrin.
Table 3.3  and 3.4  show the apparent neuropharmacokinetic  constants for the 
frontal cortex and hippocampus of individual animal together with the mean values as 
calculated from the concentration versus time plots.  Although AUC values increased 
dose dependently,  frontal cortex values were  2 fold greater than those observed in the 
hippocampus.  Half-life values decreased dose dependently and this was observed to 
occur  in  both  the  frontal  cortex  and  the  hippocampus  (this  contrasts  with  the  dose- 
halflife relationship  in serum and CSF).  These values of half-life in brain ECF were 
significantly prolonged (P < 0.001) compared to that in the serum, but values were not 
different from those observed for CSF (Table 3.2)
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Table  3.3:  Neuropharmacokinetic  constants  for  frontal  cortex  ECF  after
intraperitoneal administration of 500 and 1000 mg/kg vigabatrin
Rat No. T * ■   m a x C m a x AUC t'A
(h) (pmol/L) (pmol h/L) (h)
Vigabatrin 500 mg/kg
1 0.7 20.5 83.3 3.0
2 1.0 24.9 112.6 3.0
3 0.7 13.7 90.2 3.8
4 0.7 23.5 90.5 2.7
5 1.3 14.4 95.9 4.5
6 1.7 21.1 145.2 4.7
7 1.3 39.4 194.4 3.0
Mean 1.0 22.5 115.9 3.6
±SEM 0.1 3.2 15.3 0.3
Vigabatrin  1000 mg/kg
1 0.7 142.5 284.8 1.9
2 0.7 132.9 540.4 3.3
3 0.7 70.7 531.8 2.2
4 0.7 108.3 421.1 3.1
5 0.7 148.7 334.6 2.2
6 0.7 114.4 408.0 2.6
7 1.0 96.5 349.5 2.3
Mean 0.7 113.4 410.0 2.5
±SEM 0.1 10.1 36.8 0.2
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Table  3.4:  Neuropharmacokinetic  constants  for  hippocampal  ECF  after
intraperitoneal administration of 500 and 1000 mg/kg vigabatrin
Rat No. T  m a x c ^   m a x AUC tYi
(h) (pmol/L) (pmol h/L) (h)
Vigabatrin 500 mg/kg
1 1.0 10.0 48.9 4.6
2 0.7 13.9 53.3 4.0
3 0.7 19.9 63.7 3.4
4 1.0 10.4 48.2 3.0
5 1.0 14.5 41.8 2.5
6 1.0 13.8 57.8 3.3
7 0.7 6.2 30.4 4.5
Mean 0.9 12.7 49.2 3.6
±SEM 0.1 1.6 4.1 0.3
Vigabatrin  1000 mg/kg 
1 1.0 44.8 160.0 3.1
2 0.7 41.7 72.0 1.4
3 1.0 54.7 123.0 2.1
4 0.7 33.4 121.7 3.4
5 0.7 68.8 190.2 2.9
6 0.7 52.6 143.6 2.2
7 0.7 66.4 141.3 1.8
Mean 0.8 51.7 135.9 2.4
±SEM 0.1 4.9 13.9 0.2
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3.3.4  Comparison of serum, CSF and ECF kinetic parameters of vigabatrin
Figure 3.6 shows CSF/serum of vigabatrin concentration ratios after 250, 500 
and  lOOOmg/kg vigabatrin administrations.  Values rose gradually during first 7 hours 
post  vigabatrin  administration,  and  tended  towards  an  equilibrium  at  7-8  hours  (as 
measured by a constant CSF/serum vigabatrin concentration ratio).
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Figure 3.6:  CSF/serum vigabatrin concentration ratio versus time profiles for 
250 mg/kg (•), 500 mg/kg (♦) and lOOOmg/kg (■) vigabatrin. Date are mean 
± sem of 6 animal.
Figures 3.7 and 3.8 show the ECF/serum vigabatrin concentration ratios for the 
frontal  cortex  and  hippocampus  respectively  after  500  and  lOOOmg/kg  vigabatrin 
administrations.  It can be seen that the ECF/serum ratios followed a similar pattern as 
for  the  CSF/serum  ratios,  rising  slowly  during  the  first  7  hours  post  vigabatrin 
administration, and with a tendency towards equilibrium at 7-8 hours (as measured by a 
content ECF/serum vigabatrin concentration ratio).
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Figure 3.7:  ECF/serum vigabatrin concentration ratio versus time profiles for 
frontal  cortex  (♦)  and  hippocampus  (■)  after  500  mg/kg  vigabatrin 
administration.  Data are mean ± sem of 6 animals.
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Figure 3.8:  ECF/serum vigabatrin concentration ratio versus time profiles for 
frontal  cortex  (♦)  and  hippocampus  (■)  after  vigabatrin  1 0 0 0  mg/kg 
administration.  Data are mean ± sem of 6 animals.
The  relationship  between  vigabatrin  concentration  in  serum  and  CSF  after 
vigabatrin administration (250, 500 and 1000 mg/kg) is shown in Figure 3.9.  It can be 
seen that the relationship  is  linear (R2 =  0.704).  Similarly,  the relationship between
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vigabatrin  concentration  in  serum  and  ECF  after  vigabatrin  administration  (500  and 
1000 mg/kg) and are linearly related ( R2 = 0.9355) (Figure 3.10).
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Figure 3.9:  Relationship between serum and CSF concentration.  R2 = 
0.704 (n= 17).
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Figure 3.10:  Relationship serum and ECF concentration.  The equation 
for linear regression is R2= 0.9355 of the average in two doses (•).
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3.4  DISCUSSION
Pharmacokinetics and neuropharmcokinetics of vigabatrin
The present study sought to investigate the blood, CSF and ECF (frontal cortex 
and hippocampus) kinetic the inter-relationship using a rat model which allows serial 
sampling  of blood,  CSF  and  ECF  under  conditions  that  involve  in  minimal  animal 
handling  and  thus  pharmacokinetic  parameters  are  obtained  under  physiological 
conditions.
3.4.1  Serum pharmacokinetics
In man the blood pharmacokinetics of vigabatrin is well characterised (Rey et 
al.,  1992).  However,  there  is  a  sparcity  of data  on  the  blood  pharmacokinetics  of 
vigabatrin  in  animal  species  (Smithers  et  al.,  1985)  and  those  that  are published  in 
relation to the rat represent composite values obtained from individual animals killed at 
different time points after drug administration.  Valdizan et al. (1999) have reported on 
the time  course  of vigabatrin in rat plasma  after  single  and multiple  dose vigabatrin 
administration.  Sills et al. (2001, 2003) have reported plasma vigabatrin concentrations 
at a single time point after a single vigabatrin dose.  In the dog study of Smithers et al. 
(1985), vigabatrin was observed to be rapidly absorbed after oral ingestion with a blood 
Tm ax value of 1  hour and a tm value of 7 hours.
In the present study vigabatrin was administered as a single dose (250, 500 or
1 ,0 0 0   mg/kg) by intraperitoneal injection and the major serum pharmacokinetic findings 
of this  study  are  that:  (1)  the  pharmacokinetics  of  vigabatrin  in  serum  are  dose- 
dependent; (2) vigabatrin rm ax values (mean value 0.4 h) would suggest that vigabatrin 
is readily and quickly absorbed from the peritoneal cavity; (3) vigabatrin is not protein
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bound in serum and therefore readily distributed and available for entry and distribution 
into the brain;  (4) the elimination of vigabatrin from serum is rapid (mean tm values, 
1.1-1.4  h)  and  there  is  dose  independent  at  250-500  mg,  but  demonstrates  dose 
independence at higher doses (500-1000mg).
Although there  are reports  of single point  (at 2  hours  of 4 hours post-dose) 
concentration analysis of serum vigabatrin in the rat after acute administration of 250, 
500  and  1000  mg/kg  vigabatrin,  such  data  do  not  allow  any  calculation  of 
pharmacokinetic  parameters  (Sills  et  al.,  2001,  2003).  The  study  of Vladizan  et  al 
(1999) reported on the serum vigabatrin concentration versus time profile after a single 
intraperitoneal administration of 200 mg/kg vigabatrin. Blood samples were collected by 
heart puncture (thus requiring a single rat per time point) and samples were collected 
only at 4, 24, 48 and 72 hours post-dose.  Although the calculated t\n value from these 
data is  11  hours, the fact that vigabatrin was not detectable at 48 hours post-dose and 
that the t\n value is based on only two time points (4 and 24 hours) would suggest that 
the value  cannot be considered as  accurate.  In the present  study mean t\a values  for 
serum  vigabatrin,  as  calculated  from  vigabatrin  concentration  versus  time  profiles 
characterised by 17-time points over a sampling period of 8 hours, varied between  1 .1  
and 1.4 hours (Table 3.1).
3.4.2  CSF neuropharmacokinetics
As the CSF compartment is suggested to be kinetically indistinguishable from 
that  of the biophase or site of brain action  of drugs  that  are  active  in  the brain,  the 
present study used a well established and validated rat model so as to determine CSF
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neuropharmacokinetics of vigabatrin after single dose vigabatrin (250,  500 and  1,000 
mg/kg) administration.
In patients with epilepsy, analysis of CSF obtained by single lumber puncture 
after single dose vigabatrin ingestion has shown vigabatrin to be present at 6 hours post­
ingestion  and  CSF  vigabatrin  concentrations  to  be  approximately  10-15%  of blood 
concentrations  (Ben-Menachem  1989;  Ben-Menachem  et  al.,  1989).  Vigabatrin 
concentrations  in CSF increase dose-dependently and show a tendency to accumulate 
after  multiple-doses  (Riekkinen  et  al.,  1989).  In  animal  study,  the  time  course  of 
vigabatrin has also been reported in rat CSF  (Halonen et al,  1990;  1991)  and mouse 
brain (Jung et al., 1997; Sills et al., 2001; 2003).
In the present study, the major vigabatrin CSF neuropharmacokinetic findings 
after single-dose intraperitoneal vigabatrin administration (250, 500 or 1,000 mg/kg) are 
that:  (1)  vigabatrin  rapidly  (mean  rm ax  values,  0 .8-1 .2  h)  penetrated  the  blood-brain 
barrier and was detectable at the time of first CSF sampling (30 minutes post-dose); (2) 
although the  CSF pharmacokinetics  of vigabatrin paralleled  that  seen  in serum,  CSF 
vigabatrin concentrations represented only 3-5% of serum vigabatrin concentrations and 
did not reflect free drug concentrations in serum; (3) the efflux of vigabatrin from the 
CSF  compartment  was  significantly  slower  (mean  1 1/2  values,  2.2-3.3  h)  than  that 
suggested by serum values (mean t\/2 values, 1.1-1.4 h).
That vigabatrin enters the CSF compartment was confirmed by Halonen et al 
(1990) who reported on cisternal CSF vigabatrin concentrations after a single vigabatrin 
dose (1,000 mg/kg) administered intraperitoneally. CSF samples were collected at 5, 24,
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48  and  96  hours  after  vigabatrin  administration  and  showed  that  vigabatrin 
concentrations  were  at  their highest  at  5  hours  and  interestingly vigabatrin  was  still 
measurable in CSF samples collected at 96 hours. Unfortunately, the data do not allow 
for any meaningful calculation of CSF pharmacokinetic data. However, comparing the 
CSF  vigabatrin  concentrations  achieved  at  5  hours  post  dose  with  concentrations 
observed  in  the  present  study (Figure  3.3)  vigabatrin  concentrations  are  significantly 
different  ( 8 8  pmol/L versus  18  pmol /L for the present study).  The  fact that the two 
studies used different rat strains may in part explain the difference.
Two  physiochemical  characteristics  of  drug  which  determine  the  rate  and 
degree  of entry  into  the  CSF  and brain  are  lipid  solubility and  the  degree of serum 
protein binding.  Because vigabatrin has high water solubility, it would not be expected 
to gain rapid entry into the brain.  Nevertheless, vigabatrin did rapidly enter the central 
compartment  since  vigabatrin  was  detectable  in  CSF  at  time  of first  sampling  (30 
minutes; Figure 3.3).  Additionally, the rate of entry into the CSF was dose-dependent, 
as there was difference in rm ax values after vigabatrin dose administration (250, 500 and
1,000  mg/kg).  Indeed, serum and CSF vigabatrin concentrations were linearly related 
(Figure  3.9).  These  data  suggest that  vigabatrin  may be  actively transported  into  the 
brain.
As the serum protein binding of a drug is a determinant of the available drug 
that can enter the brain/CSF, it might be expected that vigabatrin, which is not protein 
bound in serum, would be located in high concentrations in these central compartments. 
However, this is not the case with CSF concentrations representing but a small fraction 
(3-5%) of the concentrations observed in serum.  In man the equivalent figure is  10%
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(Ben-Menachem  et  al.,  1989).  The  reason  for  this  is  unknown,  but  these  data  with 
vigabatrin parallel that observed with another GAB  A acting drug, tiagabine (Wang et 
al., 2004), and would also be consistent with an active transport mechanism.
3.4.3  ECF neuropharmacokinetics
Although  the  CSF  compartment  is  considered  to  be  kinetically 
indistinguishable from that of the biophase or site of brain action of drugs that are active 
in the brain,  some drugs (e.g. phenytoin) are known not to be uniformly distributed in 
the  brain  (Walker  et  al.,  1996).  Consequently,  microdialysis  monitoring  of ECF  in 
specific brain sites is considered to be a more appropriate index of events that occur at 
the synaptic level and thus at the site of drug action.
There  have  been  no  reports  on  vigabatrin  ECF  neuropharmacokinetics, 
although  as  highlighted  earlier  some  composite  brain  data  have  been  reported  from 
which some tentative kinetic parameters can be deduced (Jung et al.,  1997; Sills et al., 
2001; 2003).  In the present study the ECF neuropharmacokinetics of vigabatrin were 
simultaneously determined in the rat frontal cortex and hippocampus after 500 and 1000 
mg/kg vigabatrin administration by intraperitoneal injection. Vigabatrin entered the ECF 
compartment rapidly with Tm ax values at 0.7-1.7 hours.  However, vigabatrin distribution 
was brain region specific with vigabatrin concentrations in the frontal cortex being  2 - 
fold greater compared with that in the hippocampus.  This concentration difference was 
observed  for  both  500  mg/kg  and  1000  mg/kg  vigabatrin  administration.  Mean 
vigabatrin t\/2 values were identical for frontal cortex (2.5-3.6 hours) and hippocampus 
(2.4-3.6 hours),  which would suggest that the  elimination processes  in the two brain
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regions  are  similar.  There  is  no  evidence  that  vigabatrin  is  transported by  PGP.
Vigabatrin is transported by amino acid transporters (Abbot et al, 2006). It is possible 
that vigabatrin is transported into brain.  So the two explanations are either it is being 
pumped out  faster (e.g. via PGP) or that it is being pumped in more efficiently. Since the
rate  of  elimination  is  similar  for  frontal  cortex  and  hippocampus,  then the  only
explanantion is that there is a difference in the efficiency of transport of vigabatrin into 
the brain.
3.4.4  Vigabatrin kinetic inter-relationship between serum, CSF and ECF
Compared  to  serum,  the  CSF  neuropharmacokinetic  characteristics  of
vigabatrin are somewhat different.  Firstly, mean Tm ax values in the CSF (0.8-1.2 hours) 
were larger than that in  serum (0.4 hours). However, this would be expected since the
difference represents the time needed  for vigabatrin to pass from the blood compartment
to the CSF compartment. Secondly, although there was a tendency towards equilibration 
of vigabatrin  concentrations  between  the  blood  and  CSF  compartments  this  was  not 
achieved by  8 hours after vigabatrin administration ((Figure 3.6).  This is corroborated 
by the fact that there appears to be some significant scatter in vigabatrin concentrations 
when serum and CSF values are compared (Figure3.9).
Compared  to  serum,  the  ECF  neuropharmacokinetic  characteristics  of
vigabatrin are also different. Firstly, unlike the CSF compartment, equilibration between 
the ECF compartment (both frontal cortex and hippocampus) and the blood compartment 
was attained by approximately 7 hours after vigabatrin administration (Figures 3.7 and 
3.8). This is corroborated by the fact that there is a significant correlation between ECF
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and  serum  vigabatrin  concentrations  (figure  3.10).  Secondly,  and  perhaps  more 
importantly, the vigabatrin concentrations achieved in ECF were not only substantially 
lower than that seen in serum but additionally there was specific region distribution of 
vigabatrin. Thus vigabatrin concentrations in the frontal cortex were 2-fold greater than 
concentrations achieved in the hippocampus.
3.4.5  Summary
This  is  the  first  study  to  investigate  the  temporal  pharmacokinetic  inter­
relationship of vigabatrin in rat blood, CSF and brain (frontal cortex and hippocampus) 
ECF.
1.  Vigabatrin is associated with linear peripheral and central kinetics and with 
rapid  penetration  into  the  CSF  and  brain  (frontal  cortex  and  hippocampus)  ECF 
compartment.
2.  Although vigabatrin is not protein bound in serum, CSF concentrations are 
only 3-5% of those in serum and thus do not reflect free drug concentrations.
3.  Vigabatrin was associated with differential brain region distribution in that 
vigabatrin  concentrations  in  the  frontal  cortex  were  2 -fold  greater  than 
concentrations achieved in the hippocampus.
These data support an active uptake mechanism in the central nervous system. 
This would explain the means by which a highly water soluble drug passes into the central 
nervous system, and also the different concentrations attained in different brain areas.
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4.1  INTRODUCTION
Levetiracetam  is  a  novel  AED  that  not  only  possesses  potent  anticonvulsant 
properties but also exhibits antiepileptogenic effects (Gowers et al., 1992; Loscher et al., 
1998).  It  exhibits  a  broad  spectrum  of  action  and  is  licensed  for  clinical  use  as 
adjunctive treatment  for the management of patients with partial  seizures  (Perucca & 
Johannessen,  2003;  Czapinski  et al,  2005).  The pharmacokinetics of levetiracetam in 
man have been extensively determined, and are simple and straight forward comprising 
of rapid  absorption  following  oral  ingestion  resulting  in  peak  plasma  concentrations 
within 20 minutes and an elimination half-life of 6 - 8  hours (Patsalos, 2003, 2004). Such 
linear dose-dependent pharmacokinetic characteristics have recently been confirmed in a 
freely behaving rat model (Doheny et al.,  1999). Levetiracetam was observed to rapidly 
and readily enter the CSF compartment, however, its efflux from CSF (mean t\a  range, 
4.4-4.9  hours)  was  significantly slower  than  that  suggested  by  serum  concentrations 
(mean  0 /2  range,  1.8-2.8  hours).  Since  the  brain  neuropharmacokinetics  of 
levetiracetam are unknown, the present study sought to investigate the serum and ECF 
(frontal cortex and hippocampus) kinetic inter-relationship of levetiracetam.
4.2  EXPERIMENTAL PROTOCOL
Male Sprague-Dawley rats (Charles River,  Margate,  Kent) weighing 300-3 5 Og 
were used.  A venous catheter was surgically implanted into the right jugular vein and 
two microdialysis probes (one in the cerebral cortex and the other in the hippocampus) 
were  stereotaxically implanted.  The  surgical  procedures  are  described  in  Chapter 2. 
Two  days  after  surgery,  baseline  samples  were  collected  and  the  rats  were  then
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administered  levetiracetam  (40  and  80mg/kg)  by  intrapeartoneal  injection.  Venous 
blood samples (100 pL) were withdrawn at 20 minute intervals for the first hour and at 
30 minute intervals for a further 7 hours.  Dialysate samples (20 pL) were collected at 
20 minute intervals for 4 hours and then subsequently at 30 minute intervals for a further 
4 hours.  Levetiracetam concentrations were determined by HPLC using the method of 
Ratnaraj et al (1996) as described in Chapter 2.
4.3  RESULTS
4.3.1  Serum pharmacokinetics
The  serum  concentrations versus  time profiles  of levetiracetam  after 40mg/kg 
and  80mg/kg  levetiracetam  administration  are  shows  in  Figure  4.1.  Levetiracetam 
demonstrated  rapid  absorption  and  dose  dependent  kinetcis.  Peak  levetiracetam 
concentrations (Tm ax) were achieved at 0.4-0.7 ± 0.1  h (mean ± sem) and there was no 
significant  effect  of  dose  (p  >  0.05),  although  there  was  a  tendency  for  the 
concentrations to peak later at the higher dose.
Table  4.1  shows  that  apparent  pharmacokinetic  constants  for  individual  rats 
together with the mean values, as calculated from the concentration versus time plots. 
The pharmacokinetic constants for individual rats showed some variability within each 
dose  group.  The  mean  CmaX   and  AUC  values  for  levetiracetam  increased  dose- 
independently and the values of Cm ax and AUC are more twice higher than that of 40mg. 
However,  tm  values  were  not  dose  dependent.  The  Cm ax  and  Tm ax  values  for 
levetiracetam  were  determined by visual  inspection  of the  concentration  versus  time
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curves and as the first sampling time point was at 2 0  minute,  these  values  may  have 
been overestimated  or underestimated respectively.
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Figure  4.1:  Serum  levetiracetam  concentration  versus  time  profiles  after
intraperitoneal  administration  of  40  mg/kg  (♦),  and  80  mg/kg  (■) 
levetiracetam. Values are mean ± sem of seven animals.
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Table  4.1:  Serum  levetiracetam  pharmacokinetic  constants  after  intraperitoneal
administration of 40 and 80 mg/kg levetiracetam
Rat No. Tm ax Cmax AUC * 1/2
(h) ((imol/L) (fxmol /L/h) (h)
Levetiracetam 40mg/kg
1 0.3 211.9 648.6 2.3
2 0.7 212.4 590.8 1.9
3 0.3 227.1 814.6 2.3
4 1 .0 2 2 2 .8 709.9 2 .1
5 1 .0 263.3 1029.7 3.0
6 1 .0 192.0 703.6 2.5
7 0.7 269.8 630.6 1.7
Mean 0.7 228.5 732.5 2 .2
± s.e.m 0 .1 10.7 56.5 0.15
Levetiracetam 80mg/kg
1 0.3 709.6 2651.9 2 .6
2 0.7 650.5 1874.2 2 .1
3 0.3 705.3 2098.5 2 .0
4 0.7 834.8 3507.8 2.5
5 0.3 902.9 2247.2 1.9
6 0.3 660.1 2182.9 2.3
7 0.3 432.7 1665.0 2.3
Mean 0.4 699.4 2318.2 2 .2
± s.e.m 0 .1 56.7 230.0 0 .1
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The  free  non-protein  bound  levetiracetam  concentration  was  determined  in  9 
serum samples that spanned the concentration range and the time range studies in this 
study.  Figure 4.2  shows the free/total  levetiracetam  concentration  ratio  for the nine 
samples and the calculated mean free fraction was 0.99 ± 0.06.  These data suggest that 
levetiracetam is not protein bound.
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Figure 4.2:  Levetiracetam free/total concentration ratios versus time profile.
4.3.2  ECF neuropharmacokinetics
The  mean  ±  SEM  in  vitro  relative  recovery  for  levetiracetam  from  24 
microdialysis probes was  13.00 ± 0.69 % at a dialysate flow rate of 2 pL/min.  These 
data were used to adjust the in vivo concentration data accordingly.  Following 40 and 
80  mg/kg  levetiracetam  administrated  intraperitoneally,  levetiracetam  was  rapidly 
detected in the dialysate of both the frontal cortex and the hippocampus (Figure 4.3 A & 
B).
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Dialysate  levetiracetam concentrations peaked at  1.8  hour (frontal  cortex)  and
2 .5   hour  (hippocampus)  post  levetiraceam  administration  and  then  declined 
exponentially.  A similar profile was seen after 80mg/kg levetiracetam administration 
and, the levetiracetam concentration peaked at 2.1  hours (frontal cortex) and  1.9 hour 
(hippocampus).  Cm ax values in the frontal cortex were similar to those observed in the 
hippocampus at both doses (69.5 pmol/L ± 8.7 for frontal cortex and 58.0 pmol/L ±5.3 
for  hippocampus  after  40  mg/kg  levetiracetam  and  155.0  pmol/L ±21.4  for frontal 
cortex  and  172.7  pmol/L  ±  0.2  for  hippocampus  after  80  mg/kg  levetiracetam 
administration).  The neuropharmacokinetics of levetiracetam in the frontal cortex and 
hippocampus were indistinguishable and there is no evidence of any differential regional 
brain  distribution  of  levetiracetam  (Figure  4.4  A  &  B).  With  increased  dose 
concentrations both brain areas showed the same time profile for levetiracetam (Figure
4.3  A & B).
The mean ±  s.e.m  neuropharmacokinetic  constants  as  calculated  from the  log 
concentration versus time plots of individual rats are shown in Tables 4.2 and 4.3.  Both 
AUC  and  Cm ax mean  values  increased dose-dependently and  linearly.  Levetiracetam 
was detectable at the time of first microdialysate sampling (15 min) with concentrations 
peaking some what later (mean  rm ax >   2.0-2.5 hours) than  serum (0.4-0.7hours).  T\a 
values were not significantly different when the two doses are compared.
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Figure  4.3:  Levetiracetam  ECF  concentration  versus  time  profiles  for  the
frontal  cortex  (♦)  and  the  hippocampus  (■)  after  an  intraperitoneal 
administration of levetiracetam (A) 40 mg/kg and (B) 80 mg/kg.  Values are 
mean ± sem of 6 animals.
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Figure  4.4:  Levetiracetam  ECF  concentration  versus  time profiles  for 40 
mg/kg  (♦)  and  80  mg/kg  (■)  after  an  intraperitoneal  administration  of 
levetiracetam (A) in the frontal cortex and (B) in the hippocampus.  Values 
are mean ± sem of 6 animals.
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Table 4.2:  Neuropharmacokinetic constants for frontal cortex ECF after intraperitoneal
administration of 40 and 80 mg/kg levetiracetam
Rat No. Tm ax Cm ax AUC * 1/2
(h) (pmol/L) (pmol /L/h) (h)
Levetiracetam 40mg/kg
1 1 .8 82.8 415.7 3.5
2 2.5 75.0 375.4 2.9
3 1 .8 37.3 335.1 2 .8
4 1 .8 76.0 461.8 3.3
5 1.5 94.8 383.4 2.7
6 1.3 51.3 189.6 3.1
Mean 1.8 69.5 360.2 3.1
± s.e.m 0.2 8.7 34.9 0.1
Levetiracetam 80mg/kg
1 3.5 93.4 543.8 3.4
2 2 .0 216.2 1035.9 3.1
3 1 .8 147.2 718.3 3.3
4 2.5 2 0 2 . 0 913.6 3.1
5 2.5 175.3 940.5 3.3
6 3.0 95.8 392.2 2.9
Mean 2.5 155.0 757.4 3.2
± s.e.m 0.3 21.4 86.7 0.1
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Table 4.3: Neuropharmacokinetic constants for hippocampal ECF after intraperitoneal 
administration of 40 and 80 mg/kg levetiracetam_______________________________
Rat No. Tnax Cm ax AUC hi  2
(h) (pmol/L) (pmol /L/h) (h)
Levetiracetam 40mg/kg
1 2.5 71.6 433.0 3.2
2 1 .8 60.4 760.0 2.9
3 2.5 36.8 159.0 2.7
4 1.5 6 8 .2 408.8 3.2
5 2.5 62.1 419.1 3.4
6 1.5 49.1 349.3 3.6
Mean 2.1 58.0 421.5 3.2
± s.e.m 0.2 5.3 79.4 0.1
Levetiracetam 80mg/kg
1 2.5 235.0 1350.1 3.5
2 1 .8 122.5 554.5 3.4
3 2 .0 207.6 1159.4 3.7
4 2 .0 168.7 723.6 3.3
5 2 .0 175.0 758.3 2.9
6 1.3 127.3 480.8 2 .8
Mean 1.9 172.7 837.8 3.3
± s.e.m 0.2 18.0 140.6 0.1
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4.3.3  Levetiracetam kinetic inter-relationship between serum and ECF
After intraperitoneal administration levetiracetam demonstrated rapid absorption 
into both the serum and ECF compartments and the concentration of levetiracetam rose 
dose-dependently.  The t\n values of ECF were however longer than for serum.  The 
AUC  values  and  Cm ax values  in the  serum were  three times  higher than  in the ECF 
(Figure: 4.5 and 4.6).  However, compared to the levetiracetam  6 /2  in serum, the ECF 
t\/2 values were significantly longer (P < 0.05).
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Figure 4.5:  Serum (▲ ), frontal cortex ( ♦  ) and hippocampal (■ ) ECF 
concentration  versus  time  profiles  for  levetiracetam  following  I.P. 
administration 40mg/kg levetiracetam.  Date are mean ± sem of 6 animals.
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Figure 4.6: Serum (A ), frontal cortex ( ♦  ) and the hippocampal (■ ) ECF 
concentrations  versus  time  profiles  for  levetiracetam  following  I.P. 
administration  of  80mg/kg  levetiracetam.  Date  are  mean  ±  sem  of  6  
animals.
Figure 4.7  and 4.8  show the ECF/serum  levetiracetam concentration ratios for 
the  frontal  cortex  and hippocampus respectively after levetiracetam 40 and 80 mg/kg 
levetiracetam administrations.  It can be seen that at 5.0 - 7.5 hour post levetiracetam 
administration,  there  is  a  tendency towards  equilibration  (as  measured  by a constant 
ECF/serum  levetiracetam  concentration  ratios)  between  the  blood  and  ECF 
compartments.
148Chapter 4 Pharmacokinetics and neuropharmacokinetics of levetiracetam
E
(0
E
3 L_ < D JO
l H o H I
.2  1.5
2
c
o
c I o
o  0.5  o
1 2 3 4 5 7 8 9 0 6
Time (hours)
Figure  4.7:  ECF/serum  levetiracetam  concentration  ratio  versus  time
profiles for the frontal cortex  (♦) and the hippocampus (■) after 40mg/kg 
levetiracetam administration.  Data are mean ± sem of 6 animals.
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Figure  4.8:  ECF/serum  levetiracetam  concentration  ratio  versus  time 
profiles  for  the  frontal  cortex  (♦)  and  the  hippocampus  (■)  after  80 
mg/kg levetiracetam administration.  Data are mean ± sem of 6 animals.
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4.4  DISCUSSION
Previously, Doheny et al (1999) reported on the temporal pharmacokinetic inter­
relationship of levetiracetam in rat serum and CSF.  In the present study, these data are 
extended  to  include  the  study  of the  temporal  pharmacokinetic  inter  relationship  of 
levetiracetam  in  rat  serum  and  frontal  cortex  and  the  hippocampus  ECF.  The 
pharmacokinetic profile of levetiracetam in serum, as observed in the present study, was 
similar to that reported by Doheny et al (1999) and these data not only serve to further 
validate  the  animal  model  used,  but  also  further  confirm  the  predictable 
pharmacokinetic and neuropharmacokinetic nature of levetiracetam.
4.4.1  Serum pharmacokinetics
In  this  study,  the  temporal  pharmacokinetics  of levetiracetam  in  serum  was 
determined after acute intraperitoneal administrations of 40 and 80mg/kg levetiracetam. 
Serum concentrations of levetiracetam rose quickly  and dose-dependently.  The mean 
Cm ax were 229 ± 10.7 pmol/L and 699 ± 56.7 pmol/L for 40 and 80 mg/kg levetiracetam 
respectively.  values  were  0.4 -   0.7  hours,  which  suggests  that  levetiracetam  is
quickly absorbed from the peritoneal cavity into the systemic  circulation.  The serum 
elimination  half-life  of  levetiracetam  was  2 .2   hours  for  both  levetiracetam  doses. 
Furthermore, levetiracetam was not protein bound in serum.
The  pharmacokinetics  of levetiracetam  in  the  rat  was  previously reported  by 
Doheny et al  (1999).  Levetiracetam were administered at three doses (20, 40 and 80 
mg/kg) and the results showed that levetiracetam rapidly appeared in serum (mean  Tm ax
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0.25-0.5  hours) and these data are similar to those obtained in the present study (rm ax
0.4-0.7).  Similarly, the serum free/total concentration ratio (free fraction) reported by 
Doheny et al (1999) was 1.01 ± 0.02 (mean ± S.E.M.), which is almost identical to the 
present result of 0.99 ± 0.06  (mean ±  S.E.M).  Furthermore, the serum levetiracetam 
elimination half-life values observed by Doheny et al (1999) were 1.8 -  2.8 hours whilst 
in the present study a value of 2 .2  hours was observed.
Following  250  to  5000  mg/kg  levetiracetam  oral  administration  to  human 
healthy volunteers,  levetiracetam  was  rapidly  and  almost  completely  absorbed.  The 
absolute oral bioavailability was nearly  1 0 0%.  Peak plasma concentrations (Cm ax) were 
achieved within  1   hour.  The  Vd  of levetiracetam was 0.5-0.7L/kg and was similar to 
total body water (0.6 L/kg) (Cereghino et al, 2000; Shorvon et al, 2002; Patsalos, 2000, 
2003).  In healthy young volunteers, the elimination half-lives of levetiracetam ranged 
from  6 - 8  hours.  Levetiracetam was not bound (<  10%) to plasma proteins (Patsalos, 
2000).
4.4.2  ECF neuropharmacokinetics
There  are  no  published  data  describing  the  central  neuropharmacokinetics  of 
levetiracetam in the ECF.  The present data are the first to report on the temporal ECF 
neuropharmacokinetics of levetiracetam in rat frontal cortex and hippocampus.  These 
data reveal some interesting characteristics:  1.) The ECF concentration of levetiracetam 
rose linearly and dose-dependently  2.)  ECF  levetiracetam  rm ax values were longer 
compared to that observed in serum.  3.)  The half-life values of levetiracetam in the 
ECF were longer than that in the serum;  4.) ECF levetiracetam concentrations in the
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frontal cortex and the hippocampus  were essentially  identical and the distribution in 
the brain was not region special.
After intraperitoneal administration,  levetiracetam rapidly appeared in both the 
frontal cortex and the hippocampus; levetiracetam was detected in ECF at time of first 
sample (0.25 hour).  Peak levetiracetam concentrations in brain ECF occurred somewhat 
later (rm ax were 1.8 -  2.5 hours) than in serum (rm ax 0.4 -0.7 hours).  These longer ECF 
Tm ax values represents the time for levetiracetam to pass from the serum compartment 
into to the brain ECF compartment (1.4-  1.8 hours).  Furthermore,  ECF  rm ax values 
were slightly longer than  rm ax values previously reported for CSF (rm ax  mean  1.6-1.9 
hour)  by Doheny  et  al  (1999).  The  observed  difference between  the  ECF  and  CSF 
compartments  may be  attributed,  in part,  to  the  methodology used,  in  that  CSF  was 
directly sampled whereas ECF was not, but may also represent differences between the 
ECF and CSF compartments.
ECF  levetiracetam  mean  Cm ax  values  were  3.2  -   4.0  folds  lower  than  those 
observed  in  serum  and  this  difference  may  be  attributed  to  the  brain  penetration 
characteristics of levetiracetam.  However, a more likely explanation relates to the fact 
that ECF levetiracetam concentrations were calculated based on the in  vitro recovery 
characteristics of microdialysis probe and is not dependent on Pgp or MRP transparters 
(Potschka  et  al,  2004).  That  ECF  levetiracetam  concentration  increased  dose- 
dependently  and  linearly  would  suggest  that  transport  across  the  BBB  was  not  rate 
limiting  over the  concentration range observed  in  the present  study.  This  is  further 
emphasised by the dose-dependent increase in ECF AUC values.  Furthermore, as the
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neuropharmacokinetic profiles of levetiracetam in the frontal cortex and hippocampus 
were essentially identical, it can be concluded that levetiracetam distribution in the brain 
is not region specific.
The  efflux  of levetiracetam  from  the  brain  ECF  compartment  appeared to  be 
restricted, as demonstrated by the half-life of levetiracetam, which was approximately 
50% longer than that observed in the blood.  These data, combined with similar data for 
CSF  (where  efflux  of levetiracetam  from  the  CSF  compartment  was  170%  slower. 
Doheny et al, 1999), may in part explain the substantial clinical efficacy of levetiracetam 
during  twice  a  day  dosing  (Ben-Menachem  &  Falter,  2000;  Cereghino  et  al,  2000; 
Shorvon et al, 2002), despite the fact that its blood pharmacokinetics (half-life 6 - 8 hour) 
would suggest that three times a day dosing is more appropriate.
Previously,  it  was  reported  that  at  equilibrium,  the  CSF/serum  concentration 
ratio  was similar to that of the blood free  fraction  (0.96 versus  1.01),  suggesting the 
blood levetiracetam concentration reflected central brain concentrations (Doheny et al, 
1999).  However, in the present study, there was a tendency towards equilibration at 5.0 
-7.5 hours post levetiracetam administration and the ECF/serum concentration ratios for 
both  the  frontal  cortex  and  the  hippocampus  ranged  from  approximately  0.7-0.8  
(80mg/kg dose) to 0.9-1.0 (40mg/kg dose) at this time point.  This would suggest that, 
in the acute situation, serum levetiracetam concentrations do reflect the concentrations 
at its site of action in the brain but that equilibration is achieved by 5 hours.  However, it 
should be noted that since the ECF levetiracetam concentration data have been adjusted
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on the basis of in vitro relative recovery and since in vitro recovery can be expected to 
be greater than in vivo recovery, ECF/serum concentration ratio may 
be overestimated.
4.4.3  Conclusions
1.  Levetiracetam exhibits linear pharmacokinetics in serum and is not protein 
bound to serum proteins.
2.  Levetiracetam rapidly and readily entered the brain ECF (frontal cortex and 
hippocampus) with mean rm ax values of 1.8 -  2.5 hours.
3. The neuropharmacokinetic profiles of levetiracetam in the frontal cortex and 
hippocampus are essentially identical and levetiracetam distribution in the brain is not 
brain region specific.
154Chapter 5 The effect of vigabatrin on CSF and ECF amino acids
Chapter 5
The effect of vigabatrin 
on CSF and ECF amino acids
155Chapter 5
5.1  INTRODUCTION
The effect of vigabatrin on CSF and ECF amino acids
Excitatory and inhibitory amino acids, especially GABA and glutamate, have 
been proposed to play a critical role in the development and maintenance of epileptic 
seizures.  GABAergic  drugs  have  been  developed  in  an  effort  to  inhibit  epileptic 
excitability and some of the new AEDs appear to directly or indirectly change brain 
GABA concentrations rather than act at a receptor or an ion channel (Czapinski et al, 
2005).  Vigabatrin  is  a  drug  that  has  a  close  structure  to  GABA  but  possesses  a 
terminal  vinyl  group  binding  irreversibly  to  GABA-T,  resulting  in  a  blockage  of 
metabolic degradation and an accumulation of GABA in neurones and glia (Bialer et 
al, 1999; Patsalos, 1999).
Vigabatrin affects on amino acid concentrations in CSF have been reported in 
many studies in both animal models and in patients  (Ben-Menacham et al,  1988  & 
1989; Ylinen et al,  1992; Riekkinen et al,  1989b; Halonen et al,  1990).  However, the 
results  are  contradictory,  but  most  studies  show  that  CSF  GABA,  glycine, 
homocamosine and taurine are increased, whilst glutamate and aspartate are reduced 
(Smolders et al,  1997; Jolkkonen et al,  1992; During et al,  1995; Richards et al,  1995; 
Schiffer et al, 2001).  Furthermore, there are no studies that have investigated the inter­
relationship between the neuropharmacokinetics of vigabatrin and concurrent changes 
in GABA and other amino acids.  The present study sought to investigate these inter­
relationships in a rat model,  and to determine the  effects of vigabatrin on CSF and 
ECF amino acids.
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5. 2  EXPERIMENTAL PROTOCOL
Amino  acid  concentrations in  CSF  and ECF  were  measured  using the 
methods described in Chapter 2.  Male Sprague-Dawley rats (Charles River, Margate,
Kent) weighing 300-350 g were used.  CSF cannulae were implanted into the cistema
magna  and  microdialysis  probes  were  inserted  into  the  frontal  cortex  and  the
hippocampus  as  described  in  Chapter 2.  Two  days  after surgery, baseline  samples
were  collected  and  the  rats  were  administered  intraperitoneally with  500  and  1000
mg/kg vigabatrin for CSF and lOOOmg/kg for microdialysis studies.  CSF samples (10
pL) were collected every 30 minutes for  8 hours and dialysate samples (20 pi) were
collected at 20 minute intervals for the first 4 hours and at 30 minute intervals for a
further 4 hours.
5.3  RESULTS
5.3.1  CSF amino acid concentrations
Of the 16 amino acids that were measured in CSF and only the concentrations 
of 5  amino acids changed after vigabatrin administration.  The results are shown in 
Table 5.1., 5.2 and Figures 5.1-5.5  show the data graphically.  The other amino acid 
including  alanine,  asparagine,  aspartate,  glutamate,  glutamine,  isoleucine, 
phenylalanine,  leucine,  serine  and  threonine  were  unaffected  by  vigabatrin 
administration.
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Table  5.1:  Decreases  of Arginine  and  Tyrosine  concentrations  in  rat  CSF
expressed as a % of baseline after 500 and 1000 mg/kg  vigabatrin administrations
Time
(Hours)
Arginine 
500mg/kg  1000 mg/kg 500 mg/kg
Tyrosine
1000 mg/kg
Baseline 100  ±10 100  ±16 100 ±9 100 ±4
0.5 95* ± 11 102  ±17 89* ±7 86* ±6
1.0 84* ± 10 99  ±14 79* ±4 69* ±3
1.5 78* ±  7 85* ± 12 75* ±3 63* ±5
2.0 71* ± 8 86* ± 12 59* ±2 56* ±4
2.5 63* ±7 84  ±11 60* ±5 58* ±5
3.0 57* ±6 67* ±6 54* ±7 49* ±3
3.5 61* ±4 68  ±9 66* ±6 54* ±4
4.0 55* ±6 61  ±9 54* ±5 58* ±5
4.5 53* ±5 65* ±8 56* ±2 49* ±4
5.0 51* ± 6 60* ±9 59* ±6 47* ±3
5.5 56* ±5 60* ±6 59* ±4 47* ±4
6.0 52* ±6 56* ±7 58* ±3 49* ±4
6.5 51* ± 6 52* ±8 58* ±6 51* ± 3
7.0 48* ±6 55* ±6 62* ±5 47* ±3
7.5 51* ± 6 54* ±4 71* ± 6 50* ±3
8.0
-
H
*
o
o 48* ±3 60* ±4 47* ±3
*
Data are mean of 5-6 animals 
*  =P< 0.05 compared to baseline
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Table 5.2:  Increases of glycine, homocamosine and taurine concentrations in 
rat CSF  expressed as a % of baseline after 500 or  1000 mg/kg  vigabatrin 
administrations
Time  Glycine  Homocarnosine  Taurine
lOOOmg/kg  500mg/kg  lOOOmg/kg  500mg/kg  lOOOmg/kg
Baseline 100  ± 11 100  ±  8 100 ± 10 100  ±  9 100  ±  4
0.5 108  ± 12 9 1   ±1 104 ± 13 96  ±  6 91  ±  7
1.0 100  ±  9 98  ±  5 101 ± 13 85* ±  4 91  ±  7
1.5 122  ±11 98  ±  5 108 ± 11 91  ±  7 102 ±  4
2.0 102  ± 10 99  ±  6 101 ± 13 94  ±  6 124 ±  8
2.5 100  ±  8 100  ±  10 121 ± 10 107  ±  6 136 ± 10
3.0 122  ± 10 92  ±  12 116 ± 9 103  ±  7 135 ± 11
3.5 140  ± 13 101  ±  8 120 ± 8 120* ±  8 153 ± 13
4.0 126  ± 12 110* ±  9 133 ± 10 126* ± 8 172*±14
4.5 132  ±  5 111 * ± 10 132 ± 11 135* ± 8 172*±14
5.0 116  ±  2 112* ±  9 132 ± 10 131* ± 10 174*±13
5.5 136  ±  5 120*± 110 149* ± 6 145* ±8 175*±14
6.0 159* ±7 120* ±  10 146* ± 13 163* ± 9 182*±15
6.5 158* ±7 117* ±  11 150* ± 7 158* ± 9 191*±13
7.0 171* ±11 125* ±  9 161* ± 13 170*±  14 192*±15
7.5 151  ±  4 124* ±  9 159* ± 13 159*±  10 199*±18
8.0 132  ±  9 125* ±  11 178* ± 14 138* ± 13 195*±11
Data are mean of 5-6 animals
*  = P < 0.05 compared to baseline
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Figure 5.1  shows CSF arginine concentrations over time after 500 and  1000 
mg/kg  vigabatrin  administrations.  Following  500mg/kg  vigabatrin  administration, 
arginine concentrations gradually decreased over time.  At  8 hours (the last sample 
time point), the concentration of arginine was maximally reduced (48 % compared to 
baseline).  Similarly, after 1000 mg/kg vigabatrin administration, arginine rose slightly 
at half an hour but subsequently declined to that which was observed after 500 mg/kg 
vigabatrin  administration.  The  decline  in  arginine  concentrations  compared  to 
baseline were statistically significant at both doses (P < 0.05).
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Figure  5.1:  CSF  arginine  concentration  versus  time  profiles  after 
intraperitoneal  administration  of  500  mg/kg  (■)  and  1000  mg/kg  (■) 
vigabatrin.  Values are mean ± sem of 6 animals.  * = P< 0.05
Figure 5.2 shows the temporal changes in tyrosine concentrations after 500 
and 1000 mg/kg vigabatrin administrations.  Tyrosine concentrations decreased at the 
first time point (0.5hour) and subsequently showed a time-dependent decrease.  At  8 
hours post vigabatrin administration,  tyrosine  concentrations were reduced  by 40%
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and  57%,  after  500  and  1000  mg/kg  vigabatrin  respectively,  when  compared  to 
baseline.
150  n
< />
o  1 2 0 -
k
B  0.5  1  1.5  2  2.5  3  3.5  4  4.5  5  5.5  6  6.5  7  7.5  8
Time (hours)
Figure  5.2.  CSF  tyrosine  concentration  versus  time  profdes  after 
intraperitoneal  administration  of  500  mg/kg  (■)  and  1000  mg/kg  (■) 
vigabatrin.  Values are mean ± sem of 6 animals.  * = P< 0.05
In contrast, glycine, homocarnosine and taurine concentrations increased after 
vigabatrin administration and these data are shown in Table 5.2 and Figures 5.3- 5.5. 
The  elevation  in  glycine  was  only  significant  after  1000  mg/kg  vigabatrin 
administration at 6-7 hours (P < 0.05) post dose.  Concentrations were unaffected at 
other  time  points  (Figure  5.3).  Homocarnosine  concentrations  were  elevated  at  4 
hours post vigabatrin administration and continued to rise until  8 hours (Figure 5.4). 
A  similar pattern  was  observed  for  taurine  (Figure  5.5).  Thus  at  7-  8  hours  after 
vigabatrin 1  OOOmg/kg administration, both homocarnosine and taurine were associated 
with an almost doubling of their concentration compared to baseline values.
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Figure 5.3:  CSF  glycine  concentration  versus  time  profiles  after
intraperitoneal  administration  of  500  mg/kg  (■)  and  1000  mg/kg  (■) 
vigabatrin.  Values are mean ± sem of 5-6 animals.  * = P< 0.05
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Figure 5.4: CSF homocarnosine concentration versus time profiles after intra­
peritoneal  administration  of 500mg/kg  (■)  and  1000  mg/kg  (■)  vigabatrin. 
Values are mean ± sem of 5-6 animals.  * = P< 0.05
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Figure 5.5:  CSF taurine  concentration versus  time profiles  after  intra-
peritoneal  administration  of 500  mg/kg  (■)  and  1000  mg/kg  (■)  vigabatrin. 
Values are mean ± sem of 5-6 animals.  * = P< 0.05
5.3.2.  ECF amino acid concentrations
A  total  of  19  amino  acids  were  measured  in  ECF  frontal  cortex  and 
hippocampus after  1000 mg/kg vigabatrin administration.  Four amino acids (GABA, 
isoleucine, lysine and valine) increased and two amino aicd (glutamate and citrulline) 
decreased  (Tables  5.3,  5.4  &  5.5  and Figures  5.6-5.17).  The other  13  amino  acids 
(alanine,  arginine,  asparagines,  aspartic  acid,  glutamine,  glycine,  leucine, 
phenylalanine, serine, taurine, threonine, tryptophan and tyrosine) were unchanged by 
vigabatrin administration (the data were not shown).
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Table 5.3:  Increases of GABA and isoleucine concentrations in ECF expressed as a % 
of baseline after  lOOOmg/kg vigabatrin administration for the frontal cortex (FC) and 
hippocampus (HC) compared to control group__________________________________
Time  GABA  Isoleucine
(h)  vigabatrin  control  vigabtrin  control
FC HC FC HC FC HC FC HC
0 100 ±7 100 ±7 100 ±3 100 ±4 100 ±7 100 ±3 100 ±5 100 ±4
0.3 67  ±8 117 ±8 136 ±5 107 ±5 110 ±11 148 ±13 108 ±7 102 ±9
0.7 123 ±10 110 ±11 119 ±7 116 ±7 96  ±8 120 ±11 93  ±6 88 ±8
1.0 144 ±13 86  ±11 85  ±7 118 ±7 89 ±6 122 ±10 87  ±7 85 ±9
1.3 161 ±16 99  ±10 111 ±6 129 ±9 95 ±7 113 ±9 92  ±8 91 ±7
1.7 137 ±15 113 ±14 85  ±7 144 ±11 109 ±10 169 ±10 100 ±9 116 ±12
2.0 119 ±16 97  ±12 104 ±8 120 ±13 97 ±11 131 ±14 91  ±6 85 ±10
2.3 127 ±17 76  ±6 99  ±7 107 ±10 111 ±8 147 ±16 99  ±9 111 ±11
2.7 205 ±19 109 ±9 99  ±6 110 ±11 113 ±6 133 ±16 92  ±9 100 ±13
3.0 162 ±13 87  ±8 104 ±9 101 ±12 98 ±13 132 ±14 78  ±6 106 ±12
3.3 209*±10 79  ±7 102 ±10 110 ±15 111 ±10 156 ±14 103 ±10 97 ±10
3.7 221*±16 109  ±14 107 ±10 130 ±11 116 ±11 153 ±12 98 ±11 102 ±11
4.0 203*±12 126  ±12 128 ±11 114 ±10 123 ±9 173 ±12 85 ±8 106 ±13
4.5 232*±17 97  ±7 115 ±9 103 ±9 125 ±13 161 ±11 83 ±7 117 ±9
5.0 281*±12 92  ±6 91 ±8 98 ±8 141 ±10 162 ±11 100 ±8 102 ±11
5.5 301*±16 106  ±9 153 ±10 112 ±9 121 ±12 176 ±16 107 ±10 104 ±6
6.0 334*±18 97  ±10 122 ±11 112 ±7 166 ±11 168 ±18 99 ±11 112 ±10
6.5 408*±23 102  ±13 146 ±14 107 ±7 170 ±17 183 ±25 108 ±12 107 ±11
7.0 442*±24 110  ±11 125 ±14 124 ±6 144 ±9 166 ±14 105 ±11 112 ±12
7.5 505*±29 142  ±13 137 ±13 108 ±10 174*±17 162 ±11 97 ±10 112 ±13
8.0 649*±18 140  ±14 123 ±12 123 ±11 191*±20 154 ±10 103 ±11 107 ±12
The data are mean data from  6 animals, *  P< 0.05 compared to saline control.
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Table 5.4:  Increases of lycine and valine concentrations in ECF expressed as a % of 
baseline  after  lOOOmg/kg  vigabatrin  administration  for  the  frontal  cortex  (FC)  and 
hippocampus (HC) compared to control group___________________________________
Time  Lysine  Valine
vigabatrin  control  vigabatrin  control
(h) FC HC FC HC FC HC FC HC
0 100 ±4 100 ±3 100 ±3 100 ±5 100 ±3 100 ±5 100 ±5 100 ±4
0.3 88 ±7 136 ±8 108 ±5 107 ±9 87 ±8 103 ±8 105 ±13 96 ±3
0.7 105 ±8 117 ±9 90 ±8 83 ±6 102 ±6 113 ±9 127 ±15 101 ±8
1.0 91 ±7 99 ±10 85 ±7 93 ±5 108 ±11 106 ±14 120 ±14 98 ±9
1.3 94 ±7 131 ±6 101 ±8 90 ±7 115 ±9 100 ±10 108 ±10 91 ±7
1.7 91 ±10 135 ±12 81 ±11 111 ±13 121 ±10 91 ±6 110 ±11 77 ±6
2.0 96 ±6 110 ±8 91 ±10 88 ±8 104 ±14 109 ±11 118 ±9 97 ±10
2.3 88 ±6 126 ±10 100 ±7 100 ±10 117 ±8 120 ±15 101 ±8 86 ±9
2.7 110 ±11 99  ±6 112 ±12 98 ±8 129 ±13 108 ±11 92 ±7 103 ±9
3.0 111 ±9 103 ±6 109 ±11 91 ±11 118*±8 109 ±7 96 ±7 98 ±8
3.3 109 ±10 136 ±10 90  ±8 93 ±10 140*±11 118 ±12 93 ±8 100 ±7
3.7 115*±11 141*±6 90  ±9 91 ±7 133*±10 106 ±8 96 ±9 98 ±6
4.0 113  ±11 133  ±13 90  ±7 94 ±6 142*±5 125 ±13 101 ±’ 10 86 ±9
4.5 124*±11 137*±14 86  ±7 91 ±8 139*±6 130 ±9 104 ±10 95 ±7
5.0 124  ±15 128  ±12 101 ±10 113 ±9 147 *±7 124 ±15 80 ±6 95 ±8
5.5 122  ±11 144  ±13 104 ±11 93 ±7 139*±9 126 ±8 79 ±5 94 ±7
6.0 144  ±10 110  ±13 100 ±8 89 ±8 166*±6 115 ±11 81 ±6 90 ±6
6.5 139  ±15 134  ±15 104 ±12 96 ±8 171*±10 115 ±12 87 ±7 85 ±7
7.0 130  ±12 115  ±12 107 ±13 88 ±7 135*±12 125 ±9 88 ±8 84 ±7
7.5 158  ±12 126  ±7 103 ±9 122 ±10 166  ±6 120 ±14 89 ±9 99 ±5
8.0 156  ±13 131  ±7 85 ±7 99 ±9 157  ±12 105 ±7 100 ±11 109 ±8
* This is the mean data (n = 6) from one way ANOVA  P < 0.05
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Figure  5.6  shows  ECF  GABA  concentrations  in  the  frontal  cortex  time 
profiles  after  1000  mg/kg  vigabatrin  administration.  It  can  be  seen  that  GABA 
concentrations  gradually  increased  over  time.  So  that  at  8  hours  post-vigabatrin 
administration,  GABA  concentrations  were  6.5  fold  higher  compared  to  that  of 
baseline values  (P <  0.05).  In  contrast,  GABA  concentrations  in the hippocampus 
were unaffected by vigabatrin administration (Figure 5.7).
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Figure  5.6:  ECF  GABA  concentrations  in  the  frontal  cortex  before  and 
after administration of 1000 mg/kg vigabatrin (♦) or 0.9 % saline (■) of 6  
animals.  Data are expressed as percentage of baseline;  vertical bars show 
s.e.m.
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Figure 5.7:  ECF GABA concentrations in the hippocampus before and after 
administration of 1000 mg/kg vigabatrin (♦) or 0.9 % saline (■) of 6 animals. 
Data are expressed as percentage of baseline; vertical bars show s.e.m.
ECF  glutamate  concentrations  in  both  the  frontal  cortex  and  hippocampus 
decreased.  The decreases occurred some after vigabatrin concentrations continued to 
decline  up  to  8  hours  (Table  5.5).  However,  whist  the  decrease  in  glutamate 
concentrations  attained  statistical  significance  in  the  frontal  cortex  (Figure  5.8),  the 
decrease was not statistically significant in the hippocampus (Figure 5.9).  The latter 
observation can be attributed to the fact that saline (control) administered showed a 
concurrent decrease in hippocampal ECF glutamate concentrations.
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Table 5.5:  Decreases of glutamate and citrulline concentrations in ECF expressed as a 
% of baseline after lOOOmg/kg vigabatrin administration for the frontal cortex (FC) and 
hippocampus (HC) compared to control group__________________________________
Time
(h)
Glutamate 
VGB  control
Citrulline
VGB control
FC HC FC HC FC HC FC HC
0 100  ±2 100  ±16 100  ±2 100  ±3 100  ±3 100  ±2 100  ±13 100  ±4
0.3 66  ±10 84  ±21 97  ±17 73  ±16 95  ±7 122  ±27 109  ±22 104 ±21
0.7 67  ±11 69  ±10 118  ±23 70  ±14 96  ±6 113  ±21 120  ±19 144 ±25
1.0 63  ±8 74  ±24 126  ±26 62  ±14 78  ±9 102  ±21 110  ±16 97 ±11
1.3 62  ±13 74  ±20 114  ±28 63  ±11 89  ±9 103  ±19 106  ±24 83 ±13
1.7 66  ±12 62  ±23 125  ±27 63  ±11 89  ±7 112 ±22 124  ±24 72 ±21
2.0 51 *±9 61  ±6 97  ±16 65  ±6 72  ±6 88  ±10 130  ±21 79 ±9
2.3 50*±9 54  ±18 109  ±26 57  ±9 75  ±8 98  ±13 117  ±26 116 ±26
2.7 61  ±13 51  ±9 100  ±21 64  ±9 95  ±18 77  ±8 77  ±16 108 ±7
3.0 44*±8 68  ±15 115  ±16 60  ±11 79  ±10 83  ±16 106  ±22 106 ±15
3.3 54*±18 70  ±16 118  ±21 61  ±8 77*±11 78  ±25 119  ±17 93 ±8
3.7 39*±10 56  ±11 130  ±27 58  ±6 74  ±7 86  ±22 129  ±20 96 ±7
4.0 52  ±13 76  ±23 115  ±13 62  ±10 81  ±8 79  ±15 107  ±20 71 ±13
4.5 51 *±6 67  ±15 126  ±13 56  ±12 82  ±5 81  ±13 118  ±18 95 ±9
5.0 50  ±12 80  ±19 125  ±15 60  ±13 102 ±27 87  ±20 95  ±19 92 ±11
5.5 43 *±7 71  ±16 118  ±18 66  ±13 71  ±6 72*±10 108  ±25 110 ±16
6.0 60  ±6 59  ±17 114  ±27 79  ±19 80  ±13 72  ±12 120  ±19 95 ±9
6.5 59  ±10 72  ±16 125  ±20 69  ±18 81  ±7 63  ±15 111  ±17 92 ±13
7.0 57  ±9 70  ±11 102  ±26 84  ±15 73  ±11 58*±13 113  ±22 111 ±13
7.5 54  ±5 63  ±8 124  ±27 73  ±12 74  ±9 69*±8 118  ±11 93 ±10
8.0 49  ±9 54  ±12 100  ±25 55  ±7 67*±7 64*±19 117  ±17 111 ±12
* This is the mean data (n = 6) from one way ANOVA,  P < 0.05
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Figure 5.8:  ECF glutamate concentrations in the frontal cortex before and 
after administration of 1000 mg/kg vigabatrin (♦) or 0.9 % saline (■) of 6  
animals.  Data  are  expressed  as percentage  of baseline;  vertical  bars  show 
s.e.m.
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Figure 5.9:  ECF glutamate concentrations in the hippocampus (♦) before 
and after administration of 1000 mg/kg vigabatrin or 0.9 % saline (■) of 6  
animals.  Data are expressed as percentage of baseline; vertical bars show 
s.e.m.
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ECF valine concentration time profiles in the frontal cortex and hippocampus 
after  1000  mg/kg  vigabatrin  administration  are  shown  in  Figure  5.10  and  5.11 
respectively.  It can be seen that valine concentrations in the frontal cortex increased 
gradually after vigabatrin  administration and that  peak concentration  occurred  by 7 
hours.  The increase in valine concentrations achieved statistical significance by 3.0 
hours  post  vigabatrin  administration.  In  contrast,  whilst  hippocampal  valine 
concentrations  showed  a  tendency to  increase,  the  increase  did  not attain  statistical 
significance.
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Figure  5.10:  ECF valine concentrations  in  the  frontal  cortex  before  and 
after administration of 1000 mg/kg vigabatrin (♦) or 0.9 % saline (■) of 6  
animals.  Data are expressed as percentage of baseline; vertical bars show 
s.e.m.
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Figure  5.11:  ECF valine  concentrations  in  the  hippocampus  before  and 
after administration of 1000 mg/kg vigabatrin (♦) or 0.9 % saline (■) of 6  
animals.  Data are expressed as percentage of baseline; vertical bars show 
s.e.m.
Figure 5.12 and 5.13 showed respectively ECF isoleucine concentrations over 
time after  1000 mg/kg vigabatrin administration.  Isoleucine concentration showed a 
tendency to  increase in both frontal  cortex  and hippocampus.  However,  significant 
isoleucine  increases  were  only  obtained  in  the  frontal  cortex  at  7.5  - 8   hours  post 
vigabatrin  administration  (Table  5.3).  Similarly  lysine  ECF  concentrations  also 
showed a tendency to increase in the frontal cortex and hippocampus (Figure 5.14 & 
5.15).  The increases in ECF lycine concentrations, however, only occurred between 
approximately 3.7 to 4.5  hours post vigabatrin administration (P<0.05).  In contrast, 
ECF  citrulline  concentrations  appeared  to  decrease  in  both  the  frontal  cortex  and 
hippocampus (Figure 5.16 and 5.17), but the changes were only statistically significant 
at 7-8 hours in both brain areas (Table 5.5).
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Figure 5.12:  ECF isoleucine concentrations in the frontal cortex before and 
after administration of vigabatrin  1000 mg/kg vigabatrin (♦) or 0.9 % saline 
(■) of 6 animals.  Data are expressed as percentage of baseline; vertical bars 
show s.e.m.
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Figure 5.13:  ECF isoleucine concentrations in the hippocampus before and 
after administration of vigabatrin  1000 mg/kg (♦) or 0.9 % saline (■) of 6  
animals.  Data are expressed as percentage of baseline; vertical bars show 
s.e.m.
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Figure 5.14:  ECF lysine concentrations in the frontal cortex before and 
after  administration  of vigabatrin  1000  mg/kg  vigabatrin  (♦)  or  0.9  % 
saline  (■)  of  6  animals.  Data  are  expressed  as  percentage  of baseline; 
vertical bars show s.e.m.
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Figure 5.15:  ECF lysine concentrations  in the  hippocampus before and 
after administration of 1000 mg/kg vigabatrin (♦) or 0.9 % saline (■) of 6  
animals.  Data are expressed as percentage of baseline; vertical bars show 
s.e.m.
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Figure 5.16:  ECF citrulline concentrations in the frontal cortex before and 
after administration of 1000 mg/kg vigabatrin (♦) or 0.9 % saline (■) of 6  
animals.  Data are expressed as percentage of baseline; vertical bars show 
s.e.m.
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Figure 5.17:  ECF citrulline concentrations in the hippocampus before and 
after administration of 1000 mg/kg vigabatrin (♦) or 0.9 % saline (■) of 6  
animals.  Data are expressed as percentage of baseline; vertical bars show 
s.e.m.
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5.3.3  Inter-relationship  between  ECF  amino  acid  and  ECF  vigabatrin 
concentrations
In  this  section  the  ECF  vigabatrin  concentration  versus  time  profiles 
presented in Chapter 3 after 1000 mg/kg vigabatrin administration are plotted with that 
of ECF amino acid concentration versus time profiles that have been described in the 
previous section.  The aim of this approach is to ascertain whether or not there is a 
relationship between vigabatrin concentration and amino acid concentration in brain 
ECF.
After  lOOOmg/kg  vigabatrin  administration,  GABA  concentrations  rose 
gradually in the  frontal  cortex but not in the hippocampuas (Figure  5.18  and 5.19). 
Interestingly vigabatrin concentrations were also two-fold higher in the frontal cortex 
than  that  in  the  hippocampus.  Furthermore,  there  was  no  correlation  between  the 
vigabatrin  concentration  versus  time  profile  and  GABA  concentration  versus  time 
profile.  Thus at the time when peak ECF vigabatrin concentration were achieved in 
the frontal cortex, GABA concentrations hardly changed.  Subsequently, as vigabatrin 
concentration decline, GABA concentration increased and peaked at the time of last 
sampling time ( 8 hours).
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Figure 5.18:  ECF concentration versus  time profiles  for vigabatrin (♦) 
and  GABA  (■)  in  the  frontal  cortex  after  1000  mg/kg  vigabatrin 
administration.  Values are mean ± s.e.m of 6 animals.
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Figure 5.19:  ECF concentration versus time profiles for vigabatrin (♦)
and  GABA  (■)  in  the  hippocampus  after  1000  mg/kg  vigabatrin 
administration.  Values are mean ± s.e.m of 6 animals.
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Figure  5.20  and  5.21  show  respectively  the  ECF  vigabatrin  concentration 
profiles  for  frontal  cortex  and  hippocampus  after  lOOOmg/kg  vigabatrin 
administration.  Also  plotted  in  these  figures  are the  ECF  glutamate  concentrations 
versus time profiles.  It can be seen that in contrast to GABA, glutamate concentration 
changes  parallel  somewhat the  concentration  profile  of vigabatrin.  Thus  glutamate 
concentrations declined at the time as maximum vigabatrin concentrations.
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Figure 5.20:  ECF concentration versus time profiles for vigabatrin (♦) and 
glutamate  (■)  in  the  frontal  cortex  after  1 0 0 0   mg/kg  vigabatrin 
administration.  Values are mean ± s.e.m of 6 animals.
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Figure 5.21:  ECF concentration versus time profiles for vigabatrin (♦)
and  glutamate  (■)  in  the  hippocampus  after  1 0 0 0  mg/kg  vigabatrin 
administration.  Values are mean ± s.e.m of 6 animals.
As  occurred  with  GABA,  the  amino  acids  valine  and  isoleucine  exhibited 
increased concentrations in the frontal cortex but not in the hippocampus (Figure 5.22 
&  5.23).  Also,  as  occurred  with  GABA  concentration,  the  maximum  increase  in 
valine and isoleucine concentrations occurred at a time after vigabatrin concentrations 
had peaked and indeed vigabatrin concentration were at their lowest level at the time 
of maximal amino acid concentration increases.
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Figure  5.22:  ECF concentration versus  time  profiles  for vigabatrin  (♦) 
and  valine  (■)  in  the  hippocampus  after  1 0 0 0  mg/kg  vigabatrin 
administration.  Values are mean ± s.e.m of 6 animals.
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Figure  5.23:  ECF concentration versus time profiles  for vigabatrin (♦) 
and  isolecine  (■)  in  the  frontal  cortex  after  1 0 0 0  mg/kg  vigabatrin 
administration.  Values are mean ± s.e.m of 6 animals.
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5.4  DISCUSSION
5.4.1  CSF amino acid concentrations and vigabatrin
There have been numerous studies of the effect of vigabatrin on CSF amino 
acid  concentrations.  Vigabatrin  was  observed  not  only  to  elevate  GABA 
concentration in CSF in animal models (Piredda et al,  1987; Bemasconi et al,  1988) 
and  in  patients  with  epilepsy  (Schechter  et  al,  1984;  Pitkanen  et  al,  1988;  Ben- 
Menachem et al,  1989; Riekkinen et al,  1989b), but also to affect other amino acids 
(Perry et al,  1979; Grove et al,  1981; Bemasconi et al,  1988; Ben-Menachem,  1989). 
These observations were of interest because 1.  Many other amino acids, in addition to 
GABA, act as neurotransmitters and regulate normal brain function.  2.  Some amino 
acids seem to have a role in the initiation, spread and suppression of seizures.  3. The 
neuropathological  findings  obtained  from  patients  with  chronic  epilepsy  or  from 
animal  models  of  epilepsy  suggested  that  amino  acid-mediated  transmission 
(glutamate/aspartate) may participate in epileptic cell damage (Czapiriski et al, 2005).
The main findings in the present study were that vigabatrin affected several 
amino  acids  by  increasing  or  decreasing  their  concentrations  in  rat  CSF.  These 
changes did not reflect nor parallel the concentration time course of vigabatrin in CSF. 
Neuropharmacokinetic analysis showed that vigabatrin rapidly crossed the BBB and 
that  maximal  concentration  in  CSF  was  achieved  at  1   hour;  however,  amino  acid 
concentration changes only occurred at 3-5 hours post vigabatrin administration.  In 
the following section,  each CSF amino  acid change (in Tables  5.1  and 5.2) will be 
discussed.  As the HPLC method was not sufficiently sensitive to measure the low 
concentrations of GABA in the CSF, GABA concentrations were not determined.
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5.4.LI  Homocarnosine
Homocarnosine,  a  dipeptide,  is  a major  GABA  conjugate  found  in  patient 
CSF  (Jansen  et  al,  2006).  The  interrelationships  of  homocarnosine  and  GABA 
metabolism are shown in Figure 5.24.  The exact biologic function of homocarnosine 
in  mammalian  systems  remains  almost  unknown.  Homocarnosine  may  serve  as  a 
repository for GABA production (Jackson et al,  1994c).  There is increasing evidence 
that homocarnosine has antiepileptic properties (Saransaari et al, 1999).
Figure 5.24:  Interrelationships of homocarnosine and GABA metabolism. 
Numbered enzymes include:  (1) camosinase,  (2) GAD, (3) GABA-T, (4) 
SSADH  and  (5)  succinate semialdehyde reductase.  Not all  steps  in this 
pathway are shown (Jansen et al, 2006).
In  present  study,  CSF  homocarnosine  concentrations  began  to  increase  at 
approximately  2  hours  after  500  and  1000  mg/kg  vigabatrin  administration.  The 
increases  were  particularly  apparent  for  the  1 0 0 0  mg/kg  vigabatrin  dose,  whereby 
homocarnosine concentrations significantly increased by up to 78% at 8 hours (Figure 
5.4).  After 500 mg/kg vigabatrin administration, CSF homocarnosine concentrations
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were only increased by 25% at  8 hours post vigabatrin administration.  Halonen and 
colleagues  (1990)  also  reported  the  effect  of  vigabatrin  on  homocarnosine 
concentrations in rat CSF.  CSF samples were collected at the 5, 24, 48 and 96 hours 
after  1000  mg/kg  vigabatrin  administration.  Homocarnosine  concentrations  were 
increased  by  56%  and  123%  at  5  and  24  hours  respectively  after  vigabatrin 
administration.  This  latter concentration remained at the  same level  for the next 3 
days.  In the present study CSF samples were not collected at 24 hours post vigabatrin 
administration.  However, the samples collected at  8 hours, suggest that comparable 
changes  in  CSF  homocarnosine  were  observed  to  those  reported by Halonen  et  al
(1990).
Two  early  studies  have  been  reported  on  the  effect  of  vigabatrin  on 
homocarnosine concentrations in animal models (Palffeyman et al, 1980; Bohlen et al, 
1980).  Brain  and  CSF  homocarnosine  concentrations  showed  a  time-dependent 
elevation  following  administration  of  500mg/kg  vigabatrin  to  rats.  CSF 
homocarnosine concentrations increased by 25% at 4 hours and peak concentrations 
occurred at 48 hours post vigabatrin administration (Palffeyman et al, 1980). Bohlen et 
al (1980) also found that vigabatrin elevated CSF homocarnosine concentrations in a 
dose-dependent manner.  They administered vigabatrin at doses of 250, 500, 1000 and 
2000 mg/kg and observed that CSF  homocarnosine concentration increased linearly 
and dose dependently.  The data presented in this thesis are consistent with these data.
There  have  been  several  reports  of  the  effect  of  vigabatrin  on  CSF 
homocarnosine concentrations in patients with epilepsy (Ben-Menachem et al,  1989; 
Pitkanen et al,  1988; Kalviainen et al,  1993; Rothman et al,  1997; Petroff et al,  1998b
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&  1999).  Ben-Menachem  (1989)  used  different  vigabatrin  dose  intervals  in  11 
patients  with  drug-resistant  complex  partial  seizures.  CSF  concentrations  of total 
GABA  and  homocarnosine  both  increased  dose  dependently compared  to baseline. 
Their results  showed that daily dosing resulted  in the highest concentration of CSF 
total  GABA  and homocarnosine compared to that of every second day dose,  every 
third day and a single dose regimen.  A similar study was reported by Halonen et al 
(1988)  whereby  patients  with  complex  partial  epilepsy  were  administered  3g 
vigabatrin  per  day  for  three  months.  In patients  that  experienced  more  than  50% 
reduction in seizures, free GABA, total GABA and homocarnosine concentrations in 
the CSF were increased by 104%, 151% and 194% respectively.
It is  rather controversial  whether or not homocarnosine  free concentrations 
are  a reflection  or are correlated to  GABA  concentrations  in  the  CSF  and brain of 
animal models.  An early study (Bohlen et al,  1980) has suggested that elevated CSF 
GABA  concentrations  primarily  relate  to  altered  GABA  metabolism  in  the  brain. 
Thus  by  measuring  homecamosine  concentration  it  may  be  possible  to  monitor 
indirectly changes in brain or CSF GABA content during vigabatrin therapy.  They 
also  highlighted  the  fact  that  since  homocarnosine  occurred  in  relatively  high 
concentrations in CSF, it can therefore be assayed more easily than free GABA which 
is  present  at  very  low  concentrations  in  CSF.  Recently  Jansen  et  al  (2006)  have 
characterized the potential relationship between GABA and homocarnosine in patient 
CSF,  they  determined  the  total  GABA  levels  in  all  control  samples  using  gas 
chromatography  and  mass  spectrometry.  There  was  a  highly  significant  linear 
correlation  between  total  GABA  and  homocarnosine  in  control  CSF.  However, 
Palffeyman et al (1980) were not convinced that there is a good relationship between
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CSF homocarnosine and GABA concentrations.  Indeed their results showed that the 
correlation between the two parameters was not impressive (r = 0.64) and concluded 
that CSF homocanosine concentration is of only limited usefulness as an indicator of 
GABA concentrations in the CSF and brain.
It is not entirely clear as to how homocarnosine concentrations increase when 
GABA concentrations are also increased by vigabatrin.  However, a likely explanation 
is that the enzyme, homocarnosine synthetase, might normally not be saturated with its 
substrate  GABA  (Palfreyman  et  al,  1980).  Furthermore  vigabatrin  blocks  normal 
GABA  metabolism  by  inhibiting  GABA-T;  the  increased  intracellular  GABA  may 
also inhibit the metabolism of homocarnosine to GABA (Jansen et al, 2006).  Overall, 
the  increases  in  CSF  homocarnosine  concentration  following  vigabatrin 
administrations  are  likely  to  be  related  to  altered  GABA  metabolism.  Therefore 
monitoring  of homocarnosine  concentrations  may  provide  a  useful  index  of CSF 
GABA concentrations.
5.4.1.2  Glycine
In  the  present  thesis,  CSF  glycine  concentrations  began  to  increase  at 
approximately 1.5 hour after 1000 mg/kg vigabatrin administration.  Thus compared to 
baseline concentrations, glycine concentrations were significantly increased (by 56 %) 
at 7 hours and the increase was somewhat lower (31%) at 8 hours.  Although a similar 
pattern was observed after 500 mg/kg vigabatrin, the changes did not attain statistical 
significance.  To date, only one other study has determined the effect of vigabatrin on 
glycine  concentrations  in  rat  CSF  (Halonen  et  al,  1990).  The  data presented  here
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confirm  the  data  presented  by  Halonen  et  al  (1990).  Their  study  entailed  the 
administration  of  lOOOmg/kg  vigabatrin  intraperiteally  to  freely  moving  rat.  CSF 
samples were collected at the 5, 24, 48 and 96 hours post vigabatrin administration. 
CSF glycine concentration increased by 31% at 5 hours post vigabatrin administration, 
but concentrations failed to continually increase up to 24 hour.
In  patients  with  epilepsy,  glycine  concentrations  have  been  reported  to 
increase consequent to chronic vigabatim treatment.  Halonen et al (1988) investigated 
65  patients  with complex partial  epilepsy.  CSF  samples  were collected before and 
after vigabatrin treatment for three months.  Approximately 55% of patient showed a 
greater than 50% reduction in complex partial  seizures.  In these patient responders, 
CSF glycine concentrations increased significantly (P<0.001) compared with baseline 
values.  In  addition,  however,  CSF GABA  and homocarnosine concentrations were 
also increased.  Pitkanen et al (1988)  using a group of patients with epilepsy,  who 
were  treated  with  vigabatrin  for  7  months,  reported  that  there  was  a  28%  increase 
glycine  in  CSF  compared  to  baseline  values.  Furthermore,  CSF  glycine 
concentrations in responders and non-responders patients were compared and it was 
observed that patients responding to treatment with vigabatrin had significantly higher 
CSF  glycine  concentrations  (128%,  compared  to  baseline  values)  than  the  non­
responders.
That CSF glycine concentrations  increase after vigabatrin administration in 
both  the  rat  and  patient  with  epilepsy  may  be  contributable  to  two  possible 
mechanisms.  First, vigabatim may enhance the release of glycine in the brain, where 
glycine may play a role as an inhibitory neurotransmitter.  This possible mechanism
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has been corroborated in part by the observation that CSF glycine concentrations are 
increased in patients with epilepsy that have good seizure control.  The observation 
that the maximal protective activity occurred at 4 hours after vigabatrin administration 
to audiogenic  sensitive rats whilst GABA-T was maximally inhibited 24 hours after 
the  single dose of vigabatrin  (Engelborghs  et al,  1998)  suggests that an increase in 
GABA may not be the sole mechanism of action of vigabatrin; alternative mechanisms 
may be  via  areduction  in  excitatory  amino  acid  concentrations  in  the  brain  and/or 
elevation of glycine content (Czapinski et al, 2005).  Second, glycinergic innervation 
is greatest at the level of the spinal cord (Ottersen & Storm-Mathisen,  1984).  Thus, 
the  enhancement  of glycine  concentration in  CSF might be partly due to  increased 
glycine release in the spinal cord consequent to vigabatrin treatment.  The exact effect 
of vigabatrin treatment on the release of glycine and the role of increased glycine on 
the  anti epileptic  efficacy of vigabatrin treatment  is not known  and warrants  further 
study.
5.4.1.3  Taurine
In the present study, CSF taurine concentrations were increased by 41% and 
75  % at 5  hours after 500 and  1000 mg/kg of vigabatrin administration respectively 
(Table  5.2  and  Figure  5.5).  These  observations  are  in  agreement  with  another rat 
study  in  which  CSF  taurine  concentration  also  increased  after  vigabatrin 
administration (Halonen et al  1990).  Using a freely moving rat model, Halonen et al
(1991)  collected CSF samples at 5, 24, 48 and 96 hours after  1000 mg/kg vigabatrin 
administration.  Taurine concentrations were observed to increase by 63% compared
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to baseline at 5 hours post vigabatrin administration.  However, this increased was not 
sustained at 24 hours.
Differing results have been observed in patient CSF studies of taurine.  CSF 
taurine concentrations were shown either unchanged (Halonen et al,  1988; Pitkanen et 
al,  1988;  Kalviainen  et  al,  1993)  or  reduced  in  different  types  of  epilepsy  after 
vigabatrin  administration  (Crawford  &  Chadwick,  1987;  Honda,  1984)  or  without 
vigabatrin administration (Rainesalo et al, 2004).
Anti-epileptic action of taurine has been recognised for many years (Kontro et 
al,  1983).  The  precise  role  of taurine  in  synaptic  transmission  is  uncertain but  its 
antiepileptic effects have been confirmed in several models of experimental epilepsy 
and in short-term clinical studies (Fariello et al,  1985; Lombardini,  1992; van Gelder, 
1992; Richards et al,  1995).  Several clinical trials involving taurine supplementation 
in epileptic patients have been reported in various trials and variable success has been 
achieved (Timothy & Birdsall, 1998).  The mechanism of action of taurine is probably 
via  binding to  GABAa  or to  glycine  receptors  (Gupta  et  al,  2005).  Therefore  the 
increase in taurine that I observed may have an antiepileptic action.
5.4.1.4  Arginine and  tyrosine
In the present study, CSF arginine concentration was significantly decreased 
(48 %) at 8 hours post 500 and lOOOmg/kg vigabatrin administrations.  The significant 
reduction of CSF arginine observed in this study have not been described before with 
vigabatrin administrations in either animal or human.  There are different views as to 
the role of arginine in epilepsy. Arginine has been reported to have an additive effect
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on the  anticonvulsant action of diazepam (Vanaja  & Jayakumar,  2001) and there is 
some  evidence  to  suggest  that  L-arginine  might  prevent  seizure  activity  when 
administered  at  high  doses  (Noyan  &  Gulec,  2000).  Arginine  concentrations  have 
been reported to be high in the brains of animal seizure models (Gardiner et al,  1993; 
De Sarro et al,  1993) and plasma arginine concentrations are decreased during AED 
treatment of patients with epilepsy (Rao et al, 1993 and Ko et al, 1993).
The exact function of tyrosine is not known, however, there are no reported 
data on CSF or brain tyrosine concentrations after vigabatrin administration in either 
epileptic models or in patients with epilepsy.  The decreases in tyrosine were found in 
this study and from my knowledge, this is the first study to demonstrate a reduction in 
tyrosine  concentrations  by  60%  and  47%  at  8  hours  after  500  and  lOOOmg/kg 
vigabatrin administrations respectively.  The mechanism of this effect is not known. 
Some studies  indicated that CSF tyrosine concentrations were decreased in children 
with refractory epilepsy after ketogenic  diet (an  established treatment  for medically 
refractory pediatric epilepsy) treatment (Dahlin et al, 2005).  It has been proposed that 
CSF tyrosine  may be precursors  of norepinephrine  (NE),  and NE  was  found to be 
required for the antiepileptic effect of the ketogenic diet (Szot et al, 2001). The role 
and mechanism of the change in tyrosine and arginine that I observed are unknown.
5.4.1.5  Glutamate and aspartate
There is a controversy as to the effect of vigabatrin on CSF glutamate and 
aspartate  concentrations.  Thus  glutamate  and  aspartate  concentrations  have  been 
reported to decrease (Halonen et al,  1991; Kalviainen et al,  1993), increase (Halonen
188Chapter 5 The effect of vigabatrin on CSF and ECF amino acids
et al,  1990) or not to change (Pitkanen et al,  1988) after vigabatrin administrations in 
both animal  models and in patients with epilepsy.  In animal  studies,  the effects of 
inhibitory  and  excitatory  amino  acids  were  studied  1 2  days  after  intraperitoneal 
vigabatrin  administration.  The  glutamate  and  aspartate  concentrations  were 
unchanged in CSF but were increased in brain tissue of hippocampus (Halonen et al,
1991).  These results are similar to the results in this thesis as glutamate decreased 
only showed in brain dialysate of the frontal cortex and hippocampus, but not in CSF. 
The effects on CSF amino acid concentrations by chronic administration of vigabatrin 
to patients with complex partial epilepsy have been also studied (Halonen et al,  1988; 
Pitkanen et al,  1988).  In these patients, whilst vigabatrin administration resulted in a 
dose-dependent  increase  in  GABA  concentrations,  glutamate  and  aspartate 
concentrations were unaffected.  Furthermore, when vigabatrin was presented as add­
on treatment with lamotrigine  to young patients with generalised refractory epilepsy, 
no changes in CSF glutamate and aspartate concentrations were observed (Eriksson & 
O’Connor,  1999).  In the present studies, CSF glutamate and aspartate concentrations 
were unchanged and these data are in agreement with the results published by Halonen 
et al (1988,1990 and 1991), Ben-Menachem et al (1989), and Pitkanen et al (1988).
5.4.2  ECF amino acid concentrations and vigabatrin
An important observation in my thesis  is that there  are notable differences 
between CSF and ECF amino acid changes following vigabatrin administration. This 
emphasises  that these  are two  separate  compartments  and  that although  changes  in 
ECF concentrations  of a neurotransmitter would be  expected to lead to  comparable 
changes in CSF concentrations, this does not always occur. CSF and ECF production
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have different mechanisms and the diffusion of ECF into the CSF (and vice versa) is 
complex (not least because of the numerous amino acid transporters present in brain).
5.4.2.1  GABA
After vigabatrin administration, the total level of GABA concentration in the 
frontal  cortex  was  elevated,  which  was  consistent  with  the  high  vigabatrin 
concentration in this brain area.  Vigabatrin  concentration in the  frontal  cortex was 
more than two fold higher than that in the hippocampus and GABA concentration was 
6 times higher at 8 hours in the frontal cortex compared to the hippocampus.  There is 
definite relationship between GABA and vigabatrin concentrations in the brain.  In the 
following  paragraphs,  discussion  will  focus  on  how  GABA  concentration  changes 
relate to vigabatrin administration.
In the present study, vigabatrin administration (1000 mg/kg) was associated 
with a significant increase in ECF GABA concentrations in the frontal cortex but not 
in the hippocampus (Table 5.3).  The increase of GABA concentrations in the frontal 
cortex ECF only began to be apparent at 3  hours post vigabatrin administration and 
GABA  concentrations  continued  to  rise  so  that  peak  concentrations  occurred by  8 
hours post vigabatrin administration.  At this time GABA concentrations were more 
than 6-fold higher than that of baseline values.  These data are in agreement with data 
from several other studies.  Jung et al (1977) reported that brain GABA concentrations 
increased  5-fold  by  3-4  hours  after  1000  mg/kg  vigabatrin  administration.  These 
elevated GABA  concentrations  were maintained  for at least 24  hours,  subsequently 
GABA concentration slowly declined up to 5  days.  Sayin et al  (1995) studied ECF
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GABA concentration changes in substantial nigra pars reticulate following 1  OOOmg/kg 
vigabatrin  administration.  GABA concentration increased significantly after 3  hour 
(200% of control) and peak concentration (450% of control) occurred by 24 hours and 
these  elevated  GABA  concentrations  persisted  up  to  72  hours.  That  ECF  GABA 
concentrations increase 3 - 4  hours after vigabatrin administration would suggest that 
the inhibition of GABA-T by vigabatrin is not instantaneous.  Inhibition of GABA-T 
after  vigabatrin  administration  continues  for  3  days  (Jung  et  al,  1977).  The latter 
effect  can  be  explained  on  the  basis  that  as  GABA-T  is  irreversibly destroyed by 
vigabatrin  and  as  GABA-T  regeneration  requires  protein  synthesis,  this  is  time 
dependent (many days).
Interestingly,  the  time  course  of  vigabatim  associated  increases  in  ECF 
GABA concentrations  after acute perfusion of vigabatrin directly into microdialysis 
probes  is  different.  Thus  hippocampal  and  striatum  ECF  GABA  concentrations 
increased immediately after the perfusion of vigabatrin into the microdialysis probe 
(Jolkkonen  et  al,1992,  Bentiurquia  et  al,  2004).  These  elevations  of  GABA 
concentration remained  until  the  end  of vigabatrin  infusion  and  normalized rapidly 
thereafter.  A longer-term elevation of GABA concentrations by inhibition of neuronal 
and  glial  GABA-T  was  not  observed  during  the  two  hours  following  vigabatrin 
administration.  The immediate increase in GABA concentrations may be explained 
by an acute block of GABA uptake and is not the consequence of GABA-T (Richerson 
& Wu, 2004).  Thus the results of the present study are in agreement with that of Jung 
et al (1977) and Valdizan et al (1999), which suggest that vigabatrin would not be an 
appropriate drug to use in a clinical setting where stopping seizures rapidly is crucial.
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At  8  hours after vigabatrin administration ECF GABA concentrations were 
approximately 5-fold higher in the frontal cortex than that of the hippocampus (Table 
5.3).  As to the brain region variability of these effects, the mechanism is consistent 
with the neuropharmacokinetics of vigabatrin in the frontal cortex and hippocampus. 
Figure 5.18 and 5.19 show the concentration versus time profiles for ECF GABA and 
vigabatrin  in  the  frontal  cortex  and hippocampus  respectively.  It can be  seen  that 
vigabatrin AUC and Cmax values in the frontal cortex were more than two fold higher 
than  that  of  the  hippocampus.  Thus  higher  vigabatrin  concentrations  could  be 
expected to have  a greater inhibitory effect on GABA-T resulting in turn in higher 
GABA  concentrations.  This  is  the  first  description  of the  differential  kinetics  of 
vigabatrin in the brain and clearly the pharmacological effect of vigabatrin in elevating 
GABA concentrations is directly related to its central brain neuropharmacokinetics.
5.4.2.2  Glutamate
Vigabatrin  administrations  were  associated  with  a  significant  reduction  in 
frontal  cortex  ECF  glutamate  concentration  (Figure  5.8).  However,  the  effect was 
only statistically significant after 4.5 hours post vigabatrin administration.  In contrast, 
although ECF glutamate declined in the hippocampus, the decline also occurred in the 
control  group  and  therefore  does  not  appear  to  be  vigabatrin  related.  That  ECF 
glutamate concentrations decrease in the frontal cortex after vigabatrin administration 
has been reported previously.  In an acute study,  1200 mg/kg administration vigabatrin 
was associated with a decrease in ECF glutamate concentration in the frontal cortex of 
rats after 4 hours post vigabatrin administration (Loscher & Horstermann,  1994).  In 
fact the ECF glutamate concentration versus time profile reported in that study was
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very similar to that observed in the present study, but the differences is that glutamate 
concentration in their study was reduced by only 2 0 %, which is less than that observed 
by me in the present study (40-50 %).  In another study where rats were administered 
30 mg/kg vigabatrin  for  7  days,  ECF glutamate  concentrations  in the hippocampus 
were also decreased (Smolders et al, 1997).
My  results  differ  however  from  results  obtained  by  direct  perfusion  of 
glutamate throught the microdialysis probe into the striatum (Benturquis et al, 2004). 
In  this  study,  glutamate  concentrations  exhibited  a  37%  increase  immediately after 
acute  infusion  Similar  to  GABA  concentration,  this  increase  of  glutamate 
concentration remained elevated until the end of the vigabatrin infusion and return to 
baseline  quickly  afterward.  The  mechanism  of this  increase  and  the  disparity with 
other studies remains unexplained.
The mechanisms by which vigabatrin reduces ECF glutamate concentrations 
in  thisstudy  are  unknown.  One  possible  explanation  is  that  reduction  of GABA 
transaminase activity prevents the conversion of alpha-ketoglutarate from the Kreb’s 
cycle to glutamate, so decreasing the glutamate pool. The decrease in this excitatory 
transmitter would be expected to have an antiepileptic effect.
5.4.2.3  Valine,  isoleucine and lysine
ECF  valine,  isoleucine  and  lysine  concentrations  after  vigabatrin 
administration increased in the frontal cortex and the hippocampus, but changes in the 
frontal cortex were greater (Figure 5.10 to 5.15).  The increases occurred at 4-8 hours 
after vigabatrin administration.  There is only one other on the effect of vigabatrin on
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these amino acids (Bemasconi et al,  1988) and interestingly vigabatrin was similarly 
observed to increase these amino acid concentrations in the frontal cortex.
Valine,  leucine  and  isoleucine  ,  the  branched-chain  amino  acids  (BCAAs) 
have been reported to reduce brain excitability by increasing the latency to convulsive 
seizures induced by picrotoxin and pentylenetetrazol (PTZ) (Dufour et al,  1999), and 
also play an important role in brain neurotransmitter metabolism (Brosnan & Brosnan, 
2006).  It appears that neurological dysfunction can occur when BCAAs are too low or 
too high.  How high or low levels of BCAAs can cause neurological dysfunction is not 
know (Harris et al, 2005).  In the present study, although these three amino acids all 
increased  in  ECF  of both  brain  areas,  only  valine  and  isoleucine  changes  were 
statistically  significant.  ECF  valine  concentrations  in  the  frontal  cortex  were 
increased by 20-70 % from 3-7 hours after vigabatrin administration.  The observed 
increases  are  similar  to  those  observed  in  studies  of  animal  and  patients  with 
ischaemic brain damage  (Kuchiwaki et al,  1994;  Shimada et al,  1993; Karkela et al,
1992).  In  contrast  CSF  valine  concentrations  after  vigabatrin  administration  were 
unaffected.  The contribution of valine to the mechanism of action of vigabatrin,  is 
presently unknown.
Isoleucine is another amino acid for BCAAs and previously acts as nitrogen 
donors  in  the  cerebral  glutamate-glutamine  cycle.  Approximately  one  third  of 
glutamate  is  derived  from branched-chain  amino  acids.  In  the present  study,  ECF 
isoleucine concentration increase by 10-90% in the frontal cortex and the hippocampus 
after 3  to  8 hours  after vigabatrin administration.  However,  the changes were only 
statistically significant at 7.5- 8 hours.  Hippocampus ECF concentration changes were
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less substantial with concentration increases of 30-50% for isoleucine; these changes 
were not statistically significant.
As to how vigabatrin affect these two amino acids is unclear, but valine and 
isoleucine may have a role in reducing brain excitability (Dufour et al,  1999).  Using 
PTZ, Dufour et al (1999) observed that 300 mg/kg leucine and isoleucine increased the 
latency to absence-like and tonic-clonic seizures but did not influence the duration of 
tonic-clonic  seizures.  A  further  study  (Dufour  et  al,  2001)  showed  that  BCAAs 
decreased brain glutamate concentrations in the thalamus and cortex without affecting 
GABA concentrations.  Thus, BCAAs, by decreasing glutamatergic neurotransmission 
could  decrease  neuronal  excitability  (Dufour  et  al,  2001).  Overall,  therefore,  the 
increase  in  ECF  BCAAs  as  observed  in  the  present  study  along  with  the  data  of 
Dufour et al (1999 and 2001) would suggest that valine and isoleucine, and possibly 
leucine may decrease ECF glutamate concentrations.  This mechanism may contribute 
to anticonvulsant action of vigabatrin.
ECF  lysine  concentrations  in  both  frontal  cortex  and  hippocampus  also 
appeared to increase after vigabatrin administration (Figures 5.146 and 5.15).  A  10- 
50% increase was observed at 3-8 hours post vigabatrin administration.  There is very 
little information as to the role of lysine in epilepsy.  Bemasconi  et al  (1988) have 
reported  a  time-  and  dose-dependent  elevation  in  lysine  concentrations  in  cortical 
tissue.  However, the increase in lysine concentration was less pronounced compared 
to the other amino acids studies.  The mechanism as to how vigabatrin may increase 
lycine concentrations is not known.
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5.4.2.3  Citrulline
There was  a tendency for ECF citrulline concentrations, both in the frontal 
cortex and hippocampus to decrease after vigabatrin administration (Figures 5.16 and 
5.17).  These decreases were observed at 3 to  8 hours but were statistically significant 
only at 3.3 -3.7 hours in the frontal cortex.  There are no published data on the effect 
of vigabatrin  on  ECF  citrulline  concentrations.  The  mechanism  of this  effect  is 
unknown.  Nevertheless,  it has  been  shown  that  citrulline  can  suppress  seizures  in 
models of epilepsy (Talavera et al,  1997;  Paul, 2002); a reduction in nitric-citrulline 
formation may be the mechanism by which this is mediated (Smith et al, 1996).  In an 
animal  seizure  model,  an  increase  in  citrulline  concentration  was  also  seen  with 
elevated  glutamate  and glycine  concentrations  (Richards  et al,  2000).  Whether the 
decrease  in  ECF  citrulline  concentrations  is  related  to  the  mechanism  of 
anticonvulsant action of vigabatrin needs further study.
5.5  CONCLUSIONS
1.  In the  CSF compartment,  vigabatrin administration was associated with 
reduction  in  arginine  and  tyrosine  concentrations  and  increases  in  homocarnosine, 
glycine  and  taurine  concentrations.  Other  amino  acids  were  not  affected.  GABA 
concentrations were not measured in CSF.
2.  In  the  frontal  cortex  and  hippocampus,  ECF  compartment,  vigabatrin 
administration  was  associated  with  significant  changes  in  a  variety of amino  acids 
(GABA, glutamate, isoleucine, lysine, citrulline and valine).  However, not all amino 
acid concentration changes were statistically significant.
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3.  The vigabatrin associated amino acid changes in the CSF differ somewhat 
from  those  observed  in  ECF,  emphasising  that  CSF  and  ECF  represent  distinct 
compartments.
4.  Whilst  ECF  GABA  concentration  in  the  frontal  cortex  increased  after 
vigabatrin  administration,  ECF  GABA  concentration  was  unaffected  in  the 
hippocampus.  These  changes  can  be  explained  on  the  basis  that  vigabatrin 
concentrations  in  the  frontal  cortex  are  2 -fold  higher  than  those  achieved  in  the 
hippocampus.  The  absence  of  changes  in  extracellular  GABA  detected  by 
microdialysis in the hippocampus does not exclude that there may be local changes or 
changes in specific subregions of the hippocampus.
5.  The observed increase in the frontal  cortex ECF GABA concentrations, 
however,  did  not  parallel  the  concentration  versus  time  profile  of ECF  vigabatrin. 
Instead ECF GABA concentration increased as ECF vigabatrin concentration declined. 
This indicate that the change in GABA is not due to a direct effect of vigabatrin and is 
consistent with the known mechanism of action (GABA transaminase inhibition).
197Chapter 6 The effect of levetiracetam on ECF amino acids
Chapter 6
The effect of levetiracetam 
on ECF amino acids
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6.1  INTRODUCTION
The effect of levetiracetam on ECF amino acids
Studies  aimed  at  elucidating  whether  levetiracetam  exerts  its  antiepileptic 
effects  by  an  interaction  with  GABAergic  mechanisms  have  led  to  somewhat 
contradictory results.  Levetiracetam failed to interact with classical receptor and ion 
channel sites in the brain (Noyer et al,  1995).  The drug has, however, been proposed 
to bind in a stereoselective manner to a specific site in CNS membranes where it was 
weakly displaced by several other AEDs and GABA-related substances (Noyer et al, 
1995).
Loscher  et  al  (1996)  reported  that  levetiracetam  induces  changes  in  GABA 
metabolism  and  turnover  in  discrete  areas  of rat  brain.  Their  results  showed  that 
systemic levetiracetam administration resulted in  significant alterations in GAD and 
GABA-T activities in several brain regions, but these enzyme alterations were not the 
consequence of direct drug effects but rather a consequence of postsynaptic changes in 
either GABAergic or other amino acid related systems.  Sills et al (1997) also studied 
several  GABA-related neurochemical parameters  in mouse brain after levetiracetam 
administration.  They found that levetiracetam failed to influence the concentrations of 
GABA,  glutamate and glutamine in mouse brain following both single and repeated 
levetiracetam  administration.  Similarly  levetiracetam  was  without  effect  on  the 
activities of GABA-T and GAD.  These results suggest that the GABAergic system is 
probably not involved in the mechanism of action of levetiracetam.  In this thesis, the 
effect  of levetiracetam  on  ECF  concentrations  of several  excitatory  and  inhibitory 
amino  acid  neurotransmitters  (see  introduction)  in  the  rat  frontal  cortex  and  the 
hippocampus was investigated by use of in vivo microdialysis model.
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6.2  EXPERIMENTAL PROTOCOL
Amino acid concentrations in ECF were measured at the Brain Repair Centre, 
Cambridge.  Male Sprague-Dawley rats (Charles River, Margate, Kent) weighing 300- 
350 g were used.  Microdialysis probes were implanted in the frontal cortex and the 
hippocampus as previously described in Chapter 2.  Two days after surgery, baseline 
samples were taken and the rats were administered I.P. with 80 mg/kg levetiracetam. 
Dialysate samples (30  pi) were collected at  15  minutes intervals for 2 hours and 30 
minute  intervals  for  a  further  6  hours.  Samples  were  stored  frozen  (-70°C)  until 
required for the measurement of amino acid content.
6.3  RESULTS
6.3.1  ECF amino acids concentrations
Of the  19 amino acids measured in frontal cortex and hippocampal ECF, only 
two  amino  acids,  namely  taurine  and  glutamate,  concentrations  changed  after 
levetiracetam  (80  mg/kg)  administration  (Table  6.1).  Taurine  and  glutamate 
concentrations  significantly change  in  two  brain  areas  (the results  are  expressed as 
percentage  changes  with  respect  to  baseline).  In  this  experiment,  three  baseline 
samples were collected in each experiment and mean sample values are shown.  Mean 
± s.e.m basal dialysate values for taurine in the frontal cortex and hippocampus were 
5.91 ± 0.69 pM and 10.61 ± 0.59 pM respectively.
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Table 6.1:  Changes in ECF taurine concentrations, expressed as a % of 
baseline, after 80 mg/kg levetiracetam administration
Time
(h) FC
Taurine
HC FC
control
HC
Baseline 100  ±6 100  ±7 100  ±7 100  ±13
0.3 59*±11 68*±15 115  ±12 110  ±9
0.7 68*±13 70*±11 140  ±16 119  ±12
1.0 58*±8 84*±10 113  ±13 110  ±15
1.3 67*±15 66  ±8 102  ±10 117  ±21
1.7 53*±12 63*±11 119  ±10 107  ±8
2.0 57*±13 62*±14 117  ±8 93  ±7
2.3 47*±8 70*±11 125  ±16 92  ±3
2.7 44 *±9 62*±10 110  ±15 83  ±2
3.0 44*±11 72*±14 108  ±11 87  ±2
3.3 49*±8 64*±12 115  ±28 102  ±6
3.7 55*±8 79*±8 112  ±14 98  ±6
4.0 49 *±6 62*±12 109  ±13 99  ±8
4.5 50*±9 62*±15 140  ±12 109  ±6
5.0 41 *±5 54*±12 116  ±15 102  ±10
5.5 50*±12 57*±12 115  ±16 102  ±12
6.0 44 *±7 60*±12 122  ±16 105  ±12
6.5 56*±9 55*±11 121  ±13 98  ±10
7.0 47*±11 60*±11 121  ±16 95  ±8
7.5 47*±5 50*±5 113  ±15 92  ±4
8.0 36*±5 56*±13 96  ±12 99  ±4
These data are mean data from 6 animals.
*P <  0.05 compared to saline controls (one way ANOVA)
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Table 6.2:  Changes in ECF glutamate concentrations, expressed as a % of 
baseline, after 80 mg/kg levetiracetam administration
Time
(h) FC
Glutamate
HC
control
FC HC
Baseline 100  ±10 100  ±19 100  ±2 100  ±3
0.3 63  ±5 60  ±14 97  ±17 73  ±16
0.7 79  ±14 64  ±16 118  ±13 70  ±14
1.0 80  ±9 65  ±11 130  ±16 62  ±14
1.3 89  ±16 63  ±11 105  ±18 63  ±11
1.7 73  ±8 58  ±6 125  ±17 63  ±11
2.0 78  ±10 42  ±3 97  ±16 65  ±6
2.3 78  ±9 64  ±11 101  ±16 57  ±9
2.7 64  ±9 58  ±12 99  ±21 64  ±9
3.0 88  ±18 75  ±12 115  ±16 60  ±11
3.3 82*±13 54  ±12 118  ±20 61  ±11
3.7 65*±13 52  ±9 130  ±17 58  ±6
4.0 59*±14 50  ±11 115  ±23 62  ±10
T  4.5 63  ±20 47  ±11 126  ±23 56  ±12
5.0 69  ±18 53  ±9 126  ±25 60  ±13
5.5 52*±11 39  ±14 118  ±21 66  ±18
6.0 49  ±18 52  ±10 113  ±17 79  ±19
6.5 53*± 3 66  ±20 124  ±21 69  ±12
7.0 43*±11 43  ±12 102  ±15 84  ±15
7.5 40*±15 52  ±11 124  ±17 73  ±12
8.0 45*±13 49  ±20 99  ±14 55  ±7
These data are mean data from 6 animals.
*P < 0.05 compared to saline controls (one way ANOVA)
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Figure 6.1  and 6.2 shows respectively ECF taurine concentrations over time in 
the  frontal  cortex  and  hippocampus  after administration  of 80  mg/kg  levetiracetam. 
Compared to  the saline control  group,  it can be  seen that taurine concentrations are 
significantly  reduced  in  both  the  frontal  cortex  and  the  hippocampus  after 
levetiracetam administration.  In the frontal cortex,  a decrease was observed in ECF 
taurine  concentrations  which  began  gradual  decline  almost  immediately  after 
levetiracetam  administration and finally decrease to 36 % of baseline at  8 hours.  A 
similar  pattern  was  seen  in  the  hippocampus,  with  hippocampal  ECF  taurine 
concentrations decreased to 56 % of baseline at 8 hours.
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Figure 6.1:  ECF taurine concentrations in the frontal cortex (♦) before after 
the  administration  of  80mg/kg  levetiracetam  or  0.9%  saline  (■  control). 
Values are mean of 6 animals and are expressed as percentage of baseline; 
vertical bars show s.e.m.
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Figure 6.2:  ECF taurine concentrations in the hippocampus (♦) before and 
after the administration of 80mg/kg levetiracetam or 0.9% saline (■ control). 
Values are mean of 6 animals and are expressed as percentage of baseline; 
vertical bars show s.e.m.
Figures  6.3  and  6.4  show  respectively  ECF  glutamate  concentrations  time
profiles  in  the  frontal  cortex  and  hippocmaus  after  80  mg/kg  levetiracetam
administration.  It  also  can  be  seen  that  although  80  mg/kg  levetiracetam
administration  was  associated  with  a  reduction  of glutamate  concentration  in  the
hippocampus (Figure 6.4), the changes were not statistically significance.  In contrast,
the frontal cortex ECF glutamate concentrations begin to decline after 3.5 hours and
continued to decline to 45% of baseline at  8 hours after levetiracetam administration.
These decreases were statistically significant (see Table 6.2).
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Figure 6.3:  ECF glutamate concentrations  in the frontal cortex  (♦) before 
and  after the  administration  of 80mg/kg  levetiracetam  or 0.9%  saline  (■ 
control).  Values are mean of 6 animals and are expressed as percentage of 
baseline; vertical bars show s.e.m.
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Figure 6.4: ECF glutamate concentrations in the hippocampus (♦) before 
and  after the administration of 80mg/kg levetiracetam or 0.9% saline (■ 
control).  Values are mean of 6 animals and are expressed as percentage 
of baseline; vertical bars show s.e.m.
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ECF concentration for alanine, arginine,  asparagines,  aspartic acid, citrulline, 
GABA,  glutamine,  glycine,  isoleucine,  leucine,  lysine,  methionine,  phenylalanine, 
serine, threonine, tryptopham, tyrosine and valine were unaffected by levetiracentam 
administration.
6.3.2  Relationship  between  ECF  amino  acid  and  ECF  levetiracetam 
concentrations
In  this  section,  the  ECF  of levetiracetam  concentration  versus  time profiles 
presented  in  Chapter 4  after  80mg/kg  levetiracetam  administration  are plotted with 
that of the  ECF  taurine  and  glutamate  concentration versus  time profiles that have 
been  described  in  the  previous  section.  The  aim  of this  approach  is  to  ascertain 
whether or not there is a relationship between levetiracetam concentration and amino 
acid concentrations in brain ECF.
After 80 mg/kg levetiracetam administration taurine concentrations decreased 
almost  immediately  and  this  occurred  in  both  the  frontal  cortex  and  hippocampus 
(Figures 6.5 and 6 .6).  Taurine concentrations continued to decrease and reached their 
lowest concentration at 8 hours post levetiracetam administration.  ECF Levetiraceam 
concentrations  increased  and  reached  to  peak  values  at  3  hours  after  80  mg/kg 
levetiracetam administration.  Clearly, although there does not appear to be a direct 
relationship  between  ECF  levetiracetam  concentrations  and  ECF  frontal  cortex  and 
hippocampal  taurine  concentrations,  the  observed  changes  can  be  attributed  to 
levetiracetam.  A similar pattern was also observed in relation to ECF frontal cortex 
glutamate concentration changes after levetiracetam administration (Figure 6.7).
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Figure 6.5:  ECF concentration versus time profiles for levetiracetam (♦) 
and  taurine  (■)  in  the  frontal  cortex  after  80  mg/kg  levetiracetam 
administration.  Values are mean ± s.e.m of 6 animals.
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Figure  6 .6 :  ECF concentration versus time profiles for levetiracetam (♦) 
and  taurine  (■)  in  the  hippocampus  after  80  mg/kg  levetiracetam 
administration.  Values are mean ± s.e.m of 6 animals.
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Figure  6.7:  ECF  concentration versus time profiles for levetiracetam (♦) 
and  glutamate  (■)  in  the  frontal  cortex  after  80  mg/kg  levetiracetam 
administration.  Values are mean ± s.e.m of 6 animals.
6.4  DISCUSSION
In the present study levetiracetam administration (80 mg/kg) was without effect 
on ECF  concentration  of  18  of the 20  amino  acids studies.  That levetiracetam was 
without effect on ECF GABA concentration further indicates that the mechanism of 
action of levetiracetam  is not a consequence of altering brain GABA concentrations. 
Levetiracetam administration was associated with significant changes in ECF taurine 
and glutamate concentrations and these effects will now be discussed in turn.
6.4.1  Taurine
Levetiracetam  administration  (80  mg/kg)  was  associated  with  a  significant 
reduction  in  ECF  taurine  concentrations  in  both  the  frontal  cortex  and  the 
hippocampus  in  present  study.  Taurine  concentrations  deceased  at  1   hour  after
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levetiracetam administration and continued to decrease up to 8 hours.  As there are no 
other published data on the effect of levetiracetam on ECF taurine concentrations, it is 
not possible  to  make  any  comparison.  However,  the  baseline  taurine  concentration 
observed in the present study are comparable to values reported in other microdialysis 
studies (Wilson et al, 1996; Sejima et al, 1999; Dahlin et al, 2005).
Taurine is known to possess some mild anticonvulsant activity in both animal 
models  and human.  In vitro  studies  in various  species have demonstrated that low 
levels  of taurine  are  associated with  epilepsy and other  seizure  disorders  (Birdsall, 
1998).  Using rat cortex and hippocampus slices, an antiepileptic effect of taurine were 
investigated.  The  results  showed  seizure-like  events  were  suppressed  by  taurine 
administration.  Their findings suggest that taurine, as a glycine agonist, could serve as 
potential  antiepileptic  agents  (Kirchner et  al,  2003).  A potential role of taurine on 
epilepsy  were  also  studied  in  a  rat  seizure  model.  Taurine  had  a  significant 
antiepileptic effect at 20, 40 and 80 mg/kg doses and the results indicated that taurine 
may play an inhibitory role against epilepsy as an inhibitory amino acid in CNS (Li et 
al,  2005).  In a patient series,  Wilson et al  (1996) reported on twelve patients with 
epilepsy.  ECF  concentrations  of  eight  amino  acids  were  monitored  during 
spontaneous seizures.  They observed that ECF taurine concentrations were increased 
in the hippocampus of epileptic patients. Taurine-like compounds, such as  taltrimide 
and  MY103,  have  been  used  in  clinical  trials  of epileptic  patients.  Other taurine 
structural  analogues,  such  as  phosphonates  and  guanidine  derivatives,  were  also 
studied  (Gupta et al, 2005).
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The  evidence above indicates that taurine  and its analogues  seem to possess 
antiepileptic activity. It is thus difficult to reconcile the decrease in brain taurine with 
the  antiepileptic  effect  of  levetiracetam.  What  is  the  mechanism  by  which 
levetiracetam reduces taurine levels?  Changes in extracellular taurine concentrations 
occur  with  changes  in  osmolarity  and  neuronal  swelling  or  shrinkage.  In  addition, 
neuronal depolarisation has been shown to increase taurine levels (Garcia Dopico et al, 
2004). It is possible that the reduced taurine levels are not relevant to the antiepileptic 
action of levetiracetam,  but are due to the antiepileptic action of levetiracetam (e.g. 
levetriacetam reduces neuronal depolarisation and so reduces extracellular taurine).
6.4.2  Glutamate
In the present study, although ECF glutamate concentrations decreased in both 
the frontal  cortex and the hippocampus after 80 mg/kg levetiracetam administration, 
the changes were only statistically significant in the frontal cortex.  Sills et al (1997) 
have  reported  on  glutamate  concentrations  in  the  mouse  brain  after  300  mg/kg 
levetiracetam  administration.  Neither  acute  nor  chronic  (5  days)  levetiracetam 
administration  was  associated  with  any  changes  in  brain  glutamate  concentrations. 
The  differences  between  the  present  study  and  that  of  Sills  et  al  (1997)  may  be 
attributable to the fact that whole brain concentrations may not accurately reflect ECF 
concentrations.  There is no patient or human volunteer studies published reporting the 
effect of levetiracetam in ECF, CSF or brain glutamate concentrations.
The  mechanism  by  which  ECF  glutamate  concentrations  are  changed  by 
levetiracetam  is  unknown.  Glutamate  concentrations  in  ECF  are  low  (3-4  pM) 
compared to  concentrations  in the  intracellular  fluid  (ICF).  Glutamate  transporters
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carry glutamate from the ECF to the ICF reuptake of glutamate into glial cells where 
glutamate is  converted to  glutamine which in turn is  converted back into glutamate 
(Danbolt,  2001).  Therefore,  there  are  two  possible  mechanisms  by  which 
levetiracetam could decrease ECF glutamate concentrations.  1.  Levetiracetam could 
decrease glutamate release. 2.  Levetiracetam could increase glutamate uptake.
6.4.3  GABA and other amino acids
Levetiracetam did not affect ECF GABA or other amino acid concentrations in 
the present study.  These results are in agreement with previous observations by Sills 
et al (1997), Poulain & Margineanu (2002) and Gower et al (1994).  A lack of effect 
on mouse brain GABA concentrations and on the enzymatic activities of GABA-T and 
glutamic  acid  decarboxylase  by  levetiracetam  was  reported  by  (Sills  et  al,  1997). 
Extensive experiments on the receptor binding assay profile of levetiracetam indicated 
that levetiracetam was inactive at all of the more than 30 neurotransmitter receptors 
and ion channel sites, which indicated that the levetiracetam binding site in the brain 
was not directly related to any site that standard AEDs act upon (Noyer et al,  1995, 
Poulain & Margineanu, 2002).
6.4.4  Conclusions
1.  Levetiracetam  administration  (80  mg/kg)  was  associate  with  significant 
reductions  in  ECF  taurine  concentrations  in  both  the  frontal  cortex  and  the 
hippocampus. The mechanisms by which levetiracetam affects taurine or the role of 
taurine in the mechanism of action of levetiracetam  is unknown.
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2.  ECF  glutamate  concentrations  were  also  reduced  by  levetiracetam 
administration  but  in  contrast  to  taurine,  the  reduction  was  only  significant  in  the 
cerebral cortex.  This effect may be via an increase in glutamate uptake or by decrease 
of glutamate  release.  Both  these  mechanisms  could  contribute  to  the  antiepileptic 
action of levetiracetam.
3.  ECF  GABA  and  other  amino  acid  concentrations  were  unaffected  by 
levetiracetam administration providing further evidence that the anticonvulsant action 
of levetiracetam  is unlikely to be mediated via an action on the GABAergic systems.
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7.1  INTRODUCTION
Vigabatrin  is  effective  in numerous  animal  seizure  models  including those 
induced  by  strychnine,  isoniazid,  low  dose  bicuculline,  picrotoxin  and 
pentylenetetrazol  (Lewis  &  Wallace,  2001;  Haugvicova  et  al,  2002).  It  is  an 
efficacious AED in patients with intractable epilepsy (Turanli et al, 2006), but it may 
precipitate  status  epilepticus  (de  Krom  et  al,  1995).  The  explanation  for the  dose 
dependant  effects  of  vigabatrin  and  why  vigabatrin  loses  anticonvulsant  effect  at 
higher doses is  unknown.  It is possible that the increased extracellular GABA after 
vigabatrin  administration,  possibly  reduces  GABA  release  through  activation  of 
GABAb  receptors.  In  addition  GABA  accumulation  may  desensitise  GABAa 
receptors (Mott & Lewis,  1994).  Using hippocampal slice preparations, vigabatrin has 
been  shown  to  inhibit  early  GABAa receptor-dependent  paired  pulse  inhibition  in 
dentate and this disinhibition is thought to be due to activation of pre-synaptic GABAb 
receptors (Sayin et al,  1997).  Vigabatrin also showed an effect reducing paired pulse 
inhibition in rat dentate gyrus in  vivo and in  vitro, which suggests that activation of 
presynaptic  GABAb  receptors  by  increased  extracellular  GABA  may be  one  of the 
contributing  factors  to  the  apparent  paradoxical  effect  of  vigabatrin  on  synaptic 
inhibition (Sayin et al, 2001).
Although the binding site of levetiracetam in the CNS has been identified as 
synaptic  vesicular protein  2a  (SV2a)  (Lynch  et al,  2004,  Lambeng  et al,  2006),  the 
mechanism by which binding to  this protein mediates  the anticonvulsant effect and 
whether  this  is  the  only  mechanism  of action  for  levetiracetam  remains  unclear. 
Previous studies have shown that levetiracetam does not bind to any neurotransmitter
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receptors  (Noyer  et  al,  1995)  and  no  definite  GABAergic  mechanism  has  been 
identified  (Margineanu  &  Wulfert,  1995).  Levetiracetam  has  a  neuroprotective 
function in animal models of status epilepticus (Gibbs et al, 2006; Willmore, 2005), 
but this relates to its antiepileptic effect is still not completely clear.
In this section, using perforant path stimulation the effects of vigabatrin and 
levetiracetam on paired-pulse inhibition in vivo were further investigated so as to the 
characterise mechanisms and to compare the action these two AEDs on GABAergic 
inhibition.
7.2  EXPERIMENTAL PROTOCOL
The methods used are those described by Albertson & Joy (1987) and Joy et
al (1992) and have been detail in Chapter 2.  Male Sprague-Dawley rats had bipolar
stimulating electrodes implanted under halothane anaesthesia in the perforant path, and
recording  electrodes  placed  in  the  dentate  granule  cell  layer.  The  electrodes  were
positioned so as to obtain a maximal population spike response at the lowest stimulus
strengths.  The  electrodes were held in place with dental  cement,  and the rats were
allowed to  recover.  Three days later,  constant current paired-pulse  stimulation was
delivered  at  0.1  Hz.  After  obtaining  a  consistent  evoked  response  and  stable
population  spike  recordings,  the  stimulus  intensity that  produced  the  half maximal
population  spike amplitude was determined and was used for single or paired pulse
recordings.  Data were gathered before drug administration periods and during drug
exposure  periods.  Vigabatrin  (lOOOmg/kg)  and  levetiracetam  (80mg/kg)  were  then
constituted in saline and administered after a pre-drug period of 30 minutes recording.
Subsequent  recordings  occurred  for  5  minutes  at  the  beginning  of each  30 minute
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period for a total of 8 hours.  Finally a single point recording at 24 hour for 5 minutes 
was undertaken.  A granule-cell excitability curve was obtained using pairs of stimuli 
of fixed  intensity with  interpulse  intervals ranging between 20-100 ms.  The paired 
pulse index was defined as the population spike amplitude resulting from the second 
pulse  (p2)  divided by the population  spike  amplitude  resulting  from the  first pulse 
(pi).  Since early paired pulse inhibition is dependent on size of conditioning pulse, 
the intensity of the stimulating pulse was adjusted, so that size of pi remained constant 
throughout the experiment at half maximum.  Paired-pulse ratio values were obtained 
using 8-10 pairs of stimuli at a fixed time interval.  Paired pulse intervals of 20, 50 and 
100 ms were used.
In previous paired pulse studies of perforant path, a chloride-dependent phase 
of inhibition  occurred  at  10-40  ms  inter-pulse  interval.  These  intervals  reflect the 
recurrent or feed-forward stimulation of intemeurones and resultant activation of fast 
chloride-mediated GABAa receptor inhibition.  A facilitation at 40-100 ms intervals is 
observed (Oliver & Miller,  1985).  Comparisons at these three intervals can be used to 
determine whether alterations in granule-cell excitability are associated with changes 
in inhibition or other processes (Joy et al, 1992).
7.3  RESULTS
7.3.1  Conditioning stimulus
In these experiments great care was taken to maintain a constant conditioning 
population spike amplitude.  In animals, over the first 8 hours following vigabatrin and 
levetiracetam  administration,  the  stimulus  intensity had  to  be  increased  in  order to
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maintain the constant population spike.  By 24 hours, however, the stimulus intensity 
to evoke an identical population spike to baseline was unchanged.
7.3.2  Paired-pulse inhibition and. vigabatrin
It can be seen from Figure 7.1 that vigabatrin resulted in a decrease in paired 
pulse  inhibition  at  the  20ms  interpulse  interval  at  24  hours  post  vigabatrin 
administration.
paired pulses  prior to  VGB
paired pulses  24 hours 
after VGB
2m  V
5ms
Figure 7.1:  Paired-pulse inhibition was decreased at 20ms interval after
24 hours  lOOOmg/kg vigabatrin administration ( -  ).  The blue line ( -  ) 
shows  paired-pulse  inhibition  (PPI)  before  vigabatrin  administration.
Mean ± s.e.m for 6 animals. VGB= vigabatrin.
The maximum disinhibition  occurred at approximately  1-4 hours  and at 24
hours paired pulse inhibition was still significantly decreased (P< 0.01  2 paired /-test)
for the 20ms interpulse interval.  In the control group, there was no change of paired
pulse inhibition at any time point (Figure 7.2 A & B; Figure 7.3).
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Figure 7.2:  Paired-pulse inhibition (PPI) time profile after lOOOmg/kg vigabatrin (A) 
and saline (B)  administration.  The percent change of PPI in the second population 
spike (p2) amplitude compared with the first population spike (pi) for 6 rats (mean ± 
sem) is presented at the 20 ms intervals  indicates baseline values.
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Figure  7.3:  The  paired-pulse  inhibition  was  significantly decreased  at  24 
hours after  1000 mg/kg vigabatrin administration compared to baseline, P < 
0.01.  The change  in the  second population  spike  (p2)  amplitude  compared 
with the first population spike (p 1) for 6 animals (mean ± sem) is presented at 
the 20 ms interval.
After lOOOmg/kg vigabatrin administration, the paired-pulse ratio at 50ms and 
100ms  interval was  not associated with any significant change  compared to control 
group.  Figure 7.4  illustrates that the  paired-pulses  inhibition in the two groups are 
similar when the first and the second population spikes are compared.
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A.  50 ms interval 
Vigabatrin group  Control group
5rrW
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B.  100 ms interval 
Vigabatrin group  Control group
5 mV
20 ms
Figure 7.4:  Effects of vigabatrin on paired-pulse inhibition (PPI) after 1000 
mg/kg vigabatrin administration.  The PPI was unchanged in the subsequent 
test population spikes (pink lines) compared with the baseline (blue lines).
The  interstimulus  interval (ISI) in these traces was 50ms  (A) and  100 ms 
(B).  Bar = 5mV.
Figures 7.5  and 7.6  show respectively the percentage change in the second 
population spike (p2) amplitude compared with the first population spike (pi) at 50 ms 
and  100 ms.  It is clear that there were no significant difference (P> 0.05) in paired- 
pulse inhibition between the vigabatrin  (1000 mg/kg ) administered groups and the 
control groups.
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Figure 7.5:  The paired-pulse inhibition versus time profiles after 1000 mg/kg 
vigabatrin  (♦)  and  saline  (■)  administrations.  The  percent  change  in  the 
second population spike (p2)  amplitude compared with  the first population 
spike (pi) for 6 animals (mean ± sem) is presented at the 50 ms interval.
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Figure  7.6:  The  paired-pulse  inhibition  versus  time  profiles  after  1000 
mg/kg vigabatrin (♦) and saline (■) administrations.  The percent change in 
the  second  population  spike  (p2)  amplitude  compared  with  the  first 
population spike (pi) for 6 animals (mean ± sem) is presented at the 100 ms 
interval.
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7.3.3  Paired-pulse inhibition and levetiracetam
Figure 7.7 shows that time course of the effect of levetiracetam on paired- 
pulse inhibition.  It can be seen that whilst there was no effect at 50 ms and 100 ms, 
the 20ms interval was associated with a small reduction.  However, this effect in the 
dentate gyrus did not attain statistical significance.
A.  20 ms interval
Levetiracetam group  Control group
5rrV
B.  50 ms interval
Levetiracetam group  Control group
5 mV
10ms
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C.  100 ms interval 
Levetiracetam group  Control group
5 mV
20 ms
Figure 7.7:  Effect of levetiracetam on paired-pulse inhibition (PPI) after 80 
mg/kg levetiracetam administration.  The PPI were significantly increased at 
20ms (see figure 7.8), but it is unchanged in the subsequent test population 
spikes (-) compared with the baseline (- ).  The interstimulus interval (ISI) in 
these traces was 20 (A), 50 (B) and 100 (C) ms.  Bar=5Mv.
Figures of 7.8, 7.9 and 7.10 show respectively the percentage change in the 
second population spike (p2) amplitude compared with the first population spike (pi) 
at  20  ms,  50  ms  and  100ms.  Although  there  was  small  reduction  in  paired-pulse 
inhibition by levetiracetam at 20  ms  interval during  5-8  hours  and at 24 hours,  this 
effect did not achieve statistical significance.
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Figure  7.8:  The  paired-pulse  inhibition  versus  time  profiles  after  80
mg/kg  levetiracetam  (■)  and  saline  (♦)  administrations.  The  percent 
change in the second population spike (p2) mean ± sem is presented at the 
20 ms interval amplitude compared with the first population spike (p2) for 
6 animals.
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Figure 7.9: The paired-pulse inhibition versus time profiles after 80 mg/kg 
levetiracetam (■) and saline (♦) administrations. The percent change in the 
second population spike (p2) mean ± sem is presented at the 50 ms interval 
amplitude compared with the first population spike (p2) for 6 animals.
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Figure 7.10: The paired-pulse inhibition versus time profiles after 80 mg/kg 
levetiracetam (■) and saline (♦) administrations. The percent change in the 
second population spike (p2) mean ± sem is presented at the 100 ms interval 
amplitude compared with the first population spike (p2) for 6 animals.
7.4  DISCUSSION
7.4.1  Effect of vigabatrin on paired-pulse inhibition
In this  study the changes in field potentials  in the dentate gyrus evoked by 
paired stimuli applied to the perforant path were investigated in control and vigabatrin 
administered  rats.  Two  effects  of  vigabatrin  were  observed:  (1).  Increase  in 
stimulation  intensity  in  order  to  maintain  a  constant  population  spike  following 
vigabatrin  administration.  (2).  Decrease  in  paired  pulse  inhibition  at  the  20  ms 
interval, which was still apparent by 24 hours.
The  stimulation  intensity was  adjusted  in  the  present  study  to  maintain  a 
constant  population  spike  in  all  animals.  Previous  studies  have  indicated  that  the
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stimulation intensity may be an indicator of the activation state of the brain and the 
peak  amplitudes  depended  nonlinearly  on  the  intensity  (Komssi  et  al,  2004).  A 
decrease  in  the  population  spike  by  reduced  stimulation  intensity  can  affect  feed­
forward  inhibition  and  thus  early  paired  pulse  depression,  and  thus  increased 
stimulation intensity is necessary to maintain the population spike amplitude (Sayin et 
al,  2001).  The increase in stimulation intensity needed in my experiments suggests 
that vigabatrin reduces dentate granule cell excitability.
The  second  finding  in  the  present  study  demonstrated  that  vigabatrin 
administration  was  associated  with  a  significant  decrease  in  paired-pulse  early 
inhibition at 20 ms  for at least 24 hours compared to the control group, which may 
reflect  a  reduced  feed-forward  GABAa  receptor  mediated  inhibition  in  the 
hippocampus (Sayin et al, 2001).  The mechanisms behind this remains poorly defined, 
but two possibilities could explain these results:  1) Vigabatrin increased extracellular 
GABA  concentrations  and  decreased  GABA  uptake  resulting  in  activation  of 
presynaptic  GABAb  receptors  which  decreased  GABA  release;  2)  Extracellular 
GABA increases can also desensitise the post-synaptic GABAa receptor (Figure 7.11).
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Figure 7.11: A schematic showing GABAa and GABAb receptors location 
on a pre- and postsynaptic neurone
The acute  effects  of vigabatrin  decreasing paired-pulse  inhibition at 20 ms 
interval could therefore be partially explained by a decrease in GABA uptake.  Suzuki 
et al (1991) investigated that effect of vigabatrin on GABA uptake.  They found that 
vigabatrin of 100-1 OOOpM produced a concentration-dependent decrease in net uptake 
of 36C1 in membrane vesicles, this suggested an effect of vigabatrin acting directly at 
the membrane vesicles rat GABAa receptor complex as a non-competitive antagonist. 
Vigabatrin was also reported  to  reduce  activity-dependent  suppression  that occurs 
during  a  stimuli  by  reducing the  function  of presynaptic  GABAb  autoreceptors 
(Jackson  et  al,  2000).  Using  in  vivo  and  vitro  methods  in  the  CA1  region  of rat 
hippocampus,  Sayin et al (2001) found that the decreased paired-pulse inhibition by 
vigabatim was prevented or reversed by the co-application or subsequent application 
of GABAb antagonists saclofen or CGP 35348, which indicated that these paradoxical 
effects of vigabatrin may be attributed to the presynaptic inhibition of GABA uptake at
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the  GABAergic  synapses  by  the  excessive  stimulation  of  presynaptically  located 
GABAb autoreceptors.  The release of GABA from intemeurons has been shown to be 
decreased  by  presynaptic  GABAb  autoreceptors  (Davies  &  Collingridge,  1993; 
Brucato et al,  1995).  Thus in conjunction with these reports, the data present in this 
thesis would suggest that the decrease in paired-pulse inhibition by vigabatrin might be 
explained  by  the  activation  of  presynaptic  GABAb  autoreceptors  consequent  to 
increased  ECF  GABA  concentrations.  The  observation  of reduced  inhibition  in the 
dentate  gyrus,  in this  study, may explain  some of adverse effects of vigabetrin, and 
could contribute to the paradoxical proconvulsant effects of vigabatrin in generalized 
seizures.
An alternative explanation is that increased GABA results in GABAa receptor 
desensitisation.  Vigabatrin  does  not  have  a  direct  antagonistic  effect  on  GABAa 
receptors,  as  shown  by binding  studies  (Jackson  et  al,  1994a).  However GABA-T 
inhibition  produced  by  vigabatrin  can  be  expected  to  increase  inhibition 
postsynaptically  by  elevation  of GABA  concentrations  in  the  brain.  Overstreet  & 
Westbrook  (2001)  examined  the  effects  of  vigabatrin  on  GABAergic  synaptic 
transmission in hippocampal  slices.  Vigabatrin unexpectedly reduced miniature and 
evoked  inhibitory  postsynaptic  currents  and  these  effects  were  accompanied  by  an 
increase in tonic GABAa receptor-mediated current.  The increase in tonic inhibition 
described in this  study would explain the decrease  in granule cell  excitability that I 
observed.  The  gradual  GABA  accumulation  in  extracellular  compartments  led to  a 
reduction in postsynaptic receptor sensitivity.
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7.4.2  Effects of levetiracetam on paired-pulse inhibition
In this study, levetiracetam did not cause a statistically significant change in 
paired-pulse inhibition, but there was a slight tendency for a decrease in inhibition at 
20ms.  These data are in agreement with previous animal  studies in different
models  (Margineanu  &  Wulfert,  1995;  Margineanu  &  Klitgaard,  2003)  that  have 
shown that levetiracetam did not affect paired-pulse inhibition in the dentate gyrus at 
short  intervals.  Furthermore,  levetiracetam  did not  alter the paired-pulse  inhibition 
when bicuculline, a GABAa antagonist was administered.  These data were considered 
to  suggest  that  the  anticonvulsant  mechanisms  of action  of levetiracetam  are  not 
mediated  by  GABAa  receptors.  Recently  Margineanu  &  Klitgaard  (2003)  also 
investigated the effect of levetiracetam on the paired-pulse interaction in the urethane- 
anesthetized animal model.  Their results showed that levetiracetam had no significant 
effect on paired-pulse interaction in this model, similar to my results.
7.4.3  Conclusion
1.  Vigabatrin  has  two  effects  on  perforant  path  to  dentate  granule  cell
responses in this study:  (1).  Increase in stimulation intensity in order to maintain a
constant population spike.  (2).  Decrease in paired-pulse inhibition of 20 ms interval,
which was still apparent by 24 hours.  These results can be explained on the basis of
two  mechanisms.  Firstly,  vigabatrin  increased  ECF  GABA  concentrations  and
decreased GABA uptake results in activation of presynaptic GABAb receptors which
reduced GABA release;  Secondly, the increased GABA concentration can desensitise
post-synaptic GABAa receptors, but activate extrasynaptic GABAa receptors leading
to  reduced  granule  cell  excitability.  Vigabatrin  had  a  predominant  effect  on  the
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inhibitory system resulting in disinhibition in the paired-pulse experimental paradigm, 
which would suggest that GABAa receptor-mediated feedback or forward inhibition 
does  not  underlie  its  action  as  an  anticonvulsant,  but  that  vigabatrin’s  antiepileptic 
effect  may  be  mediated  by  GABAb  receptor  and  extrasynaptic  GABAa  receptor 
activation.
2.  Levetiracetam  had  no  effect  on  excitability  or  paired-pulse  inhibition 
occurring  at  20-100  interstimulus  intervals.  These  results  are  in  agreement  with 
previous studies, which suggest that the anticonvulsant activities of levetiracetam are 
probably mediated via a non-GABAergic mechanism.
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8.1  INTRODUCTION
Approximately 80% of patients with epilepsy are rendered  seizure-free with 
the  long-established  generally  available  AEDs  (carbamazepine,  ethosuximide, 
phenobarbital,  primidone  and  valproate).  However  these  patients  may  experience 
numerous drug-related problems such as idiosyncratic reactions and acute and chronic 
CNS  adverse  effects.  For  the  remaining  20%  of patients  with  severe-treatment- 
refractory  epilepsy,  little  benefit  is  achieved  from  the  use  of  these  AEDs  as 
intolerable adverse effects occur. Therefore there has been a need for new AEDs with 
improved  risk-benefit  ratios  (i.e.  greater  efficacy  and  less  toxicity)  and  simple 
pharmacokinetic characteristics and there has been a desire to understand better the 
mechanism  of drug  action  so  that  more  rational  prescribing  could  be  entertained. 
Indeed,  since  1989,  nine  new  AEDs  (gabapentin,  lamotrigine,  levetiracetam, 
tiagabine, topiramate, oxcarbazepine, vigabatrin and felbamate and zonisamide) have 
been licensed for clinical use and despite significant effort their mechanisms of action 
are  not  fully  understood.  Similarly  their  pharmacokinetic/neuropharmacokinetic 
profiles  are  also  not  fully  understood.  Therefore  the  present  thesis  sought  to 
investigate the mechanism of action and the pharmacokinetic/neuropharmacokinetic 
inter-relationship of two of the new AEDs, namely vigabatrin and levetiracetam.
8.2  PHARMACOKINETIC/NEUROPHARMACOKINETIC INTER­
RELATIONSHIP
8.2.1  Vigabatrin
Although  the  blood  pharmacokinetics  of  vigabatrin  in  man  is  well 
characterised,  the  central  brain  neuropharmacokinetics  of  vigabatrin  are  poorly
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understood  in  that  its  CSF  kinetics  comprise  of  CSF  analysis  of  single  lumber 
puncture samples and there have been no studies of the ECF neuropharmacokinetics 
of vigabatrin. In relation to the rat, there are even sparser data. Perhaps the reason for 
the lack of data can be attributable to the notion that since vigabatrin continues to 
exert  its  pharmacological  effect  long  after  vigabatrin  is  eliminated  from  the 
blood/brain,  an understanding of its kinetic profile would not significantly enhance 
the therapeutic use of vigabatrin. However, data presented in this thesis show that the 
pharmacokinetic/ neuropharmacokinetic  inter-relationship  of vigabatrin in the rat is 
not what one would anticipate. Thus whilst the serum pharmacokinetics of vigabatrin 
are linear and dose-dependent, and indeed its neuropharmacokinetics in the CSF and 
ECF  frontal  cortex  and  hippocampus  are  similarly  linear  and  dose  dependent,  the 
kinetic inter-relationship between the three compartments is unexpected.
The rate of drug penetration into the  CSF compartment is  considered to be 
determined  by  essentially  three  physiochemical  characteristics;  ionisation,  lipid 
solubility and plasma protein binding. In relation to AEDs, lipid solubility appears to 
be  a  major  determinant.  The  blood  protein  binding  of  a  drug  determines  the 
distribution of the drug in the body. Thus with highly protein bound drugs distribution 
is  limited  whilst  for  minimally  bound  drugs  distribution  is  more  extensive. 
Furthermore  the  non-protein  bound  component  is  available  to  transfer  across  the 
blood brain barrier and to enter the CSF and brain compartments and for many AEDs 
(e.g. phenytoin and lamotrigine) there is good correlation between free concentration 
in blood with that of CSF and brain tissue. With regards to vigabatrin, data presented 
in this thesis confirm that, as previously reported, it is not bound to proteins in serum 
and CSF vigabatrin concentrations did not reflect free drug concentrations in serum.
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A possible explanation for this observation may be the fact that in the choroid plexus 
interface between the CSF and blood compartments there is  an active organic  acid 
transporter  system,  which  is  capable  of driving  CSF-bome  organic  acids  into  the 
blood  stream  and  may  also  extrude  vigabatrin  (Misra  et  al.,  2003).  A  further 
explanation may be that vigabatrin is not lipid-soluble, and requires active transport 
into the CSF compartment.
Because  ECF  vigabatrin  concentrations  in  brain  frontal  cortex  and 
hippocampus  are  adjusted  concentrations  based  on  in  vitro  microdialysis  recovery 
values  it  is  not  appropriate  to  make  direct  comparisons  with  that  of  absolute 
concentration measurements in serum and CSF. Nevertheless, it is valid to compare 
vigabatrin  concentrations  in  ECF  of the  frontal  cortex  and  hippocampus.  In  this 
regard,  vigabatrin  distribution  in  ECF  was  brain  region  specific  in  that  vigabatrin 
concentrations in the frontal cortex were 2-fold greater compared with concentrations 
achieved  in the hippocampus.  Such  specific  brain region  distribution of AEDs has 
also  been  reported  for  phenytoin  and  lamotrigine  (Walker  et  al.,  1996;  2000). 
Interestingly,  the  fact  that  vigabatrin  t\a  values  are  essentially  identical  for 
hippocampus (2.4-3.6 hours) and frontal cortex (2.5-3.6 hours) would suggest that the 
elimination processes  in the two brain regions  are  similar.  This  suggests  that there 
must be differences in the ability of vigabatrin to enter distinct brain areas.. To date, 
however,  there  have  been  no  published  data  on  the  mechanism  by  which  this 
difference may occur.
8.2.2  Levetiracetam
As  with  vigabatrin,  the  blood  pharmacokinetics  of levetiracetam  in  man  is
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well  characterised but the central brain neuropharmacokinetics of levetiracetam are 
poorly  understood.  Although  there  are  no  reports  on  the  brain  distribution  of 
levetiracetam,  levetiracetam  is  reported  to  readily  and  rapidly  enter  the  CSF 
compartment of patients with epilepsy with rm ax values of 3-5 hours (Edwards et al., 
2004).  In  relation  to  the  rat,  there  is  a  single  study  whereby  the  kinetic  inter­
relationship between the blood and CSF compartments  were  compared  (Doheny et 
al.,  1999).  Levetiracetam  was  observed  not  to  bind  to  blood  proteins  and  CSF 
concentrations  reflected  free  levetiracetam  concentrations  in  serum.  However,  the 
efflux of levetiracetam from the CSF compartment was significantly slower than that 
from  the  blood  compartment  (mean  tm  range:  4.4-4.9  hours  and  1.8-2.8  hours 
respectively).  Levetiracetam  serum  pharmacokinetic  data  presented  in  this  thesis 
confirm that reported by Doheny et al (1999). In addition, the neuropharmacokinetic 
profiles  of levetiracetam,  as  assessed  by  microdialysis  monitoring  of ECF,  in  the 
frontal  cortex  and  hippocampus  are  observed  to  be  essentially  identical  and  that 
levetiracetam  distribution  in  the  brain  is  not  brain  region  specific.  This  may  be 
attributable to the fact that brain uptake of levetiracetam is not dependent on PgP or 
MRP transporters which may be expressed differentially in different areas of the brain 
(Potschka et al., 2004).
8.3  THE  EFFECT  OF  VIGABATRIN  ON  CSF  AMINO  ACID 
NEUROTRANSMITTER CONCENTRATIONS
Because  the  CSF  compartment  is  considered  to  reflect  events  in  the  brain, 
many  studies  have  been  undertaken  whereby  measurement  of  neurotransmitter 
candidates in CSF have been used as an index of neuropathology or the mechanism of 
action  of  a  drug.  Furthermore,  since  the  CSF  compartment  is  considered  to  be
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kinetically indistinguishable from the site of action of drugs that have an effect in the 
CNS,  correlation  of  CSF  drug  concentrations  with  that  of  CSF  neurotransmitter 
concentrations have been used to explain putative mechanisms of drug action.
Vigabatrin has been described as a ‘designer drug’ because it was specifically 
developed  so  that  it  affects  the  GABA  system  and  increases  brain  GABA 
concentrations;  low  GABA  concentrations  having  been  clearly  associated  with 
seizure occurrence.  That vigabatrin increases  CSF GABA concentrations has been 
confirmed  in  both  human  (Ben  Menachem  et  al.,  1988,  1991)  and  animal  studies 
(Piredda  et  al.,  1987;  Bemasconi  et  al.,  1988).  In  the  present  thesis,  because  of 
technical difficulties it was not possible to measure GABA in the CSF. Nevertheless, 
homocamosine  concentrations  were  measured  and  as  homocamosine  is  a  major 
GABA  conjugate,  concentrations  can  be  used  as  an  indirect  index  of  GABA 
concentrations.  Indeed  in  this  thesis  vigabatrin  administration  was  associated  with 
significant increases in CSF homocamosine concentrations. In addition, CSF taurine 
concentrations  increased  whilst  a  concurrent  decrease  in  arginine  and  tyrosine 
concentrations  was  observed.  The  significance  of these  amino  acid  changes  with 
regards to the mechanism of action of vigabatrin is not known.
8.4  THE  EFFECT  OF  VIGABATRIN  AND  LEVETIRACETAM  ON  ECF 
BRAIN AMINO ACID NEUROTRANSMITTER CONCENTRATIONS
The ECF is the liquid compartment where the traffic  of compounds and the 
exchange  of  chemical  information  between  cells  take  place.  Consequently, 
monitoring of the ECF by microdialysis is considered to reflect synaptic events at the 
site of action or biophase of drugs and in this thesis ECF amino acid concentrations
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were  measured  in  the  frontal  cortex  and  hippocampus  after  vigabatrin  and 
levetiracetam administration.
8.4.1 Vigabatrin
Interestingly,  after  vigabatrin  administration  more  amino  acids  were 
associated with a concentration change in ECF compared to that in CSF. This would 
suggest that discrete changes in  specific  areas of the brain may not be reflected in 
CSF  whose  composition  is  a  composite  of the  whole  brain.  The  most  significant 
changes  in  ECF  amino  acid  concentrations  related  to  GABA,  which  increased  by 
more than 6-fold, and glutamate, which decreased by 37-57%. Both of these changes 
are compatible with an anticonvulsant effect.  What is particularly noteworthy is the 
observation that whilst ECF glutamate concentrations  decreased  in both the frontal 
cortex  and  the  hippocampus,  ECF  GABA  concentrations  were  only  significantly 
elevated in the frontal cortex. Thus there appears to be regional specificity in relation 
to the pharmacological effect of vigabatrin on GABA.
8.4.2 Levetiracetam
In  contrast  to  vigabatrin,  levetiracetam  was  without  effect  on  ECF  GABA 
concentrations and these data, along with those of Sills et al (1997) who were unable 
to  observe  an  effect  of levetiracetam  on  catabolic  and  anabolic  GABA  enzymes, 
would suggest that indeed levetiracetam does not exert its anticonvulsant effect via an 
action on the GABA system.  ECF taurine concentrations  in both the  frontal cortex 
and hippocampus were significantly reduced (16-64%).
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8.5  RELATIONSHIP BETWEEN VIGABATRIN ECF NEUROPHARMA­
COKINETICS AND GABA CONCENTRATIONS
The  regulation  of  GABA  has  been  a  particularly  attractive  target  as  a 
mechanism  of action of new AEDs.  Many new AEDs  (e.g.  vigabatrin,  gabapentin, 
tiagabine, felbamate, oxcarbazepine and topiramate [Fish et al., 2003]) are considered 
to at least in part act in this manner.  In the present thesis ECF GABA concentrations 
were used as a pharmacodynamic end point and their inter-relationship with that of 
the ECF AED concentrations were determined with a view to ascertaining whether or 
not there is a direct correlation between the two parameters.
After  intraperitonial  administration,  vigabatrin  rapidly  entered  the  ECF 
compartment  and  peaked  at  approximately  1   hour  after  vigabatrin  administration. 
ECF  vigabatrin  concentrations  then  declined  exponentially.  This 
neuropharmacokinetic  profile  was  apparent  in  both  the  frontal  cortex  and  the 
hippocampus.  However,  peak  ECF  vigabatrin  concentrations  in  the  frontal  cortex 
were twice those seen in the hippocampus (113 pmol/L versus 52 prnol/L; Tables 3.3 
and 3.4). Furthermore, when the ECF vigabatrin concentration versus time profile is 
compared to  the ECF GABA concentration versus time profile,  it can be  seen that 
whilst ECF GABA concentrations in the hippocampus were unaffected (Figure 5.21), 
ECF GABA concentrations in the frontal were  significantly elevated (Figure  5.20). 
However,  the  elevation  in  frontal  cortex GABA  concentrations  did not parallel the 
ECF  vigabatrin  concentrations  and  indeed  GABA  concentrations  only  began  to 
increase at approximately 3  hours post vigabatrin administration when in fact ECF 
vigabatrin  concentration  were  in  decline  (concentrations  were  approximately  50% 
those achieved at Cm ax)- Also, by 8 hours post vigabatrin administrations, when ECF
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vigabatrin concentrations were at their lowest, ECF GABA concentrations were still 
increasing. These data would suggest that there is a lack of concordance between ECF 
vigabatrin concentrations and ECF GABA concentrations and extend data presented 
in  other  studies  whereby  a  lack  of concordance  between  CSF  GABA  and  blood 
vigabatrin  concentrations  have  been  reported  (Ben-Menachem  et  al.,  1989,  1991). 
This delayed affect on GABA would be in line with the clinical observation that there 
is a time lag between ingestion of vigabatrin and achieving a clinical response.
A particular interesting observation, however, is that in the present thesis ECF 
GABA  concentration  were  unaffected  in  the  hippocampus  even  though  vigabatrin 
distributed  readily  in  the  hippocampus;  albeit  ECF  vigabatrin  concentration  were 
approximately 50% those achieved in the frontal cortex.  Possible explanations for 
this include:  (1) that a threshold vigabatrin concentration (> 50 pmol/L) needs to be 
achieved  before  significant  GABA-T  inhibition  occurs,  and  (2)  that  hippocampal 
GABA-T has a different Ki to that that occurs in the frontal cortex.
In  the  present  thesis  it  was  not  possible  to  show  that  ECF  GABA 
concentrations increase dose-dependently since only one dose was investigated (1000 
mg/kg).  Previous  studies,  however,  have  shown  that  CSF  GABA  concentrations 
increase  dose-dependently  (Ben-Menachem  et  al.,  1989;  Riekkinen  et  al.,  1989b; 
Erdal  et  al.,  1999)  and  serial  NMRS  has  shown  very  clearly  that  brain  GABA 
concentrations increase dose-dependently over a dose range up to 3 g/day (Petroff et 
al.,  1996c).  Interestingly,  it has been reported that clinically there is a ceiling above 
which increasing the dose of vigabatrin is without effect with regards to increasing 
the  efficacy  of the  drug  (McKee  et  al.,  1993).  An  explanation  for  this  clinical
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observation  relates  to  the  fact  that  although  brain  GABA  concentrations  increase 
dose-dependently  there  is  a  ceiling  (3  g/day)  above  which  increasing  the  dose  of 
vigabatrin  is  not  associated  with  any  further  increase  in  GABA  concentrations 
(Petroff  et  al.,  1996c).  That  ECF  GABA  concentrations  were  not  affected  by 
vigabatrin  in  the  hippocampus  may suggest that  there  may be  a  lower  dose  (ECF 
concentration) which has to be achieved before GABA-T inhibition is significant and 
would result in increased GABA concentrations.
8.6  EFFECTS  OF  VIGABATRIN  AND  LEVETIRACETAM  ECF  ON 
PAIRED-PULSE INHIBTION
Data presented in this thesis clearly show that vigabatrin administration was 
associated with a reduction in paired-pulse inhibition recorded in the rat dentate gyrus 
evoked by perforant path stimulation at 20 ms interpulse interval but not at 50 ms and 
100  ms  interpulse  intervals.  As  paired-pulse  responses  at  15-25  ms  interpulse 
intervals are sensitive to GABAa receptor inhibition, it would suggest that vigabatrin 
may act by  (a)  a  direct  effect of vigabatrin  on postsynaptic  GABAa  receptors  via 
increased ECF GABA concentrations, (b) a presynaptic effect on GABAb receptors 
which serves to regulate GABA release, or (c) by other electrophysiological effects of 
vigabatrin  as  yet  not  defined.  These  data  are  in  agreement  with  those reported by 
Sayin et al. (2001).
Vigabatrin increases ECF GABA concentrations by at least two mechanisms. 
The primary mechanism is through its irreversible binding to the enzyme GABA-T 
that is responsible for the breakdown of GABA in neurones and glia. The secondary 
mechanism relates to the ability of vigabatrin to block the uptake of GABA from the
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synaptic  cleft.  The  lack  of  an  increase  in  ECF  GABA  levels  noted  in  the 
microdialysis studies may not directly relate to GABA in the synaptic cleft, because: 
1) increased GABA release or increased GABA present in the synaptic cleft may be 
removed by glial and extrasynaptic neuronal GABA transporters or 2) there may be 
only  subregional  or  subcellular  specific  increases  in  GABA  whilst  microdialysis 
samples over a larger region. The possible increased GABA concentrations associated 
with  vigabatrin  administration  are  expected  to  have  effects  at  both  GABAa and 
GABAb  receptors.  An  effect  on  presynaptic  GABAb  receptors  might  reduce  the 
efficacy  of  inhibitory  synaptic  transmission  and  may  explain  the  paradoxical 
proconvulsant  effects  of  vigabatrin  that  have  been  reported  in  patients  with 
generalized seizures.
Using anaesthetized rats, Margineanu and Wullfert (1995) were able to show 
that  levetiracetam  was  without  effect  on  paired-pulse  inhibition.  These  data  are 
confirmed  in  the  present  thesis  using  freely  moving  rats.  These  data  suggest  that 
levetiracetam has no direct action on GABAa receptors.
8.7  SUMMARY AND FURTHER WORK
This thesis describes various studies designed to ascertain the pharmacokinetic 
and  neuropharmacokinetic  inter-relationship  of  vigabatrin  and  levetiracetam  in  a 
freely moving and freely behaving rat model and their effects on CSF and brain ECF 
amino acid neurotransmitters. Studies exploring a more detailed understanding of the 
mechanism  of action  of vigabatrin  and  levetiracetam  were  also  undertaken  using 
paired-pulse inhibition recorded in the rat dentate gyrus and evoked by perforant path 
stimulation.
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However,  further  studies  are  needed  to  extend  the  finings  reported  in  this 
thesis:  (1)  In  terms  of  the  brain  neuropharmacokinetics  of  vigabatrin  and 
levetiracetam,  other  brain  regions  apart  from  the  frontal  cortex  and  hippocampus, 
should be investigated so as to establish the exact drug distribution in the brain ECF 
compartment; (2) To ascertain whether or not the differential effect of vigabatrin on 
ECF  GABA  concentrations  extends  to  other  brain  regions;  (3)  To  determine  the 
GABA  versus  time profile beyond  8  hours  post vigabatrin  administration  so  as  to 
ascertain the exact magnitude and time course of the GABA concentration changes 
that  were  observed  in  the  frontal  cortex;  (4)  To  determine  whether  or  not  ECF 
GABA  concentration  changes  are  vigabatrin  dose  and  concentration  (ECF) 
dependent.  (5)  Further  mechanism  studies  for  vigabatrin  and  levetiracetam, 
especially given the novel binding site now identified for levetiracetam.
Other  neurotransmitters  and  biologically  active  substances  are  undoubtedly 
also  important  in  epileptogenesis.  Nitric  oxide  (NO)  plays  a  critical  role in  signal 
transduction  in  the  CNS  with  major  functions.  It  was  recently  shown  that 
levetiracetam  increase  the  expression  of inducible NO  in  cultured  astrocytes.  The 
effect  of levetiracetam  on  NO  is  due  to  an  interaction  with  NMDA  and  AMPA 
pathways (Dagonnier et al, 2005).  Levetiracetam increased the baseline production 
of NO after 20 minutes administration.  The pre-treatment with levetiracetam induced 
an NMDA-mediated NO  increase  and these  increases  were  dose  related.  In brain 
synapses,  NO  synthase  activation  is  coupled  to NMDA-mediated  calcium  entry at 
postsynaptic densities through regulatory protein complexes, and NMD  A/NO inhibits 
the release of pre-synaptic glutamate (Sequeira et al, 2001).  The inhibitory retrograde
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action  of postsynaptic  NO  on  presynaptic  terminals  might  also  contribute  to  the 
mechanism  of action  of levetiracetam.  Therefore,  the  further  study  on  ECF  NO 
concentrations  in  different  brain  region  after  levetiracetam  or  vigabatin 
administrations should also be considered.
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